

# Battelle

*The Business of Innovation*

Study Number CN49730G

Internal Distribution

Z Ma  
J Feng  
D Fallacara

Date February 29, 2012

To **STUDY FILE**From Jingyu Feng, Statistics and Information Analysis  
(SIA)

Subject Statistical Analyses Performed for CN49730G

## OVERVIEW

This memo and its attachments document the data summary and statistical analysis performed on survival and tumor incidence data collected for Battelle study CN49730G. In this study, 960 Wistar Han rats were used, of which 480 were females and 480 were males. Animals were assigned to the eight study groups by sex and body weight, such that there were 60 rats per sex per study group. The eight study groups were defined by the treatment received, as control A (Group1), control B (group 2), tobacco blend low (0.2 mg/kg/day, group 3), tobacco blend intermediate (2 mg/kg/day, group 4), tobacco blend high (5 mg/kg/day, group 5), tobacco extract low (0.2 mg/kg/day, group 6), tobacco extract intermediate (2 mg/kg/day, group 7) and tobacco extract high (5 mg/kg/day, group 8). Throughout this memo and the attached documents, the eight dose groups were also abbreviated as CF, CBF, B0.2F, B2F, B5F, E0.2F, E2F, and E5F for female animals, and CM, CBM, B0.2M, B2M, B5M, E0.2M, E2M, and E5M for male animals, respectively.

## SYSTEM OVERVIEW AND REQUIREMENTS

Data summarization and statistical analysis were performed on the survival data and the tumor incidence data using Version 11 (Release 11.1) of STATA, which is licensed to Battelle and is designed to run in a Windows 7 operating environment.

## RESPONSIBLE INDIVIDUAL

James Ma and Jingyu Feng of the Statistics and Information Analysis (SIA) product line are responsible for the development and maintenance of the STATA programs used in the analysis.

## DATA INPUTS AND OUTPUTS

Survival and tumor incidence data were stored in a file named "49730CAR FINAL Microscopic Data Extract on 12-22-2011 All Groups.xlsx" (Attachment 1). The data file was sent to SIA by Dawn Fallacara of Toxicology Columbus product line (Attachment 1). **No changes were made directly to the data file by the statisticians.**

## STATISTICAL ANALYSIS

Statistical analyses were performed according to the "Statistical Analysis" section of the study protocol. The methods and results of the data analysis are documented in the statistical analysis report in Attachment 4 of this memo.

February 29, 2012

**DOCUMENTATION FOR STATISTICAL ANALYSIS FOR CN49730G**

Page 2

## ATTACHMENTS

The following attachments document the statistical methods applied to the survival and tumor incidence data collected in this study.

Attachment 1: Email sent from Dawn Fallacara to James Ma with attaching data file. Hard copies of the data listings, as well as the codes for the tissues, tumor types, death status, and tumor classification were also included in this attachment. These data were read into STATA for statistical analysis and data summary. Also included in this attachment is the email from Dawn for a survival data entry.

Attachment 2: Listing of the STATA program named "CN49730G Analysis\_trend.do," which read in the survival and tumor incidence data file and conducted summarization and statistical analysis for the data.

Attachment 3: Outputs generated directly by executing the STATA programs in Attachment 2. A guide for reviewing the statistical output follows:

- Numbers of early deaths and final sacrificed (for Table 1) and Kaplan Meier Median and Restricted Mean Survival Time (for Table 2), as saved into file "check.log".
- Test for Difference in Survival Times (for Table 3).
- Numbers of females with tumors, as calculated for each tumor types in each tissue. These numbers were displayed in Table 4 and 5.
- Numbers of males with tumors, as calculated for each tumor types in each tissue. These numbers were displayed in Table 6 and 7.
- The trend test results for females, which were also incorporated into tables 4 and 5. Tumor analyses performed separately according to the tumor contexts and three trend tests were performed: Cochran Armitage (CA) trend tests for incidental tumors, Tarone trend tests for fatal tumors, and Peto trend test for combination of incidental and fatal. See section 1 of the stat report in attachment 4 for the six trend tests being conducted. The p-values for the tests were saved into file named "Analysis Female.csv". The excel file contains columns "sex", "Tissue\_code", "Diagnose\_code", "Pvalue", "Pvalue\_1345", "Pvalue\_2345", "Pvalue\_12345", "Pvalue\_1678", "Pvalue\_2678" and "Pvalue\_12678", where the numbers after "\_" are the dose groups included in the trend tests. For example, "Pvalue\_1345" column lists the p-values for trend test among dose group 1, 3, 4 and 5. The blank entries in the excel file were the result of "untestable data" due to identical tumor instance rate among the groups. Therefore they can be regarded as "Pvalue=1".
- The trend test results for males, which were also incorporated into tables 6 and 7. The p-values for the tests were saved into file named "Analysis Male.csv".

In order for a given trend test to be significant, the p-value has to be less than or equal to  $0.05/3=0.0167$ . Notice only the p-value less than or equal to 0.0167 were reported in tables 4 through 7.

Attachment 4: Statistical report detailing the study data and statistical methods applied to the data. All tables and figures are also included in this attachment.

Data summaries and analyses were generated using Version 11 (Release 11.1) of STATA, which is licensed to Battelle. Batch procedures (i.e., program code) written in STATA language to transform data must be verified using an appropriate performance test to confirm the accuracy of the results. As the attachments of this memo allow one to track a data point through the entire summary process (i.e., from raw data file to final summary tables), information necessary to perform this validation is provided in the attachments.

February 29, 2012

**DOCUMENTATION FOR STATISTICAL ANALYSIS FOR CN49730G**

Page 3

**APPLICATION LISTING**

The STATA programs used in the analyses are provided in the above attachments.

**PERFORMANCE TEST METHODS AND RESULTS**

The STATA procedures contained herein were developed by Battelle statisticians and were augmented by the responsible individual for this study-specific analysis to define input data structures, custom data transformations (if any), variable assignments, time-dependent data partitions and output formats. Because of these code modifications the system's STATA code was independently reviewed by a qualified individual to ensure technical validity.

The below-listed signatures attest to the fact that the system was independently reviewed and is operating in accordance with the pre-determined (and protocol driven) requirements for the statistical analysis of survival and tumor incidence data.

**SIGNATURES**

Zhenxu Ma / <i>Zhenxu Ma</i>	3/8/2012
Responsible Individual (Printed/Signature)	Date
Jingyu Feng / <i>Jingyu Feng</i>	3/8/2012
Concurrence (Printed/Signature)	Date
Robert Lardo / <i>Robert Lardo</i>	3/8/2012
Manager (Printed/Signature)	Date

**Battelle Study Number: CN49730G**

**ATTACHMENT 1**



**Ma, James**

*John Smith 1/9/2012*

**From:** Fallacara, Dawn M  
**Sent:** Tuesday, December 27, 2011 2:52 PM  
**To:** Ma, James  
**Cc:** Hejtmancik, Milton R; Reed, Kathleen E; Feder, Paul I; Feng, Jingyu  
**Subject:** RE: CN49730G NEW Data Set  
**Attachments:** 49730CAR FINAL Microscopic Data Extract on 12-22-2011 All Groups.xlsx

James: I have attached the fully QAU'd data set for use in the final analyses.

Thanks again,  
 Dawn

**Dawn M. Fallacara, Ph.D.**

Study Director/Toxicologist  
 Health & Life Sciences Global Business  
 Battelle  
 6-2-14E  
 (614) 424-4591

*Dawn Fallacara 1/9/12*

**From:** Ma, James  
**Sent:** Tuesday, December 27, 2011 10:14 AM  
**To:** Fallacara, Dawn M  
**Cc:** Hejtmancik, Milton R; Reed, Kathleen E; Feder, Paul I; Feng, Jingyu  
**Subject:** RE: CN49730G NEW Data Set

Yes. We will use the QAU 's data.

James.

**From:** Fallacara, Dawn M  
**Sent:** Tuesday, December 27, 2011 9:05 AM  
**To:** Ma, James  
**Cc:** Hejtmancik, Milton R; Reed, Kathleen E; Feder, Paul I; Feng, Jingyu  
**Subject:** RE: CN49730G NEW Data Set

Excellent. Thanks, James. Yes, the trends listed below are correct. Thank you for the detailed description. Did you get my emails about providing you and Jingyu with a new data set for the analyses? During the QAU audit, we discovered that the study pathologist made several changes that I was unaware of. Therefore, I had to re-extract the data last week. I currently submitted the new data set to QAU for a new review. I will provide this to you as soon as possible.

Thanks so much,  
 Dawn

**Dawn M. Fallacara, Ph.D.**

Study Director/Toxicologist  
 Health & Life Sciences Global Business  
 Battelle  
 6-2-14E  
 (614) 424-4591

**From:** Ma, James  
**Sent:** Tuesday, December 27, 2011 9:00 AM  
**To:** Fallacara, Dawn M  
**Cc:** Feder, Paul I; Feng, Jingyu  
**Subject:** RE: CN49730G NEW Data Set

Dawn and Paul,

We knew that I had not provided you the trend test results since there are two chemicals (B and E) and two control articles (C and CB) involved. A trend test should be performed in the same chemical to determine whether there is an increasing/decreasing trend as the dose increases. I was just wanting to provide you the overall dose effects and mainly the frequency of tumor instances as the first step. For the three comparisons you have asked for as below, I was thinking about pairwise comparisons if there is an overall dose effects.

1 vs. 3, 4, 5, 6, 7, 8

2 vs. 3, 4, 5, 6, 7, 8

1+2 vs. 3, 4, 5, 6, 7, 8

In order to perform a trend test, should we only do it for the following trends:

Tobacco Blend:

Groups 1, 2, 3, 4, 5 (trends 1 3 4 5, 2 3 4 5, 1&2 3 4 5)

Tobacco Extract:

Groups 1, 2, 6, 7, 8 (trends 1 6 7 8, 2 6 7 8, 1&2 6 7 8)

I am writing the trend contrasts now. I will address Dawn's email once I can pass along the trend test codes to Jingyu. I will be in office around 10am.

James.


---

**From:** Fallacara, Dawn M  
**Sent:** Thursday, December 22, 2011 3:09 PM  
**To:** Ma, James; Reed, Kathleen E  
**Cc:** Feng, Jingyu; Feder, Paul I; Reed, Kathleen E  
**Subject:** CN49730G NEW Data Set

James: I will be providing you with a new dataset on Tuesday 12/27/11. The QAU review of the data set you are currently using identified several changes made by the study pathologist that I was not aware of. From your perspective the changes are minor, but they do include the addition of 1-2 tumors. I do need to make sure your data package matches what is in the study file, so the time spent on an additional extraction of the data is well worth the effort.

Kathy: the new data set is ready for QAU review Tuesday morning. I am currently performing the technical review. Since the extraction is in a validated system and was conducted today (12/22/11), you will only need to do a 10% check. Everything should be good to go.

After talking to Paul this week, it appears that the Trend analyses needs some adjustments. I will touch base with everyone on Tuesday regarding those issues as well.

 Happy Holidays!!

Dawn

CN49730G  
DMF 1/23/12

Dawn M. Fallacara, Ph.D.

Study Director/Toxicologist

Health & Life Sciences Global Business

elle

6-2-14E

(614) 424-4591

**Battelle Study Number CN49730G**

**ATTACHMENT 2**

(b) (4)



(b) (4)



(b) (4)



(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)



**Battelle Study Number CN49730G**

**ATTACHMENT 3**

(b) (4)



(b) (4)



(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



Analysis Female.csv

CN497309

Sex	Tissue_Coc	Diag_Code	Pvalue_1345	Pvalue_2345	Pvalue_1678	Pvalue_2678	Pvalue_12345	Pvalue_12678
F	AD	29	0.734893	0.8199589	0.7755358	0.9790502	0.7328129	0.8911933
F	AD	38		0.2784259		0.3990752	0.4272825	0.5450355
F	BO	71		0.1701494		0.1622037	0.3929301	0.3835007
F	BR	19	0.1820395	0.190995	0.6676367	0.6852366	0.0948785	0.5947629
F	BR	39	0.1825479	0.183684			0.0912368	
F	BR	68	0.1798386	0.1844868			0.0913174	
F	BR	70	0.1794253	0.1768532	0.164873	0.1645589	0.2305062	0.2141924
F	CE	38			0.6533533	0.6810157		0.5853243
F	CL	40	0.1820395	0.190995			0.0948785	
F	EYE	34	0.1868363		0.1778754		0.3910727	0.382262
F	HT	33	0.6529491	0.6189052	0.7931636	0.3492946	0.8890447	0.4224668
F	HT	81	0.6622187	0.4688902			0.461602	
F	K	25	0.1868363		0.1778754		0.3910727	0.382262
F	K	38	0.159011		0.2482131		0.4272825	0.5450355
F	K	54	0.2764567	0.2002189			0.1219501	
F	K	82	0.6622187	0.4688902			0.461602	
F	LI	3		0.25147	0.6533533	0.5139918	0.418559	0.7460682
F	LI	8	0.1868363		0.1778754		0.3910727	0.382262
F	LI	38	0.159011	0.2784259	0.9371396	0.6085902	0.2479995	0.5274993
F	LI	54			0.2901893	0.2172382		0.1580936
F	LI	63			0.2482131	0.1400165		0.0591805
F	LI	65			0.1778754	0.186041		0.0927411
F	LI	83	0.6622187	0.4688902			0.461602	
F	LNMED	38			0.2901893	0.2172382		0.1580936
F	LNMED	54	0.2764567	0.2002189			0.1219501	
F	LNMED	63		0.25147		0.208524	0.418559	0.3455257
F	LNMED	85	0.6622187	0.4688902			0.461602	
F	LNMES	21			0.3620389	0.5139918		0.3675892
F	LNMES	38			0.2929301	0.234484		0.1592251
F	LNMES	54	0.0969069		0.5885857	0.2172382	0.418559	0.737142
F	LNMES	63		0.25147		0.208524	0.418559	0.3455257
F	LNMES	65	0.6622187	0.4688902			0.461602	
F	LNMES	86	0.6622187	0.4688902			0.461602	
F	LNO	38			0.2901893	0.2172382		0.1580936
F	LNO	54	0.0969069		0.5885857	0.2172382	0.418559	0.737142
F	LNO	62			0.1778754	0.186041		0.0927411
F	LNO	63			0.2482131	0.1400165		0.0591805
F	LNO	87	0.6622187	0.4688902			0.461602	
F	LU	4			0.6533533	0.6810157		0.5853243
F	LU	38	0.159011	0.2784259	0.7325454	0.5014594	0.2479995	0.4005315
F	LU	54	0.3672164	0.0590456	0.5885857	0.2172382	0.079853	0.737142
F	LU	63			0.2482131	0.1400165		0.0591805
F	LU	73	0.1797125		0.3319755		0.3347914	0.4595245
F	LU	79		0.1138463		0.2381849	0.3347914	0.4595245
F	LU	84	0.6622187	0.4688902			0.461602	
F	MA	1	0.1537541	0.0042252	0.702029	0.0491488	0.0164086	0.1790523
F	MA	25		0.1664604		0.158088	0.3910727	0.382262
F	MA	38	0.159011	0.25147	0.2482131	0.208524	0.2592163	0.2641994
F	MA	42	0.2007065	0.072089	0.4109389	0.0873897	0.0617391	0.1278878
F	MA	59	0.5408072	0.8326921			0.6171478	
F	ME	54	0.1540558	0.0632229	0.2901893	0.2172382	0.040172	0.1580936
F	ME	63		0.25147		0.208524	0.418559	0.3455257
F	ME	69	0.1820395	0.190995			0.0948785	

## Analysis Female.csv

CN49304

F	ME	88	0.6622187	0.4688902			0.461602	
F	NO	57	0.1868363		0.1778754		0.3910727	0.382262
F	OC	57	0.530526	0.5107821	0.1701926	0.158088	0.5087921	0.213836
F	OV	1			0.3936654	0.6692911		0.4954557
F	OV	14			0.2901893	0.2172382		0.1580936
F	OV	18			0.6911353	0.5652597		0.5233942
F	OV	20	0.5236804	0.7439154	0.3652366	0.9161707	0.8912553	0.5548874
F	OV	26			0.6533533	0.6810157		0.5853243
F	OV	35		0.25147	0.6533533	0.5139918	0.418559	0.7460682
F	OV	36	0.1820395	0.9570056		0.158088	0.5647233	0.382262
F	OV	54			0.1274295	0.0765195		0.0429995
F	OV	69	0.1820395	0.190995			0.0948785	
F	PA	38		0.2784259		0.3990752	0.4272825	0.5450355
F	PA	54	0.9370072	0.5481805	0.2901893	0.2172382	0.6470936	0.1580936
F	PA	89	0.6622187	0.4688902			0.461602	
F	PI	10	0.2475834	0.2465169	0.0639096	0.0647438	0.1943295	0.0395918
F	PI	11	0.6634437	0.0588376	0.07315	0.9178066	0.183734	0.3380853
F	PI	55	0.6237893	0.5969759	0.0680416	0.6169153	0.9700195	0.1753005
F	PTHY	1		0.1664604		0.158088	0.3910727	0.382262
F	SA	45			0.1778754	0.186041		0.0927411
F	SK	15	0.6529491	0.6814109			0.5845819	
F	SK	25			0.6533533	0.6810157		0.5853243
F	SK	28	0.2133122	0.6265672	0.1778754		0.3093406	0.382262
F	SK	47		0.1786075		0.1771648	0.3939477	0.3928813
F	SK	48	0.0532471	0.190995	0.0030998		0.4547422	0.0781154
F	SK	57	0.6632591	0.6334279			0.5665022	
F	SK	61	0.6529871	0.6760139			0.5814891	
F	SK	63	0.6547208	0.6547208			0.5700609	
F	SM	54	0.2764567	0.2002189	0.2901893	0.2172382	0.1219501	0.1580936
F	SM	72	0.1809631		0.1759208		0.39642	0.3903242
F	SM	75		0.0594029		0.0539051	0.231368	0.2195016
F	SP	21			0.6533533	0.6810157		0.5853243
F	SP	38	0.159011		0.7335155	0.1926988	0.4272825	0.252977
F	SP	62			0.6533533	0.6810157		0.5853243
F	SP	90	0.6622187	0.4688902			0.461602	
F	ST	16	0.1820395	0.8806812		0.208524	0.489007	0.3455257
F	ST	38	0.159011	0.1808493	0.2482131	0.1783309	0.2364142	0.290137
F	ST	64	0.6560312	0.664707	0.1778754	0.186041	0.5772635	0.0927411
F	STE	71	0.6529491	0.6814109			0.5845819	
F	THG	5	0.7723454	0.8380198	0.9306584	0.5126683	0.986387	0.6676177
F	THG	7	0.7595695	0.8325119	0.6912876	0.9689183	0.9546118	0.7767569
F	THG	52	0.6634437	0.6265672			0.5640759	
F	THY	38	0.159011		0.5770907	0.9495984	0.4272825	0.7982674
F	THY	63			0.2482131	0.1400165		0.0591805
F	THY	80	0.2143246	0.0588376	0.5244185	0.1614437	0.1150433	0.2996374
F	UB	54	0.1374652	0.0969503			0.0485731	
F	UB	57			0.6321939	0.6157001		0.5465993
F	UB	58	0.6563597	0.6696225			0.5799856	
F	UT	31	0.5755494	0.7126253	0.9325401	0.9769117	0.6127645	0.9862815
F	UT	46	0.069361	0.0253696	0.3552797	0.1514507	0.0117453	0.1537854
F	UT	63			0.6575284	0.6725312		0.5825075
F	UT	77	0.0808783	0.2494048	0.5143896	0.8239028	0.1447262	0.5944492
F	VA	21			0.3936654	0.6692911		0.4954557
F	VA	24		0.0497178	0.6533533	0.1614437	0.2241135	0.4858504

## Analysis Female.csv

CN497309

F	VA	30	0.6529	0.1938173	0.6507533	0.2131425	0.3241861	0.3392922
F	VA	57	0.1820395	0.190995			0.0948785	
F	VA	64			0.6260302	0.6260302		0.5488963
F	ZY	57	0.1868363	0.1754122	0.1778754	0.1618099	0.2270545	0.2146531



CN497309

Sex	Tissue_Code	Diag_Code	Pvalue_1345	Pvalue_2345	Pvalue_12345	Pvalue_1678	Pvalue_2678	Pvalue_12678
M	AD	6	0.6783782	0.6958991	0.606223			
M	AD	17	0.6783782	0.5801523	0.8310587		0.1413945	0.2521157
M	AD	29	0.0291381	0.0779141	0.0280154	0.0272032	0.0658387	0.0486635
M	AD	38				0.2999651	0.2490555	0.1940437
M	BM	38	0.2482131	0.2482131	0.1076889	0.0935441	0.0803907	0.036363
M	BM	63				0.6492944	0.6492944	0.5656676
M	BO	19	0.1746154		0.379041	0.1860623		0.3982564
M	BO	27	0.1746154		0.379041	0.1860623		0.3982564
M	BO	38				0.2999651	0.2490555	0.1940437
M	BO	71		0.1678471	0.3797566		0.16989	0.383421
M	BR	19	0.8354767	0.2348535	0.4625246	0.1860623		0.3982564
M	BR	38				0.2999651	0.2490555	0.1940437
M	BR	39	0.41983	0.3810481	0.4074065	0.0553083	0.053624	0.0873548
M	EP	69	0.0235588	0.0252965	0.0045476	0.9513822	0.7808396	0.8317044
M	EYE	38				0.2999651	0.2490555	0.1940437
M	HG	1	0.6373391	0.6148384	0.5480816			
M	HG	38				0.2999651	0.2490555	0.1940437
M	HT	33				0.5551981	0.5258916	0.43141
M	JE	41	0.6373391	0.6148384	0.5480816			
M	K	13				0.4871331	0.5084321	0.3927687
M	K	25				0.1882615	0.1942054	0.098273
M	K	38				0.1673606	0.1723209	0.0824086
M	LI	8				0.162626	0.1675631	0.0781928
M	LI	38				0.2999651	0.2490555	0.1940437
M	LI	63				0.8526837	0.8526837	0.7381666
M	LNMAN	38				0.2999651	0.2490555	0.1940437
M	LNMED	38				0.2999651	0.2490555	0.1940437
M	LNMED	66				0.1442921	0.2635525	0.0644064
M	LNMES	21				0.9959692	0.8978425	0.9087974
M	LNMES	38				0.2999651	0.2490555	0.1940437
M	LNMES	62	0.3055599	0.7069349	0.3948428	0.5502428	0.1924151	0.2568748
M	LNMES	63				0.8526837	0.8526837	0.7381666
M	LNO	38				0.2999651	0.2490555	0.1940437
M	LU	4	0.1746154		0.379041	0.4687862	0.9892324	0.6440819
M	LU	38				0.2999651	0.2490555	0.1940437
M	LU	49		0.2482131	0.4717298		0.2652054	0.51913
M	LU	50	0.1933348	0.198826	0.1027676			
M	LU	53				0.2999651	0.2490555	0.1940437
M	LU	69				0.6240703	0.6409502	0.5464798
M	LU	74		0.3710934	0.5730641		0.1948351	0.2940719
M	MA	1	0.1933348	0.3810481	0.9409672	0.3232468	0.7230584	0.7655903
M	ME	69				0.9513822	0.7808396	0.8317044
M	NO	1				0.6773266	0.6546331	0.5787696
M	OC	57	0.9671777	0.9362394	0.9512955			
M	P	67				0.6660376	0.6493816	0.5731535
M	PA	22	0.8878425	0.7244647	0.7697754	0.7024046	0.6589982	0.6395215
M	PA	38				0.2999651	0.2490555	0.1940437
M	PA	51	1	1	0.7994953			
M	PI	10	0.0334173	0.1730568	0.0532884	0.2173503	0.793893	0.3788936
M	PI	11	0.0644747	0.6148384	0.1712949	0.7594615	0.3589534	0.7820405
M	PI	38				0.2999651	0.2490555	0.1940437
M	PI	55	0.1626235	0.198826	0.6123088	0.4945211	0.1905286	0.8764369
M	PI	56				0.162626	0.1675631	0.0781928
M	PRE	43				0.162626	0.1675631	0.0781928

Analysis Male.csv

CN497309

M	PRO	1				0.6240703	0.6409502	0.5464798
M	PRO	38				0.2999651	0.2490555	0.1940437
M	PRO	44				0.6357032	0.6438995	0.5555603
M	PTHY	1	0.1746154		0.379041	0.1860623		0.3982564
M	R	24				0.6240703	0.6409502	0.5464798
M	SA	32				0.6240703	0.6409502	0.5464798
M	SA	38				0.2999651	0.2490555	0.1940437
M	SC	60	0.657434	0.6609956	0.5755873			
M	SK	2	0.1746154	0.1623474	0.2125628	0.2630846	0.2469818	0.1923334
M	SK	12		0.1623474	0.379041		0.1735008	0.3982564
M	SK	19				0.6773266	0.6546331	0.5787696
M	SK	23				0.6240703	0.6409502	0.5464798
M	SK	25	0.1746154		0.379041	0.1860623		0.3982564
M	SK	28	0.6783782	0.6958991	0.606223			
M	SK	37				0.6240703	0.6409502	0.5464798
M	SK	38	0.1903474	0.1891511	0.0972585			
M	SK	48	0.1746154	0.178598	0.2204124	0.9838939	0.9866301	0.9997408
M	SK	61	0.6783782	0.6958991	0.606223	0.162626	0.1675631	0.0781928
M	SK	78		0.1623474	0.379041		0.1735008	0.3982564
M	SM	75		0.1623474	0.379041		0.1735008	0.3982564
M	SP	21	0.1933348	0.9365385	0.5941991		0.1735008	0.3982564
M	SP	38	0.6547208	0.6582374	0.5721718	0.2999651	0.2490555	0.1940437
M	SP	62		0.1623474	0.379041		0.1735008	0.3982564
M	TE	9	0.1797416	0.2058349	0.1156224	0.5952943	0.6314618	0.5644214
M	TE	64				0.5337374	0.5374432	0.4308169
M	TE	69	0.2239762	0.2348535	0.1281929	0.9513822	0.7808396	0.8317044
M	TE	76				0.1831182	0.1843026	0.0936926
M	THG	5	0.156193	0.7334487	0.5333626	0.2825365	0.6327091	0.6348172
M	THG	7	0.1146405	0.0869707	0.076109	0.010398	0.0104615	0.0078204
M	THG	52	0.3773506	0.9937884	0.7087368	0.6240703	0.5258916	0.8640189
M	THY	38		0.1623474	0.379041	0.0397054	0.228756	0.0707953
M	THY	80	0.967914	0.198826	0.5941991	0.1860623		0.3982564
M	TO	57				0.6639584	0.6639584	0.5797958
M	UB	58	0.6783782	0.5015598	0.8185545		0.1797125	0.3942459
M	ZY	57	0.2164713	0.2304345	0.1227225	0.643002	0.6470203	0.5613725

**Battelle Study Number CN49730G**

**ATTACHMENT 4**

**STATISTICAL ANALYSIS REPORT****2-YEAR CHRONIC TOXICITY/CARCINOGENICITY STUDY OF TOBACCO  
BLEND AND AQUEOUS TOBACCO EXTRACT IN WISTAR HAN RATS**

Battelle Study No. CN49730G


March 8, 2012

Prepared By:

James Ma., Ph.D.  
Statistician

3/8/2012

Date

Jingyu Feng, M.S.  
Statistician, Concurrence

3/8/2012

Date

Approved By:

Bob Lordo, Ph.D.  
Management

3/8/2012

Date

BATTELLE  
Columbus Operations  
505 King Avenue  
Columbus, Ohio 43201

## TABLE OF CONTENTS

	Page
1.0 INTRODUCTION .....	1
1.1 Objectives of the Analysis .....	1
1.1.1 Tobacco Blend .....	1
1.1.2 Tobacco Extract .....	2
2.0 METHODS .....	2
2.1 Survival .....	2
2.2 Tumor Incidence .....	2
2.2.1 Incidental Methods.....	3
2.2.2 Fatal Methods.....	3
2.2.3 Combined Methods.....	4
2.2.4 General Comments.....	4
3.0 RESULTS .....	4
3.1 Survival Analysis .....	4
3.2 Tumor Analysis.....	5
3.2.1 Results for Tobacco Blend.....	6
3.2.2 Results for Tobacco Extract.....	6
4.0 CONCLUSIONS.....	7
5.0 REFERENCES .....	7

## LIST OF TABLES

Table 1. Frequency of Early Deaths Within the Study Period.....	8
Table 2. Kaplan Meier Median and Restricted Mean Survival Time and 95% Confidence Interval by Group (Days) .....	8
Table 3. Test for Difference in Survival Times Based on Log-Rank Test.....	9
Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females.....	13
Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females.....	21
Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males .....	29
Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males .....	34

## LIST OF FIGURES

	Page
Figure 1. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group.....	10
Figure 2. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group – Tobacco Blend .....	11
Figure 3. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group – Tobacco Extract .....	12

## LIST OF APPENDICES

APPENDIX A. TUMOR ANALYSIS RESULTS PRIOR TO MULTIPLE TEST CORRECTION.....	39
APPENDIX B. P-VALUES FOR ALL DOSE TREND TESTS .....	65
APPENDIX C. DATA SET FOR TUMOR INCIDENCE AND SURVIVAL STATISTICAL ANALYSIS .....	76
APPENDIX D. SUMMARY TABLES.....	309

## 1.0 INTRODUCTION

This report summarizes the statistical analysis of survival and tumor incidence data from a 2-year chronic toxicity/carcinogenicity study of two separate test articles, a tobacco blend and an aqueous tobacco extract from that blend, administered in the diet to Wistar Han rats. A total of 960 rats were used in this study for the core dosage groups for the 2-year timepoint, of which 480 were females and 480 were males. Animals were randomly assigned to eight core dosage groups by sex and body weight using a computer algorithm (PATH/TOX SYSTEM, Version 4.2.2), such that there were 60 rats per sex per group. There was an additional core sentinel group (30 animals per sex) that received diet without test articles. The eight dosage groups were fed diets without test articles, Control-A (Group 1) and Control-B (Group 2), or diets with two separate test articles, tobacco blend low dose (0.2 mg nicotine/kg/day, Group 3), tobacco blend intermediate dose (2 mg nicotine/kg/day, Group 4), tobacco blend high dose (5 mg nicotine/kg/day, Group 5), tobacco extract low dose (0.2 mg nicotine/kg/day, Group 6), tobacco extract intermediate dose (2 mg nicotine/kg/day, Group 7), and tobacco extract high dose (5 mg nicotine/kg/day, Group 8). In each core dosage group for the 2-year timepoint, 60 animals of each sex were used to assess potential toxicity and carcinogenicity. The dosage groups were abbreviated as CF, CBF, B0.2F, B2F, B5F, E0.2F, E2F, and E5F for females, and CM, CBM, B0.2M, B2M, B5M, E0.2M, E2M, and E5M for males, respectively.

### 1.1 Objectives of the Analysis

The objectives of the analysis were to determine whether significant differences in intercurrent mortalities occurred among the study groups within each test article versus corresponding controls, and whether significant linear dose-response trends existed in incidences of tumors among the following groups by test article:

#### 1.1.1 Tobacco Blend

- Group 1 and Groups 3 to 5
- Group 2 and Groups 3 to 5
- Groups 1 and 2 and Groups 3 to 5

### 1.1.2 Tobacco Extract

- Group 1 and Groups 6 to 8
- Group 2 and Groups 6 to 8
- Groups 1 and 2 and Groups 6 to 8

These analyses were conducted separately for males and females.

## 2.0 METHODS

(b) (4)

A large rectangular area of the document is redacted with a solid gray fill, covering the text under the 'METHODS' section header.

### 2.1 Survival

(b) (4)

A large rectangular area of the document is redacted with a solid gray fill, covering the text under the 'Survival' section header.

### 2.2 Tumor Incidence

(b) (4)

A large rectangular area of the document is redacted with a solid gray fill, covering the text under the 'Tumor Incidence' section header.



(b) (4)



#### **2.2.1 Incidental Methods**

(b) (4)



#### **2.2.2 Fatal Methods**

(b) (4)



### **2.2.3 Combined Methods**

(b) (4)



### **2.2.4 General Comments**

(b) (4)



## **3.0 RESULTS**

### **3.1 Survival Analysis**

Kaplan-Meier survival curves for male and female rats are plotted in Figure 1 for all eight dosage groups. These survival curves are also displayed in Figure 2 and Figure 3 for tobacco blend and tobacco extract, respectively. Table 1 presents the frequency of early

(unscheduled) death animals and final (scheduled) sacrifice animals. Table 2 summarizes the median survival times as well as the mean survival time restricted to the longest final sacrifice times and their associated 95 percent confidence intervals. Table 3 presents the results of statistical tests of the survival data. The mean survival times were restricted to the longest final sacrifice times (i.e., 746 days), and were therefore underestimated.

There were no statistically significant differences in survival among groups in either the tobacco blend or tobacco extract groups, for either males or females (Table 2).

At least 68 percent of female animals in any dose groups survived until the final sacrifice, and the CBF and B2F had slightly more early deaths (Table 1) compared to the other dose groups. At least 75 percent of males in any dose group survived until the final sacrifice. The CBM and E5M groups had slightly more animals die early, and the B5M group had slightly fewer animals that died early (Table 1) compared to the other dose groups; however, these differences were not statistically significant. The median survival times are larger than the final sacrifice times for either females or males, as more than 50 percent of animals survived until the final sacrifice. In general, there were slightly more early deaths in females than males.

### 3.2 Tumor Analysis

Table 4 and Table 5 present the results of statistical analyses of tumor incidence data for females for tobacco blend and tobacco extract, respectively. Table 6 and Table 7 present the results of statistical analyses of tumor incidence data for males for tobacco blend and tobacco extract, respectively. Also provided in these tables are the numbers of animals in each dose group with tumors for each tumor type of interest. As discussed in the method section, the mortality independent tumors were regarded as incidental tumors for the tumor analyses. If a specified type of tumor was observed in both incidental and fatal contexts among the dose groups involved in a given trend test, then the Peto's method was used for the given trend test for the specific tumor type. If the linear dose trends were statistically significant at the  $0.05/3=0.0167$  level, then the p-values were listed in the tables.

Trend test results with p-values  $\leq 0.05$  before multiple adjustments are presented in Appendix A. These tables were included for reporting purposes only, and were not

summarized within this report. In addition, p-values for all dose trend tests are presented in Appendix B and the data set used for the survival and tumor incidence statistical analysis is presented in Appendix C.

### 3.2.1 Results for Tobacco Blend

The trend tests detected a statistically significant dose-response trend in tumor rates at the 0.0167 significance level in the following instances:

- Two decreasing dose response trends among groups CBF, B0.2F, B2F, and B5F and among groups CF, CBF, B0.2F, B2F, and B5F, for B-ADENOMA in MAMMARY GLAND: there were eight (three incidental and five mortality independent) tumors in the CF group, fourteen (two incidental, nine mortality independent and three fatal) tumors in the CBF group, nine (two incidental, five mortality independent and two fatal) tumors in the B0.2F group, ten (two incidental, six mortality independent and two fatal) tumors in the B2F group, and two (one incidental and one mortality independent) tumors in the B5F group (Table 4).
- An increasing dose response trend among groups CF, CBF, B0.2F, B2F, and B5F, M-CARCINOMA in the UTERUS: there was one (fatal) tumor in the CF group, five (two mortality independent and three fatal) tumors in the B0.2F group, three (one incidental, one mortality independent, and one fatal) tumors in the B2F group, seven (four mortality independent and three fatal) tumors in the B5F group, and no tumors in the CBF group (Table 4).
- An increasing dose response trend among groups CM, CBM, B0.2M, B2M, and B5M, for M-MESOTHELIOMA in the EPIDIDYMIS: there were three (mortality independent) tumors in B5M group and no tumors in the other male tobacco blend and the two male control groups (Table 6).

### 3.2.2 Results for Tobacco Extract

The trend tests detected a statistically significant dose-response trend in tumor rates at the 0.0167 significance level in the following instances:

- A decreasing dose response trend among groups CF, E0.2F, E2F, and E5F, for M-CARCINOMA, BASAL CELL in SKIN: there were four (one mortality independent, one incidental, and two fatal) tumors in the CF group and no tumors in the female tobacco extract groups (Table 5).
- Three decreasing dose response trends among groups CM, E0.2M, E2M, and E5M for B-ADENOMA, FOLLICULAR CELL in the THYROID GLAND, among CBM, E0.2M, E2M, and E5M, and also CM, CBM, E0.2M, E2M, and E5M: there were seven (mortality independent) tumors in each of the CM and

CBM groups, four (three mortality independent and one incidental) tumors in E0.2M, four (mortality independent) tumors in E2M, and no tumors in E5M (Table 7).

#### 4.0 CONCLUSIONS

Analysis of the survival data indicated there was no difference in intercurrent mortalities among the study groups for either the males or females.

Summary tables including statistically significant ( $p \leq 0.0167$ ) trend tests are presented in Appendix D. The tumor analysis indicated that:

- There were decreasing dose response trends in tumor incidence rates observed for B-ADENOMA in MAMMARY GLAND for tobacco blend females, for M-CARCINOMA, BASAL CELL in SKIN for tobacco extract females, and for B-ADENOMA, FOLLICULAR CELL in the THYROID GLAND for tobacco extract males.
- There were increasing dose response trends in tumor incidences observed for M-CARCINOMA in the UTERUS for tobacco blend females, and in M-MESOTHELIOMA in the EPIDIDYMISS for tobacco blend males.
- There were no increasing dose response trends in either males or females for the tobacco extract treatment.

#### 5.0 REFERENCES

- Lin, K.K. (2000). Progress Report on the Guidance for Industry for Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals. *Journal of Biopharmaceutical Statistics*. 10(4):481-501.
- Miller, R.G., Jr. (1981). Simultaneous statistical inference. Springer Verlag, NY.
- StataCorp. (2009). Stata User's Guide: Release 11. College Station, TX:Stata Press.
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). (2001). Guidance for industry. Statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals: draft guidance May 2001. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm0792.pdf> (Searched February 14, 2012).

**Table 1. Frequency of Early Deaths Within the Study Period**

Sex	Group	Number of Early (Unscheduled)	Number of Final (Scheduled)	Total Numbers
		Deaths	Sacrifice Animals	
Female	1 (CF)	15	45	60
	2 (CBF)	19	41	60
	3 (B0.2F)	16	44	60
	4 (B2F)	18	42	60
	5 (B5F)	13	47	60
	6 (E0.2F)	12	48	60
	7 (E2F)	12	48	60
	8 (E5F)	13	47	60
Male	1 (CM)	9	51 <sup>a</sup>	60 <sup>a</sup>
	2 (CBM)	14	46	60
	3 (B0.2M)	11	49	60
	4 (B2M)	10	50	60
	5 (B5M)	6	54	60
	6 (E0.2M)	10	50	60
	7 (E2M)	11	49	60
	8 (E5M)	15	45	60

a. Animals 175 and 176 were missing on Day 547 and they were treated as censored observations (they were still alive on Day 547).

**Table 2. Kaplan Meier Median and Restricted Mean Survival Time and 95% Confidence Interval by Group (Days)**

Group	Median <sup>a</sup>		Restricted Mean <sup>b</sup>	
	Female	Male	Female	Male
1 (CF, CM)	> FS (744, <sup>c,d</sup> )	> FS (-,-)	708 (687,728)	711 (685,737)
2 (CBF, CBM)	> FS (-,-)	> FS (-,-)	697 (674,721)	697 (666,728)
3 (B0.2F, B0.2M)	> FS (-,-)	> FS (-,-)	713 (694,733)	720 (702,738)
4 (B2F, B2M)	> FS (-,-)	> FS (-,-)	699 (675,722)	707 (677,736)
5 (B5F, B5M)	> FS (745,-)	> FS (-,-)	709 (689,730)	734 (724,745)
6 (E0.2F, E0.2M)	> FS (-,-)	> FS (-,-)	723 (710,736)	707 (676,738)
7 (E2F, E2M)	> FS (-,-)	> FS (-,-)	718 (700,735)	724 (710,738)
8 (E5F, E5M)	> FS (-,-)	> FS (-,-)	726 (713,739)	710 (691,730)

FS = Final sacrifice time (censored).

a. Median survival time.



b. Mean survival time restricted to longest follow-up time (final sacrificed time) and thus mean survival times were underestimated.

c. Confidence interval could not be estimated because the value is larger than the final sacrifice time.

d. 95% confidence interval.


**Table 3. Test for Difference in Survival Times Based on Log-Rank Test**

	<b>Female</b>	<b>Male</b>
<b>Group Effect p-value</b>	0.6699	0.5226




**Figure 1. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group**





**Figure 2. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group – Tobacco Blend**



**Figure 3. Kaplan-Meier Survival Estimates Associated with Time to Death for Each Group – Tobacco Extract**

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Adrenal Gland	29	B <sup>d</sup> -PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	0	0	1	1	0			
			F	0	0	0	0	0			
	38	F <sup>e</sup> -LYMPHOMA	I	0	1	0	0	0			
Bone	71	M <sup>f</sup> -OSTEOSARCOMA	F	0	1	0	0	0			
Brain	19	B-GRANULAR CELL TUMOR	M	0	0	0	0	1			
			F	0	0	0	0	0			
	39	M-ASTROCYTOMA	F	0	0	0	0	1			
	68	M-MEDULLOBLASTOMA	F	0	0	0	0	1			
	70	M-OLIGODENDROGLIOMA	F	1	1	0	0	0			
Cecum	38	F-LYMPHOMA	M	0	0	0	0	0			
Clitoral Gland	40	M-CARCINOMA	M	0	0	0	0	1			
Eye	34	B-SCHWANNOMA, OPTIC NERVE	M	1	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	I	0	1	0	0	0			
			M	0	0	0	1	0			
			F	0	0	0	0	0			
	81	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)	I	0	0	0	1	0			
Kidney	25	B-LIPOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	82	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)	I	0	0	0	1	0			

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Liver	3	B-ADENOMA, BILIARY	I	0	1	0	0	0			
			M	0	0	0	0	0			
	8	B-ADENOMA, HEPATOCELLULAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	M	0	0	0	0	0			
LN-Mediastinal	83	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)	I	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	85	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MEDIASTINAL)	I	0	0	0	1	0			
LN-Mesenteric	21	B-HEMANGIOMA	I	0	0	0	0	0			
			M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
			M	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	I	0	0	0	1	0			

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
LN-Mesenteric	86	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MESENTERIC)	I	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
LN-Other	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	87	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-OTHER)	I	0	0	0	1	0			
	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	0			
Lung	38	F-LYMPHOMA	I	1	1	0	0	0			
			F	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	2			
			M	0	0	1	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	73	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)	I	1	0	0	0	0			
	79	M-STROMAL SARCOMA, METASTATIC (UTERUS)	I	0	1	0	0	0			
	84	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LUNG)	I	0	0	0	1	0			
Mammary Gland	1	B-ADENOMA	I	3	2	2	2	1			
			M	5	9	5	6	1	0.0042	0.0164	
			F	0	3	2	2	0			

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Mammary Gland	25	B-LIPOMA, INFILTRATIVE	M	0	1	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			
			I	0	0	0	1	0			
	42	M-CARCINOMA	M	1	0	1	0	2			
			F	0	0	1	0	2			
	59	M-CARCINOSARCOMA	I	0	0	1	0	0			
Mesentery	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	1	0	2			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	1			
	88	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)	I	0	0	0	1	0			
Nose/Turbinates	57	M-CARCINOMA, SQUAMOUS CELL	M	1	0	0	0	0			
Oral Mucosa			M	0	1	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	F	1	0	0	1	0			
Ovary	1	B-ADENOMA	I	0	0	0	0	0			
	14	B-DYSGERMINOMA	I	0	0	0	0	0			
	18	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	I	0	0	0	0	0			
			M	0	0	0	0	0			
	20	B-GRANULOSA CELL TUMOR	M	0	1	1	0	1			
	26	B-LUTEOMA	M	0	0	0	0	0			
			I	0	1	0	0	0			
	35	B-SERTOLI CELL TUMOR	M	0	0	0	0	0			

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

									Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					1, 3-5	2, 3-5	1&2, 3-5
				CF	CBF	B0.2F	B2F	B5F			
Ovary	36	B-THECOMA	M	0	1	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	1			
Pancreas	38	F-LYMPHOMA	I	0	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	2	0	1			
	89	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)	I	0	0	0	1	0			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	0	0	0	0	1			
			M	18	13	13	12	14			
			F	5	8	7	5	2			
	11	B-ADENOMA, PARS INTERMEDIA	M	0	2	1	0	0			
			F	0	0	0	0	0			
	55	M-CARCINOMA, PARS DISTALIS	M	2	0	1	3	0			
Parathyroid	1	B-ADENOMA	M	0	1	0	0	0			
Salivary Gland	45	M-CARCINOMA	M	0	0	0	0	0			
Skin	15	B-FIBROMA	M	0	0	0	1	0			
	25	B-LIPOMA	M	0	0	0	0	0			
	28	B-PAPILLOMA, SQUAMOUS CELL	M	1	0	1	0	0			
	47	M-CARCINOMA, APOCRINE GLAND	F	0	1	0	0	0			
	48	M-CARCINOMA, BASAL CELL	I	1	0	0	0	0			
			M	1	0	0	0	1			
			F	2	0	0	0	0			

5050

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Skin	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	1	0	0			
	61	M-FIBROSARCOMA	F	0	0	0	1	0			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	1	0	0			
Skeletal Muscle	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	72	M-OSTEOSARCOMA, EXTRASKELETAL	F	1	0	0	0	0			
	75	M-RHABDOMYOSARCOMA	F	0	2	0	0	0			
Spleen	21	B-HEMANGIOMA	M	0	0	0	0	0			
			I	1	0	0	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	0	0	0	0			
	90	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (SPLEEN)	I	0	0	0	1	0			
Stomach	16	B-FIBROPAPILLOMA	I	0	1	0	0	0			
			M	0	0	0	0	1			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			F	0	1	0	0	0			
	64	M-LEIOMYOSARCOMA	M	0	0	0	0	0			
Sternum			F	0	0	0	1	0			
	71	M-OSTEOSARCOMA	M	0	0	0	1	0			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	0	2	1	1	1			
			M	4	4	5	5	4			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	1	0	1			
			M	1	2	1	1	1			
	52	M-CARCINOMA, FOLLICULAR CELL	M	0	0	1	0	0			

000000



Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Thymus	38	F-LYMPHOMA	I	1	0	0	0	0			
			M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	80	M-THYMOMA	M	0	2	1	0	0			
Urinary Bladder			F	1	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			
	58	M-CARCINOMA, TRANSITIONAL CELL	F	0	0	0	1	0			
Uterus			I	0	2	0	2	0			
	31	B-POLYP, ENDOMETRIAL STROMAL	M	4	2	4	3	4			
			F	0	0	0	0	1			
			I	0	0	0	1	0			
	46	M-CARCINOMA	M	0	0	2	1	4			0.0117
			F	1	0	3	1	3			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	0	0			
			I	0	1	0	0	0			
	77	M-SARCOMA, STROMAL	M	1	0	0	0	0			
			F	2	1	0	1	0			
Vagina	21	B-HEMANGIOMA	I	0	0	0	0	0			
	24	B-LEIOMYOMA	M	0	2	0	0	0			
			M	1	0	0	0	0			
	30	B-POLYP	F	0	0	0	2	1			
	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	1			
	64	M-LEIOMYOSARCOMA	F	0	0	0	0	0			

**Table 4. Results of Analysis of Tumor Data – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	I	1	0	0	0	0			
			F	0	1	0	0	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. The significance levels for the trend tests were adjusted using the Bonferroni approach to control the overall error rate to no more than 0.05 for testing the three trend tests simultaneously. If the dose trends were significant at the Bonferroni adjusted  $0.05/3 = 0.0167$  level, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Adrenal Bland	29	B <sup>d</sup> -PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	0	0	0	0	0			
			F	0	0	0	1	0			
	38	F <sup>e</sup> -LYMPHOMA	I	0	1	0	0	0			
Bone	71	M <sup>i</sup> -OSTEOSARCOMA	F	0	1	0	0	0			
			M	0	0	0	0	0			
Brain	19	B-GRANULAR CELL TUMOR	F	0	0	0	1	0			
			F	0	0	0	0	0			
	39	M-ASTROCYTOMA	F	0	0	0	0	0			
	68	M-MEDULLOBLASTOMA	F	0	0	0	0	0			
	70	M-OLIGODENDROGLIOMA	F	1	1	0	0	0			
Cecum	38	F-LYMPHOMA	M	0	0	0	1	0			
Clitoral Gland	40	M-CARCINOMA	M	0	0	0	0	0			
Eye	34	B-SCHWANNOMA, OPTIC NERVE	M	1	0	0	0	0			
			I	0	1	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	M	0	0	2	0	0			
			F	0	0	0	1	0			
	81	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)	I	0	0	0	0	0			
Kidney	25	B-LIPOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	82	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)	I	0	0	0	0	0			
			I	0	1	0	0	0			
Liver	3	B-ADENOMA, BILIARY	M	0	0	0	1	0			

**Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	M	0	0	0	0	1			
	83	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)	I	0	0	0	0	0			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	85	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MEDIASTINAL)	I	0	0	0	0	0			
	21	B-HEMANGIOMA	I	0	0	1	0	0			
LN-Mesenteric			M	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
			M	0	0	0	1	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	I	0	0	0	0	0			
	86	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MESENTERIC)	I	0	0	0	0	0			

**Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
	62	M-HEMANGIOSARCOMA	M	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	87	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-OTHER)	I	0	0	0	0	0			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	1	1	0	0	1			
			F	0	0	0	1	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
			M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	73	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)	I	1	0	0	0	0			
	79	M-STROMAL SARCOMA, METASTATIC (UTERUS)	I	0	1	0	0	0			
Mammary Gland	84	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LUNG)	I	0	0	0	0	0			
	1	B-ADENOMA	I	3	2	3	2	0			
			M	5	9	10	5	7			
			F	0	3	1	1	1			
	25	B-LIPOMA, INFILTRATIVE	M	0	1	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			

[illegible]

Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Mammary Gland	42	M-CARCINOMA	I	0	0	0	0	2			
			M	1	0	1	0	1			
			F	0	0	0	1	0			
	59	M-CARCINOSARCOMA	I	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
Mesentery	69	M-MESOTHELIOMA	M	0	0	0	0	0			
	88	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)	I	0	0	0	0	0			
Nose/Turbinates	57	M-CARCINOMA, SQUAMOUS CELL	M	1	0	0	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	1	0	0	0			
			F	1	0	0	0	0			
	1	B-ADENOMA	I	0	0	1	0	0			
	14	B-DYSGERMINOMA	I	0	0	0	0	1			
	18	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	I	0	0	0	1	0			
			M	0	0	0	1	0			
	20	B-GRANULOSA CELL TUMOR	M	0	1	1	2	1			
Ovary	26	B-LUTEOMA	M	0	0	0	1	0			
	35	B-SERTOLI CELL TUMOR	I	0	1	0	0	0			
			M	0	0	0	1	0			
	36	B-THECOMA	M	0	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	2			
	69	M-MESOTHELIOMA	M	0	0	0	0	0			

Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)

										Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					1, 6-8	2, 6-8	1&2, 6-8	
				CF	CBF	E0.2F	E2F	E5F				
Pancreas	38	F-LYMPHOMA	I	0	1	0	0	0				
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1				
	89	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)	I	0	0	0	0	0				
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	0	0	0	0	1				
			M	18	13	19	11	11				
			F	5	8	5	4	4				
	11	B-ADENOMA, PARS INTERMEDIA	M	0	2	0	1	1				
			F	0	0	0	0	1				
	55	M-CARCINOMA, PARS DISTALIS	M	2	0	1	0	0				
F			0	0	0	0	0					
Parathyroid	1	B-ADENOMA	M	0	1	0	0	0				
Salivary Gland	45	M-CARCINOMA	M	0	0	0	0	1				
Skin	15	B-FIBROMA	M	0	0	0	0	0				
	25	B-LIPOMA	M	0	0	0	1	0				
	28	B-PAPILLOMA, SQUAMOUS CELL	M	1	0	0	0	0				
	47	M-CARCINOMA, APOCRINE GLAND	F	0	1	0	0	0				
	48	M-CARCINOMA, BASAL CELL	I	1	0	0	0	0				
			M	1	0	0	0	0	0.0031			
			F	2	0	0	0	0				
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0				
	61	M-FIBROSARCOMA	F	0	0	0	0	0				
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	0	0				





Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Thymus	80	M-THYMOMA	M	0	2	0	1	0			
			F	1	0	0	0	0			
Urinary Bladder	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	1	0	0			
	58	M-CARCINOMA, TRANSITIONAL CELL	F	0	0	0	0	0			
Uterus	31	B-POLYP, ENDOMETRIAL STROMAL	I	0	2	0	1	0			
			M	4	2	5	7	2			
			F	0	0	0	0	1			
	46	M-CARCINOMA	I	0	0	0	0	0			
			M	0	0	2	0	2			
			F	1	0	1	0	2			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	1	0			
			I	0	1	0	0	0			
	77	M-SARCOMA, STROMAL	M	1	0	0	2	0			
			F	2	1	1	1	1			
Vagina	21	B-HEMANGIOMA	I	0	0	1	0	0			
	24	B-LEIOMYOMA	M	0	2	0	1	0			
	30	B-POLYP	M	1	0	0	2	1			
			F	0	0	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
	64	M-LEIOMYOSARCOMA	F	0	0	1	0	0			

**Table 5. Results of Analysis of Tumor Data – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	ESF	1, 6-8	2, 6-8	1&2, 6-8
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	I	1	0	0	0	0			
			F	0	1	0	0	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. The significance levels for the trend tests were adjusted using the Bonferroni approach to control the overall error rate to no more than 0.05 for testing the three trend tests simultaneously. If the dose trends were significant at the Bonferroni adjusted  $0.05/3 = 0.0167$  level, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Adrenal Gland	6	B <sup>d</sup> -ADENOMA, CORTICAL	M	0	0	0	1	0			
	17	B-GANGLIONEUROMA	I	0	1	0	0	0			
			M	0	0	0	1	0			
	29	B-PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	3	2	3	0	0			
Bone Marrow	38	F <sup>e</sup> -LYMPHOMA	I	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	1	0			
			F	0	0	0	0	0			
	63	M <sup>f</sup> -HISTIOCYTIC SARCOMA	F	0	0	0	0	0			
Bone	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
	27	B-OSTEOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	71	M-OSTEOSARCOMA	F	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	1	1			
Brain	38	F-LYMPHOMA	I	0	0	0	0	0			
			M	0	2	0	0	1			
	39	M-ASTROCYTOMA	F	2	0	0	0	0			
Epididymis	69	M-MESOTHELIOMA	I	0	0	0	0	0			
			M	0	0	0	0	3			0.0045
Eye	38	F-LYMPHOMA	I	0	0	0	0	0			
Harderian Gland	1	B-ADENOMA	M	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	M	0	0	0	0	0			
Jejunum	41	M-CARCINOMA	M	0	0	1	0	0			
	13	B-ADENOMA, TUBULAR	M	0	0	0	0	0			
Kidney			M	0	0	0	0	0			
	25	B-LIPOMA	F	0	0	0	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			

**Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
LN-Mandibular	38	F-LYMPHOMA	I	0	0	0	0	0			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	0			
	66	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)	I	0	0	0	0	0			
			I	0	0	0	0	0			
LN-Mesenteric	21	B-HEMANGIOMA	M	0	0	0	0	0			
			F	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	1	1	4	0			
			F	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	0			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	49	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)	I	0	1	0	0	0			
	50	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	1			
	53	M-CARCINOMA, METASTATIC (SKIN)	I	0	0	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	0			
	74	M-OSTEOSARCOMA, METASTATIC (BONE)	I	0	1	0	0	0			

Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males (Continued)

									Significant Linear Trend (Tobacco Blend)		
Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Mammary Gland	1	B-ADENOMA	M	0	2	0	0	1			
Mesentery	69	M-MESOTHELIOMA	I	0	0	0	0	0			
Nose/ Turbinates	1	B-ADENOMA	M	0	0	0	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	1	0			
			F	0	0	1	0	0			
Penis	67	M-LYMPHOMA, EPITHELIOTROPIC	F	0	0	0	0	0			
Pancreas	22	B-ISLET CELL TUMOR	I	0	0	0	1	0			
			M	1	1	0	0	0			
			F	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	51	M-CARCINOMA, EXOCRINE	I	0	0	1	0	0			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	1	0	0	0	0			
			M	9	3	10	6	4			
			F	5	7	6	4	3			
	11	B-ADENOMA, PARS INTERMEDIA	M	2	0	1	0	0			
			F	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	55	M-CARCINOMA, PARS DISTALIS	M	3	0	0	0	1			
			F	0	0	0	0	0			
	56	M-CARCINOMA, PARS INTERMEDIA	M	0	0	0	0	0			
Preputial Gland	43	M-CARCINOMA	M	0	0	0	0	0			
Prostate	1	B-ADENOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	44	M-CARCINOMA	F	0	0	0	0	0			

Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Parathyroid	1	B-ADENOMA	M	1	0	0	0	0			
Rectum	24	B-LEIOMYOMA	M	0	0	0	0	0			
Salivary Gland	32	B-SCHWANNOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
Spinal Cord	60	M-EPENDYMOMA, ANAPLASTIC	F	0	0	0	1	0			
	2	B-ADENOMA, BASAL CELL	I	0	0	0	0	0			
			M	1	1	0	0	0			
	12	B-ADENOMA, SEBACEOUS GLAND	M	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	0	0	0	0	0			
	23	B-KERATOACANTHOMA	M	0	0	0	0	0			
Skin	25	B-LIPOMA	M	1	0	0	0	0			
	28	B-PAPILLOMA, SQUAMOUS CELL	M	0	0	0	1	0			
	37	B-TRICHOEPITHELIOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	1			
			M	1	0	0	0	0			
	48	M-CARCINOMA, BASAL CELL	F	0	1	0	0	0			
			M	0	0	0	1	0			
Skin	61	M-FIBROSARCOMA	M	0	0	0	1	0			
	78	M-SCHWANNOMA	M	0	1	0	0	0			
Skeletal Muscle	75	M-RHABDOMYOSARCOMA	M	0	1	0	0	0			
	21	B-HEMANGIOMA	M	0	1	0	0	1			
			I	0	0	0	0	0			
Spleen	38	F-LYMPHOMA	F	0	0	0	1	0			
	62	M-HEMANGIOSARCOMA	M	0	1	0	0	0			

**Table 6. Results of Analysis of Tumor Data – Tobacco Blend Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Testis	9	B-ADENOMA, INTERSTITIAL CELL	M	1	1	2	3	4			
	64	M-LEIOMYOSARCOMA	F	0	0	0	0	0			
	69	M-MESOTHELIOMA	I	0	0	0	0	0			
			M	0	0	0	1	1			
	76	M-SARCOMA	F	0	0	0	0	0			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	2	1	0	0	0			
			M	9	4	3	4	6			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	0	0	0			
			M	7	7	4	3	3			
	52	M-CARCINOMA, FOLLICULAR CELL	I	0	0	0	1	0			
Thymus			M	0	1	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
			M	0	1	0	0	0			
Tongue	80	M-THYMOMA	M	1	0	0	0	1			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			
Urinary Bladder			M	0	0	0	1	0			
	58	M-CARCINOMA, TRANSITIONAL CELL	F	0	1	0	0	0			
Zymbal's Gland			M	0	0	0	2	1			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. The significance levels for the trend tests were adjusted using the Bonferroni approach to controlling the overall error rate to no more than 0.05 for testing the three trend tests simultaneously. If the dose trends were significant at the Bonferroni adjusted  $0.05/3 = 0.0167$  level, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Adrenal Gland	6	B <sup>d</sup> -ADENOMA, CORTICAL	M	0	0	0	0	0			
	17	B-GANGLIONEUROMA	I	0	1	0	0	0			
			M	0	0	0	0	0			
	29	B-PHEOCHROMOCYTOMA	I	0	0	0	0	0			
			M	3	2	1	0	0			
Bone Marrow	38	F <sup>e</sup> -LYMPHOMA	I	0	0	0	0	1			
			I	0	0	0	0	1			
	38	F-LYMPHOMA	F	0	0	0	0	1			
	63	M <sup>f</sup> -HISTIOCYTIC SARCOMA	F	0	0	1	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
Bone	27	B-OSTEOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	71	M-OSTEOSARCOMA	F	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Brain			M	0	2	0	0	0			
	39	M-ASTROCYTOMA	F	2	0	0	0	0			
			I	0	0	0	1	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	0			
			I	0	0	0	0	1			
Eye	38	F-LYMPHOMA	I	0	0	0	0	1			
Harderian Gland	1	B-ADENOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	M	0	0	2	0	0			
Jejunum	41	M-CARCINOMA	M	0	0	0	0	0			
	13	B-ADENOMA, TUBULAR	M	0	0	1	0	1			
			M	0	0	0	0	1			
	25	B-LIPOMA	F	0	0	0	1	0			
	38	F-LYMPHOMA	F	0	0	0	0	1			



**Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	0	0	0	0	1			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	1	0	0			
LN-Mandibular	38	F-LYMPHOMA	I	0	0	0	0	1			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	1			
	66	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)	I	0	0	0	1	0			
			I	0	0	0	1	0			
LN-Mesenteric	21	B-HEMANGIOMA	M	0	0	1	2	0			
			F	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	62	M-HEMANGIOSARCOMA	M	0	1	1	0	0			
			F	0	0	1	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	1	0	0			
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	1			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	1	0	1	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	49	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)	I	0	1	0	0	0			
	50	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	0			
	53	M-CARCINOMA, METASTATIC (SKIN)	I	0	0	0	0	1			
	69	M-MESOTHELIOMA	M	0	0	0	1	0			
	74	M-OSTEOSARCOMA, METASTATIC (BONE)	I	0	1	0	0	0			

**Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Mammary Gland	1	B-ADENOMA	M	0	2	1	2	1			
Mesentery	69	M-MESOTHELIOMA	I	0	0	0	1	0			
Nose/ Turbinates	1	B-ADENOMA	M	0	0	1	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
			F	0	0	0	0	0			
Penis	67	M-LYMPHOMA, EPITHELIOTROPIC	F	0	0	1	0	0			
Pancreas	22	B-ISLET CELL TUMOR	I	0	0	0	0	0			
			M	1	1	1	2	0			
			F	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	51	M-CARCINOMA, EXOCRINE	I	0	0	0	0	0			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	1	0	0	0	0			
			M	9	3	11	5	5			
			F	5	7	5	4	6			
	11	B-ADENOMA, PARS INTERMEDIA	M	2	0	1	1	1			
			F	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	55	M-CARCINOMA, PARS DISTALIS	M	3	0	0	2	0			
			F	0	0	0	0	1			
56	M-CARCINOMA, PARS INTERMEDIA	M	0	0	0	0	1				
Preputial Gland	43	M-CARCINOMA	M	0	0	0	0	1			
Prostate	1	B-ADENOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	44	M-CARCINOMA	F	0	0	0	1	0			

2000

**Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Parathyroid	1	B-ADENOMA	M	1	0	0	0	0			
Rectum	24	B-LEIOMYOMA	M	0	0	0	1	0			
Salivary Gland	32	B-SCHWANNOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Spinal Cord	60	M-EPENDYMOMA, ANAPLASTIC	F	0	0	0	0	0			
	2	B-ADENOMA, BASAL CELL	I	0	0	1	0	0			
			M	1	1	1	0	0			
	12	B-ADENOMA, SEBACEOUS GLAND	M	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	0	0	1	0	0			
	23	B-KERATOACANTHOMA	M	0	0	0	1	0			
	25	B-LIPOMA	M	1	0	0	0	0			
Skin	28	B-PAPILLOMA, SQUAMOUS CELL	M	0	0	0	0	0			
	37	B-TRICHOEPITHELIOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			
	48	M-CARCINOMA, BASAL CELL	M	1	0	0	0	0			
			F	0	1	0	0	1			
	61	M-FIBROSARCOMA	M	0	0	0	0	1			
	78	M-SCHWANNOMA	M	0	1	0	0	0			
Skeletal Muscle	75	M-RHABDOMYOSARCOMA	M	0	1	0	0	0			
	21	B-HEMANGIOMA	M	0	1	0	0	0			
			I	0	0	0	0	1			
Spleen	38	F-LYMPHOMA	F	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	1	0	0	0			



**Table 7. Results of Analysis of Tumor Data – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Testis	9	B-ADENOMA, INTERSTITIAL CELL	M	1	1	0	2	1			
	64	M-LEIOMYOSARCOMA	F	0	0	0	2	0			
	69	M-MESOTHELIOMA	I	0	0	0	1	0			
			M	0	0	0	0	0			
	76	M-SARCOMA	F	0	0	0	0	1			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	2	1	2	1	1			
			M	9	4	6	5	6			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	1	0	0	0.0104	0.0105	0.0078
			M	7	7	3	4	0			
	52	M-CARCINOMA, FOLLICULAR CELL	I	0	0	0	0	0			
			M	0	1	0	1	0			
Thymus	38	F-LYMPHOMA	I	0	0	0	0	2			
			M	0	1	0	0	1			
	80	M-THYMOMA	M	1	0	0	0	0			
Tongue	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	1	0			
Urinary Bladder	58	M-CARCINOMA, TRANSITIONAL CELL	M	0	0	0	0	0			
			F	0	1	0	0	0			
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
			F	0	0	0	1	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. The significant levels for the trend tests were adjusted using the Bonferroni approach to controlling the overall error rate to no more than 0.05 for testing the three trend tests simultaneously. If the dose trends were significant at the Bonferroni adjusted  $0.05/3 = 0.0167$  level, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**APPENDIX A**  
**TUMOR ANALYSIS RESULTS PRIOR TO MULTIPLE TEST CORRECTION**

Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Adrenal Gland	29	B <sup>d</sup> -PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	0	0	1	1	0			
			F	0	0	0	0	0			
	38	F <sup>e</sup> -LYMPHOMA	I	0	1	0	0	0			
Bone	71	M <sup>f</sup> -OSTEOSARCOMA	F	0	1	0	0	0			
Brain	19	B-GRANULAR CELL TUMOR	M	0	0	0	0	1			
			F	0	0	0	0	0			
	39	M-ASTROCYTOMA	F	0	0	0	0	1			
	68	M-MEDULLOBLASTOMA	F	0	0	0	0	1			
	70	M-OLIGODENDROGLIOMA	F	1	1	0	0	0			
Cecum	38	F-LYMPHOMA	M	0	0	0	0	0			
Clitoral Gland	40	M-CARCINOMA	M	0	0	0	0	1			
Eye	34	B-SCHWANNOMA, OPTIC NERVE	M	1	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	I	0	1	0	0	0			
			M	0	0	0	1	0			
			F	0	0	0	0	0			
	81	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)	I	0	0	0	1	0			
Kidney	25	B-LIPOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	82	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)	I	0	0	0	1	0			

**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Liver	3	B-ADENOMA, BILIARY	I	0	1	0	0	0			
			M	0	0	0	0	0			
	8	B-ADENOMA, HEPATOCELLULAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	M	0	0	0	0	0			
LN-Mediastinal	83	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)	I	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	85	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MEDIASTINAL)	I	0	0	0	1	0			
LN-Mesenteric	21	B-HEMANGIOMA	I	0	0	0	0	0			
			M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
			M	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	I	0	0	0	1	0			

Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
LN-Mesenteric	86	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MESENTERIC)	I	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	0			
LN-Other	62	M-HEMANGIOSARCOMA	M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	87	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-OTHER)	I	0	0	0	1	0			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			
			F	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	2			
			M	0	0	1	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	73	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)	I	1	0	0	0	0			
	79	M-STROMAL SARCOMA, METASTATIC (UTERUS)	I	0	1	0	0	0			
	84	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LUNG)	I	0	0	0	1	0			
Mammary Gland	1	B-ADENOMA	I	3	2	2	2	1			
			M	5	9	5	6	1		0.0042	0.0164
			F	0	3	2	2	0			



**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Mammary Gland	25	B-LIPOMA, INFILTRATIVE	M	0	1	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			
			I	0	0	0	1	0			
	42	M-CARCINOMA	M	1	0	1	0	2			
			F	0	0	1	0	2			
	59	M-CARCINOSARCOMA	I	0	0	1	0	0			
Mesentery	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	1	0	2			0.0402
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	1			
	88	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)	I	0	0	0	1	0			
Nose/Turbinates	57	M-CARCINOMA, SQUAMOUS CELL	M	1	0	0	0	0			
Oral Mucosa			M	0	1	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	F	1	0	0	1	0			
Ovary	1	B-ADENOMA	I	0	0	0	0	0			
	14	B-DYSGERMINOMA	I	0	0	0	0	0			
	18	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	I	0	0	0	0	0			
			M	0	0	0	0	0			
	20	B-GRANULOSA CELL TUMOR	M	0	1	1	0	1			
	26	B-LUTEOMA	M	0	0	0	0	0			
			I	0	1	0	0	0			
	35	B-SERTOLI CELL TUMOR	M	0	0	0	0	0			

**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Ovary	36	B-THECOMA	M	0	1	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	1			
Pancreas	38	F-LYMPHOMA	I	0	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	2	0	1			
	89	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)	I	0	0	0	1	0			
			I	0	0	0	0	1			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	M	18	13	13	12	14			
			F	5	8	7	5	2			
			M	0	2	1	0	0			
	11	B-ADENOMA, PARS INTERMEDIA	F	0	0	0	0	0			
			M	2	0	1	3	0			
	55	M-CARCINOMA, PARS DISTALIS	F	0	0	0	1	0			
Parathyroid	1	B-ADENOMA	M	0	1	0	0	0			
Salivary Gland	45	M-CARCINOMA	M	0	0	0	0	0			
Skin	15	B-FIBROMA	M	0	0	0	1	0			
	25	B-LIPOMA	M	0	0	0	0	0			
	28	B-PAPILLOMA, SQUAMOUS CELL	M	1	0	1	0	0			
	47	M-CARCINOMA, APOCRINE GLAND	F	0	1	0	0	0			
			I	1	0	0	0	0			
	48	M-CARCINOMA, BASAL CELL	M	1	0	0	0	1			
			F	2	0	0	0	0			

**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Skin	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	1	0	0			
	61	M-FIBROSARCOMA	F	0	0	0	1	0			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	1	0	0			
Skeletal Muscle	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	72	M-OSTEOSARCOMA, EXTRASKELETAL	F	1	0	0	0	0			
	75	M-RHABDOMYOSARCOMA	F	0	2	0	0	0			
Spleen	21	B-HEMANGIOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			F	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	0	0	0	0			
	90	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (SPLEEN)	I	0	0	0	1	0			
Stomach	16	B-FIBROPAPILLOMA	I	0	1	0	0	0			
			M	0	0	0	0	1			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			F	0	1	0	0	0			
			M	0	0	0	0	0			
Sternum	64	M-LEIOMYOSARCOMA	F	0	0	0	1	0			
	71	M-OSTEOSARCOMA	M	0	0	0	1	0			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	0	2	1	1	1			
			M	4	4	5	5	4			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	1	0	1			
			M	1	2	1	1	1			
	52	M-CARCINOMA, FOLLICULAR CELL	M	0	0	1	0	0			

**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Thymus	38	F-LYMPHOMA	I	1	0	0	0	0			
			M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
	80	M-THYMOMA	M	0	2	1	0	0			
			F	1	0	0	0	0			
Urinary Bladder	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			0.0486
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			
	58	M-CARCINOMA, TRANSITIONAL CELL	F	0	0	0	1	0			
Uterus	31	B-POLYP, ENDOMETRIAL STROMAL	I	0	2	0	2	0			
			M	4	2	4	3	4			
			F	0	0	0	0	1			
	46	M-CARCINOMA	I	0	0	0	1	0			
			M	0	0	2	1	4		0.0254	0.0117
			F	1	0	3	1	3			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	0	0			
	77	M-SARCOMA, STROMAL	I	0	1	0	0	0			
			M	1	0	0	0	0			
			F	2	1	0	1	0			
Vagina	21	B-HEMANGIOMA	I	0	0	0	0	0			
	24	B-LEIOMYOMA	M	0	2	0	0	0		0.0497	
	30	B-POLYP	M	1	0	0	0	0			
			F	0	0	0	2	1			
	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	1			
	64	M-LEIOMYOSARCOMA	F	0	0	0	0	0			

**Table A-1. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CF	CBF	B0.2F	B2F	B5F	1, 3-5	2, 3-5	1&2, 3-5
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	I	1	0	0	0	0			
			F	0	1	0	0	0			

- a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.  
b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.  
c. If the p-values for the dose trends were less than or equal to 0.05, then the p-values were provided in this column.  
d. B = benign.  
e. F = infiltrative.  
f. M = malignant.

**Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Adrenal Bland	29	B <sup>d</sup> -PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	0	0	0	0	0			
			F	0	0	0	1	0			
	38	F <sup>e</sup> -LYMPHOMA	I	0	1	0	0	0			
Bone	71	M <sup>f</sup> -OSTEOSARCOMA	F	0	1	0	0	0			
Brain	19	B-GRANULAR CELL TUMOR	M	0	0	0	0	0			
			F	0	0	0	1	0			
	39	M-ASTROCYTOMA	F	0	0	0	0	0			
	68	M-MEDULLOBLASTOMA	F	0	0	0	0	0			
	70	M-OLIGODENDROGLIOMA	F	1	1	0	0	0			
Cecum	38	F-LYMPHOMA	M	0	0	0	1	0			
Clitoral Gland	40	M-CARCINOMA	M	0	0	0	0	0			
Eye	34	B-SCHWANNOMA, OPTIC NERVE	M	1	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	I	0	1	0	0	0			
			M	0	0	2	0	0			
			F	0	0	0	1	0			
	81	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)	I	0	0	0	0	0			
Kidney	25	B-LIPOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	82	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)	I	0	0	0	0	0			
Liver	3	B-ADENOMA, BILIARY	I	0	1	0	0	0			
			M	0	0	0	1	0			

**Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	M	0	0	0	0	1			
	83	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)	I	0	0	0	0	0			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	85	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MEDIASTINAL)	I	0	0	0	0	0			
LN-Mesenteric	21	B-HEMANGIOMA	I	0	0	1	0	0			
			M	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
			M	0	0	0	1	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
	65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	I	0	0	0	0	0			
	86	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MESENTERIC)	I	0	0	0	0	0			

Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	1			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
	62	M-HEMANGIOSARCOMA	M	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	87	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-OTHER)	I	0	0	0	0	0			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	1	1	0	0	1			
			F	0	0	0	1	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	1	0	0	0	1			
			M	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			
	73	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)	I	1	0	0	0	0			
	79	M-STROMAL SARCOMA, METASTATIC (UTERUS)	I	0	1	0	0	0			
Mammary Gland	1	B-ADENOMA	I	3	2	3	2	0			
			M	5	9	10	5	7		0.0491	
			F	0	3	1	1	1			
	25	B-LIPOMA, INFILTRATIVE	M	0	1	0	0	0			
	38	F-LYMPHOMA	I	1	1	0	0	0			



**Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	ESF	1, 6-8	2, 6-8	1&2, 6-8
Mammary Gland	42	M-CARCINOMA	I	0	0	0	0	2			
			M	1	0	1	0	1			
			F	0	0	0	1	0			
	59	M-CARCINOSARCOMA	I	0	0	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	1	0	0	0			
Mesentery	69	M-MESOTHELIOMA	M	0	0	0	0	0			
	88	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)	I	0	0	0	0	0			
Nose/Turbinates	57	M-CARCINOMA, SQUAMOUS CELL	M	1	0	0	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	1	0	0	0			
			F	1	0	0	0	0			
	1	B-ADENOMA	I	0	0	1	0	0			
	14	B-DYSGERMINOMA	I	0	0	0	0	1			
	18	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	I	0	0	0	1	0			
			M	0	0	0	1	0			
	20	B-GRANULOSA CELL TUMOR	M	0	1	1	2	1			
Ovary	26	B-LUTEOMA	M	0	0	0	1	0			
			I	0	1	0	0	0			
	35	B-SERTOLI CELL TUMOR	M	0	0	0	1	0			
			M	0	0	0	1	0			
	36	B-THECOMA	M	0	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	2			0.0430
	69	M-MESOTHELIOMA	M	0	0	0	0	0			

Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Pancreas	38	F-LYMPHOMA	I	0	1	0	0	0			
	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	89	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)	I	0	0	0	0	0			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	0	0	0	0	1			0.0396
			M	18	13	19	11	11			
			F	5	8	5	4	4			
	11	B-ADENOMA, PARS INTERMEDIA	M	0	2	0	1	1			
			F	0	0	0	0	1			
	55	M-CARCINOMA, PARS DISTALIS	M	2	0	1	0	0			
F			0	0	0	0	0				
Parathyroid	1	B-ADENOMA	M	0	1	0	0	0			
Salivary Gland	45	M-CARCINOMA	M	0	0	0	0	1			
Skin	15	B-FIBROMA	M	0	0	0	0	0			
	25	B-LIPOMA	M	0	0	0	1	0			
	28	B-PAPILLOMA, SQUAMOUS CELL	M	1	0	0	0	0			
	47	M-CARCINOMA, APOCRINE GLAND	F	0	1	0	0	0			
	48	M-CARCINOMA, BASAL CELL	I	1	0	0	0	0			
			M	1	0	0	0	0			0.0031
			F	2	0	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			
	61	M-FIBROSARCOMA	F	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	0	0			

**Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	E5F	1, 6-8	2, 6-8	1&2, 6-8
Skeletal Muscle	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	1			
	72	M-OSTEOSARCOMA, EXTRASKELETAL	F	1	0	0	0	0			
	75	M-RHABDOMYOSARCOMA	F	0	2	0	0	0			
Spleen	21	B-HEMANGIOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			F	0	0	0	0	1			
	62	M-HEMANGIOSARCOMA	M	0	0	0	1	0			
	90	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (SPLEEN)	I	0	0	0	0	0			
Stomach	16	B-FIBROPAPILLOMA	I	0	1	0	0	0			
			M	0	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			F	0	1	0	0	0			
	64	M-LEIOMYOSARCOMA	M	0	0	0	0	1			
			F	0	0	0	0	0			
Sternum	71	M-OSTEOSARCOMA	M	0	0	0	0	0			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	0	2	0	0	1			
			M	4	4	5	5	3			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	1	1	0			
			M	1	2	1	2	2			
Thymus	52	M-CARCINOMA, FOLLICULAR CELL	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	1	0	0	0	0			
			M	0	0	1	1	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	1	0			

**Table A-2. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Females (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CF	CBF	E0.2F	E2F	ESF	1, 6-8	2, 6-8	1&2, 6-8
Thymus	80	M-THYMOMA	M	0	2	0	1	0			
			F	1	0	0	0	0			
Urinary Bladder	54	M-CARCINOMA, METASTATIC (UTERUS)	I	0	0	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	1	0	0			
	58	M-CARCINOMA, TRANSITIONAL CELL	F	0	0	0	0	0			
Uterus	31	B-POLYP, ENDOMETRIAL STROMAL	I	0	2	0	1	0			
			M	4	2	5	7	2			
			F	0	0	0	0	1			
	46	M-CARCINOMA	I	0	0	0	0	0			
			M	0	0	2	0	2			
			F	1	0	1	0	2			
	63	M-HISTIOCYTIC SARCOMA	F	0	0	0	1	0			
			I	0	1	0	0	0			
	77	M-SARCOMA, STROMAL	M	1	0	0	2	0			
			F	2	1	1	1	1			
Vagina	21	B-HEMANGIOMA	I	0	0	1	0	0			
	24	B-LEIOMYOMA	M	0	2	0	1	0			
	30	B-POLYP	M	1	0	0	2	1			
			F	0	0	0	0	0			
	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
	64	M-LEIOMYOSARCOMA	F	0	0	1	0	0			
			I	1	0	0	0	0			
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	F	0	1	0	0	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. If the p-values for the dose trends were less than or equal to 0.05, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**Table A-3. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Males**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Adrenal Gland	6	B <sup>d</sup> -ADENOMA, CORTICAL	M	0	0	0	1	0	0.0291	0.0280	
	17	B-GANGLIONEUROMA	I	0	1	0	0	0			
			M	0	0	0	1	0			
	29	B-PHEOCHROMOCYTOMA	I	0	0	1	0	0			
			M	3	2	3	0	0			
Bone Marrow	38	F <sup>e</sup> -LYMPHOMA	I	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	1	0			
			F	0	0	0	0	0			
	63	M <sup>f</sup> -HISTIOCYTIC SARCOMA	F	0	0	0	0	0			
Bone	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
	27	B-OSTEOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	71	M-OSTEOSARCOMA	F	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	1	1			
Brain	38	F-LYMPHOMA	I	0	0	0	0	0			
	39	M-ASTROCYTOMA	M	0	2	0	0	1			
			F	2	0	0	0	0			
	69	M-MESOTHELIOMA	I	0	0	0	0	0			
Epididymis			M	0	0	0	0	3	0.0236	0.0253	0.0045
Eye	38	F-LYMPHOMA	I	0	0	0	0	0			
Harderian Gland	1	B-ADENOMA	M	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	M	0	0	0	0	0			
Jejunum	41	M-CARCINOMA	M	0	0	1	0	0			
	13	B-ADENOMA, TUBULAR	M	0	0	0	0	0			
Kidney	25	B-LIPOMA	M	0	0	0	0	0			
			F	0	0	0	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			

**Table A-3. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
LN-Mandibular	38	F-LYMPHOMA	I	0	0	0	0	0			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	0			
	66	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)	I	0	0	0	0	0			
			I	0	0	0	0	0			
LN-Mesenteric	21	B-HEMANGIOMA	M	0	0	0	0	0			
			F	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	1	1	4	0			
			F	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	0	0	0			
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	0			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	49	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)	I	0	1	0	0	0			
	50	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	1			
	53	M-CARCINOMA, METASTATIC (SKIN)	I	0	0	0	0	0			
	69	M-MESOTHELIOMA	M	0	0	0	0	0			
	74	M-OSTEOSARCOMA, METASTATIC (BONE)	I	0	1	0	0	0			

**Table A-3. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Mammary Gland	1	B-ADENOMA	M	0	2	0	0	1			
Mesentery	69	M-MESOTHELIOMA	I	0	0	0	0	0			
Nose/Turbinates	1	B-ADENOMA	M	0	0	0	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	1	0			
			F	0	0	1	0	0			
Penis	67	M-LYMPHOMA, EPITHELIOTROPIC	F	0	0	0	0	0			
Pancreas	22	B-ISLET CELL TUMOR	I	0	0	0	1	0			
			M	1	1	0	0	0			
			F	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	51	M-CARCINOMA, EXOCRINE	I	0	0	1	0	0			
Pituitary Gland	10	B-ADENOMA, PARS DISTALIS	I	1	0	0	0	0	0.0334		
			M	9	3	10	6	4			
	11	B-ADENOMA, PARS INTERMEDIA	F	5	7	6	4	3			
			M	2	0	1	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			
			I	0	0	0	0	0			
	55	M-CARCINOMA, PARS DISTALIS	M	3	0	0	0	1			
			F	0	0	0	0	0			
Preputial Gland	56	M-CARCINOMA, PARS INTERMEDIA	M	0	0	0	0	0			
	43	M-CARCINOMA	M	0	0	0	0	0			
Prostate	1	B-ADENOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
	44	M-CARCINOMA	F	0	0	0	0	0			

**Table A-3. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Males (Continued)**

									Significant Linear Trend (Tobacco Blend)		
Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Parathyroid	1	B-ADENOMA	M	1	0	0	0	0			
Rectum	24	B-LEIOMYOMA	M	0	0	0	0	0			
Salivary Gland	32	B-SCHWANNOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	0			
Spinal Cord	60	M-EPENDYMOMA, ANAPLASTIC	F	0	0	0	1	0			
Skin	2	B-ADENOMA, BASAL CELL	I	0	0	0	0	0			
			M	1	1	0	0	0			
	12	B-ADENOMA, SEBACEOUS GLAND	M	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	0	0	0	0	0			
	23	B-KERATOACANTHOMA	M	0	0	0	0	0			
	25	B-LIPOMA	M	1	0	0	0	0			
	28	B-PAPILLOMA, SQUAMOUS CELL	M	0	0	0	1	0			
	37	B-TRICHOEPITHELIOMA	M	0	0	0	0	0			
	38	F-LYMPHOMA	F	0	0	0	0	1			
	48	M-CARCINOMA, BASAL CELL	M	1	0	0	0	0			
		F	0	1	0	0	0				
Skin	61	M-FIBROSARCOMA	M	0	0	0	1	0			
	78	M-SCHWANNOMA	M	0	1	0	0	0			
Skeletal Muscle	75	M-RHABDOMYOSARCOMA	M	0	1	0	0	0			
Spleen	21	B-HEMANGIOMA	M	0	1	0	0	1			
	38	F-LYMPHOMA	I	0	0	0	0	0			
			F	0	0	0	1	0			
	62	M-HEMANGIOSARCOMA	M	0	1	0	0	0			



**Table A-3. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Blend Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Blend) p-value <sup>c</sup>		
				CM	CBM	B0.2M	B2M	B5M	1, 3-5	2, 3-5	1&2, 3-5
Testis	9	B-ADENOMA, INTERSTITIAL CELL	M	1	1	2	3	4			
	64	M-LEIOMYOSARCOMA	F	0	0	0	0	0			
	69	M-MESOTHELIOMA	I	0	0	0	0	0			
			M	0	0	0	1	1			
	76	M-SARCOMA	F	0	0	0	0	0			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	2	1	0	0	0			
			M	9	4	3	4	6			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	0	0	0			
			M	7	7	4	3	3			
	52	M-CARCINOMA, FOLLICULAR CELL	I	0	0	0	1	0			
			M	0	1	0	1	0			
Thymus	38	F-LYMPHOMA	I	0	0	0	0	0			
			M	0	1	0	0	0			
	80	M-THYMOMA	M	1	0	0	0	1			
Tongue	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	0	0			
Urinary Bladder	58	M-CARCINOMA, TRANSITIONAL CELL	M	0	0	0	1	0			
			F	0	1	0	0	0			
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	2	1			
			F	0	0	0	0	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. If the p-values for the dose trends were less than or equal to 0.05, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**Table A-4. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Males**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Adrenal Gland	6	B <sup>d</sup> -ADENOMA, CORTICAL	M	0	0	0	0	0	0.0272	0.0487	
	17	B-GANGLIONEUROMA	I	0	1	0	0	0			
			M	0	0	0	0	0			
	29	B-PHEOCHROMOCYTOMA	I	0	0	0	0	0			
Bone Marrow			M	3	2	1	0	0			0.0364
	38	F <sup>e</sup> -LYMPHOMA	I	0	0	0	0	1			
	38	F-LYMPHOMA	I	0	0	0	0	1			
			F	0	0	0	0	1			
Bone	63	M <sup>f</sup> -HISTIOCYTIC SARCOMA	F	0	0	1	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
	27	B-OSTEOMA	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Brain	71	M-OSTEOSARCOMA	F	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	1	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	39	M-ASTROCYTOMA	M	0	2	0	0	0			
Epididymis			F	2	0	0	0	0			
	69	M-MESOTHELIOMA	I	0	0	0	1	0			
Eye	38	F-LYMPHOMA	M	0	0	0	0	0			
Harderian Gland	1	B-ADENOMA	I	0	0	0	0	1			
	38	F-LYMPHOMA	M	0	0	0	0	0			
Heart	33	B-SCHWANNOMA, ENDOCARDIAL	I	0	0	2	0	0			
Jejunum	41	M-CARCINOMA	M	0	0	0	0	0			
	13	B-ADENOMA, TUBULAR	M	0	0	1	0	1			
Kidney			M	0	0	0	0	1			
	25	B-LIPOMA	F	0	0	0	1	0			
	38	F-LYMPHOMA	F	0	0	0	0	1			

**Table A-4. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Liver	8	B-ADENOMA, HEPATOCELLULAR	M	0	0	0	0	1			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	1	0	0			
LN-Mandibular	38	F-LYMPHOMA	I	0	0	0	0	1			
LN-Mediastinal	38	F-LYMPHOMA	I	0	0	0	0	1			
	66	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)	I	0	0	0	1	0			
			I	0	0	0	1	0			
LN-Mesenteric	21	B-HEMANGIOMA	M	0	0	1	2	0			
			F	0	0	1	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
LN-Mesenteric	62	M-HEMANGIOSARCOMA	M	0	1	1	0	0			
			F	0	0	1	0	0			
	63	M-HISTIOCYTIC SARCOMA	I	0	0	1	0	0			
LN-Other	38	F-LYMPHOMA	I	0	0	0	0	1			
Lung	4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	M	1	0	1	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	49	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)	I	0	1	0	0	0			
	50	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR	M	0	0	0	0	0			
	53	M-CARCINOMA, METASTATIC (SKIN)	I	0	0	0	0	1			
	69	M-MESOTHELIOMA	M	0	0	0	1	0			
	74	M-OSTEOSARCOMA, METASTATIC (BONE)	I	0	1	0	0	0			

Table A-4. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Males (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Mammary Gland	1	B-ADENOMA	M	0	2	1	2	1			
Mesentery	69	M-MESOTHELIOMA	I	0	0	0	1	0			
Nose/Turbinates	1	B-ADENOMA	M	0	0	1	0	0			
Oral Mucosa	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
			F	0	0	0	0	0			
Penis	67	M-LYMPHOMA, EPITHELIOTROPIC	F	0	0	1	0	0			
			I	0	0	0	0	0			
Pancreas	22	B-ISLET CELL TUMOR	M	1	1	1	2	0			
			F	0	0	0	0	0			
			I	0	0	0	0	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Pituitary Gland	51	M-CARCINOMA, EXOCRINE	I	0	0	0	0	0			
			I	1	0	0	0	0			
	10	B-ADENOMA, PARS DISTALIS	M	9	3	11	5	5			
			F	5	7	5	4	6			
	11	B-ADENOMA, PARS INTERMEDIA	M	2	0	1	1	1			
			F	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	55	M-CARCINOMA, PARS DISTALIS	M	3	0	0	2	0			
			F	0	0	0	0	1			
	56	M-CARCINOMA, PARS INTERMEDIA	M	0	0	0	0	1			
Preputial Gland	43	M-CARCINOMA	M	0	0	0	0	1			
Prostate	1	B-ADENOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
	44	M-CARCINOMA	F	0	0	0	1	0			

Table A-4. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Males (Continued)

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Parathyroid	1	B-ADENOMA	M	1	0	0	0	0			
Rectum	24	B-LEIOMYOMA	M	0	0	0	1	0			
Salivary Gland	32	B-SCHWANNOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	I	0	0	0	0	1			
Spinal Cord	60	M-EPENDYMOMA, ANAPLASTIC	F	0	0	0	0	0			
	2	B-ADENOMA, BASAL CELL	I	0	0	1	0	0			
			M	1	1	1	0	0			
	12	B-ADENOMA, SEBACEOUS GLAND	M	0	1	0	0	0			
	19	B-GRANULAR CELL TUMOR	M	0	0	1	0	0			
	23	B-KERATOACANTHOMA	M	0	0	0	1	0			
	25	B-LIPOMA	M	1	0	0	0	0			
Skin	28	B-PAPILLOMA, SQUAMOUS CELL	M	0	0	0	0	0			
	37	B-TRICHOEPITHELIOMA	M	0	0	0	1	0			
	38	F-LYMPHOMA	F	0	0	0	0	0			
			M	1	0	0	0	0			
	48	M-CARCINOMA, BASAL CELL	F	0	1	0	0	1			
	61	M-FIBROSARCOMA	M	0	0	0	0	1			
	78	M-SCHWANNOMA	M	0	1	0	0	0			
Skeletal Muscle	75	M-RHABDOMYOSARCOMA	M	0	1	0	0	0			
	21	B-HEMANGIOMA	M	0	1	0	0	0			
Spleen	38	F-LYMPHOMA	I	0	0	0	0	1			
			F	0	0	0	0	0			
	62	M-HEMANGIOSARCOMA	M	0	1	0	0	0			

**Table A-4. Results of Analysis of Tumor Data Prior to Multiple Test Correction ( $p \leq 0.05$ ) – Tobacco Extract Males (Continued)**

Tissue	Tumor Codes	Diagnosis	Tumor Type <sup>a</sup>	Number of Tumors Observed <sup>b</sup>					Significant Linear Trend (Tobacco Extract) p-value <sup>c</sup>		
				CM	CBM	E0.2M	E2M	E5M	1, 6-8	2, 6-8	1&2, 6-8
Testis	9	B-ADENOMA, INTERSTITIAL CELL	M	1	1	0	2	1			
	64	M-LEIOMYOSARCOMA	F	0	0	0	2	0			
	69	M-MESOTHELIOMA	I	0	0	0	1	0			
			M	0	0	0	0	0			
	76	M-SARCOMA	F	0	0	0	0	1			
Thyroid Gland	5	B-ADENOMA, C-CELL	I	2	1	2	1	1			
			M	9	4	6	5	6			
	7	B-ADENOMA, FOLLICULAR CELL	I	0	0	1	0	0	0.0104	0.0105	0.0078
			M	7	7	3	4	0			
	52	M-CARCINOMA, FOLLICULAR CELL	I	0	0	0	0	0			
			M	0	1	0	1	0			
Thymus	38	F-LYMPHOMA	I	0	0	0	0	2	0.0397		
			M	0	1	0	0	1			
	80	M-THYMOMA	M	1	0	0	0	0			
Tongue	57	M-CARCINOMA, SQUAMOUS CELL	F	0	0	0	1	0			
Urinary Bladder	58	M-CARCINOMA, TRANSITIONAL CELL	M	0	0	0	0	0			
			F	0	1	0	0	0			
Zymbal's Gland	57	M-CARCINOMA, SQUAMOUS CELL	M	0	0	0	0	0			
			F	0	0	0	1	0			

a. "Mortality independent" is treated as "incidental" in the tumor analysis. In this column, M = Mortality Independent, I = Incidental, F = Fatal.

b. Number of animals per group = 60; however, the number examined per group may vary (e.g., missing tissue) and be less than 60.

c. If the p-values for the dose trends were less than or equal to 0.05, then the p-values were provided in this column.

d. B = benign.

e. F = infiltrative.

f. M = malignant.

**APPENDIX B**  
**P-VALUES FOR ALL DOSE TREND TESTS**

Table B-1. List of all p-Values for the Tumor Dose Trend Tests - Females

Sex	Tissue Code <sup>a</sup>	Diagnosis Code <sup>b</sup>	P-Value Trend <sup>c</sup> 1,3,4,5	P-Value Trend <sup>c</sup> 2,3,4,5	P-Value Trend <sup>c</sup> 1&2,3,4,5	P-Value Trend <sup>c</sup> 1,6,7,8	P-Value Trend <sup>c</sup> 2,6,7,8	P-Value Trend <sup>c</sup> 1&2,6,7,8
F	AD	29	0.734893	0.8199589	0.7328129	0.7755358	0.9790502	0.891193
F	AD	38		0.2784259	0.4272825		0.3990752	0.545036
F	BO	71		0.1701494	0.3929301		0.1622037	0.383501
F	BR	19	0.1820395	0.190995	0.0948785	0.6676367	0.6852366	0.594763
F	BR	39	0.1825479	0.183684	0.0912368			
F	BR	68	0.1798386	0.1844868	0.0913174			
F	BR	70	0.1794253	0.1768532	0.2305062	0.164873	0.1645589	0.214192
F	CE	38				0.6533533	0.6810157	0.585324
F	CL	40	0.1820395	0.190995	0.0948785			
F	EYE	34	0.1868363		0.3910727	0.1778754		0.382262
F	HT	33	0.6529491	0.6189052	0.8890447	0.7931636	0.3492946	0.422467
F	HT	81	0.6622187	0.4688902	0.461602			
F	K	25	0.1868363		0.3910727	0.1778754		0.382262
F	K	38	0.159011		0.4272825	0.2482131		0.545036
F	K	54	0.2764567	0.2002189	0.1219501			
F	K	82	0.6622187	0.4688902	0.461602			
F	LI	3		0.25147	0.418559	0.6533533	0.5139918	0.746068
F	LI	8	0.1868363		0.3910727	0.1778754		0.382262
F	LI	38	0.159011	0.2784259	0.2479995	0.9371396	0.6085902	0.527499
F	LI	54				0.2901893	0.2172382	0.158094
F	LI	63				0.2482131	0.1400165	0.059181
F	LI	65				0.1778754	0.186041	0.092741
F	LI	83	0.6622187	0.4688902	0.461602			
F	LNMED	38				0.2901893	0.2172382	0.158094
F	LNMED	54	0.2764567	0.2002189	0.1219501			
F	LNMED	63		0.25147	0.418559		0.208524	0.345526
F	LNMED	85	0.6622187	0.4688902	0.461602			
F	LNMES	21				0.3620389	0.5139918	0.367589
F	LNMES	38				0.2929301	0.234484	0.159225
F	LNMES	54	0.0969069		0.418559	0.5885857	0.2172382	0.737142
F	LNMES	63		0.25147	0.418559		0.208524	0.345526
F	LNMES	65	0.6622187	0.4688902	0.461602			
F	LNMES	86	0.6622187	0.4688902	0.461602			
F	LNO	38				0.2901893	0.2172382	0.158094
F	LNO	54	0.0969069		0.418559	0.5885857	0.2172382	0.737142
F	LNO	62				0.1778754	0.186041	0.092741
F	LNO	63				0.2482131	0.1400165	0.059181
F	LNO	87	0.6622187	0.4688902	0.461602			
F	LU	4				0.6533533	0.6810157	0.585324
F	LU	38	0.159011	0.2784259	0.2479995	0.7325454	0.5014594	0.400532
F	LU	54	0.3672164	0.0590456	0.079853	0.5885857	0.2172382	0.737142
F	LU	63				0.2482131	0.1400165	0.059181
F	LU	73	0.1797125		0.3347914	0.3319755		0.459525
F	LU	79		0.1138463	0.3347914		0.2381849	0.459525
F	LU	84	0.6622187	0.4688902	0.461602			
F	MA	1	0.1537541	0.0042252**	0.0164086**	0.702029	0.0491488*	0.179052
F	MA	25		0.1664604	0.3910727		0.158088	0.382262
F	MA	38	0.159011	0.25147	0.2592163	0.2482131	0.208524	0.264199
F	MA	42	0.2007065	0.072089	0.0617391	0.4109389	0.0873897	0.127888
F	MA	59	0.5408072	0.8326921	0.6171478			
F	ME	54	0.1540558	0.0632229	0.040172*	0.2901893	0.2172382	0.158094



Table B-1. List of all p-Values for the Tumor Dose Trend Tests – Females (Continued)

Sex	Tissue Code <sup>a</sup>	Diagnosis Code <sup>b</sup>	P-Value Trend <sup>c</sup> 1,3,4,5	P-Value Trend <sup>c</sup> 2,3,4,5	P-Value Trend <sup>c</sup> 1&2,3,4,5	P-Value Trend <sup>c</sup> 1,6,7,8	P-Value Trend <sup>c</sup> 2,6,7,8	P-Value Trend <sup>c</sup> 1&2,6,7,8
F	ME	63		0.25147	0.418559		0.208524	0.345526
F	ME	69	0.1820395	0.190995	0.0948785			
F	ME	88	0.6622187	0.4688902	0.461602			
F	NO	57	0.1868363		0.3910727	0.1778754		0.382262
F	OC	57	0.530526	0.5107821	0.5087921	0.1701926	0.158088	0.213836
F	OV	1				0.3936654	0.6692911	0.495456
F	OV	14				0.2901893	0.2172382	0.158094
F	OV	18				0.6911353	0.5652597	0.523394
F	OV	20	0.5236804	0.7439154	0.8912553	0.3652366	0.9161707	0.554887
F	OV	26				0.6533533	0.6810157	0.585324
F	OV	35		0.25147	0.418559	0.6533533	0.5139918	0.746068
F	OV	36	0.1820395	0.9570056	0.5647233		0.158088	0.382262
F	OV	54				0.1274295	0.0765195	0.0429995*
F	OV	69	0.1820395	0.190995	0.0948785			
F	PA	38		0.2784259	0.4272825		0.3990752	0.545036
F	PA	54	0.9370072	0.5481805	0.6470936	0.2901893	0.2172382	0.158094
F	PA	89	0.6622187	0.4688902	0.461602			
F	PI	10	0.2475834	0.2465169	0.1943295	0.0639096	0.0647438	0.039592*
F	PI	11	0.6634437	0.0588376	0.183734	0.07315	0.9178066	0.338085
F	PI	55	0.6237893	0.5969759	0.9700195	0.0680416	0.6169153	0.175301
F	PTHY	1		0.1664604	0.3910727		0.158088	0.382262
F	SA	45				0.1778754	0.186041	0.092741
F	SK	15	0.6529491	0.6814109	0.5845819			
F	SK	25				0.6533533	0.6810157	0.585324
F	SK	28	0.2133122	0.6265672	0.3093406	0.1778754		0.382262
F	SK	47		0.1786075	0.3939477		0.1771648	0.392881
F	SK	48	0.0532471	0.190995	0.4547422	0.0030998**		0.078115
F	SK	57	0.6632591	0.6334279	0.5665022			
F	SK	61	0.6529871	0.6760139	0.5814891			
F	SK	63	0.6547208	0.6547208	0.5700609			
F	SM	54	0.2764567	0.2002189	0.1219501	0.2901893	0.2172382	0.158094
F	SM	72	0.1809631		0.39642	0.1759208		0.390324
F	SM	75		0.0594029	0.231368		0.0539051	0.219502
F	SP	21				0.6533533	0.6810157	0.585324
F	SP	38	0.159011		0.4272825	0.7335155	0.1926988	0.252977
F	SP	62				0.6533533	0.6810157	0.585324
F	SP	90	0.6622187	0.4688902	0.461602			
F	ST	16	0.1820395	0.8806812	0.489007		0.208524	0.345526
F	ST	38	0.159011	0.1808493	0.2364142	0.2482131	0.1783309	0.290137
F	ST	64	0.6560312	0.664707	0.5772635	0.1778754	0.186041	0.092741
F	STE	71	0.6529491	0.6814109	0.5845819			
F	THG	5	0.7723454	0.8380198	0.986387	0.9306584	0.5126683	0.667618
F	THG	7	0.7595695	0.8325119	0.9546118	0.6912876	0.9689183	0.776757
F	THG	52	0.6634437	0.6265672	0.5640759			
F	THY	38	0.159011		0.4272825	0.5770907	0.9495984	0.798267
F	THY	63				0.2482131	0.1400165	0.059181
F	THY	80	0.2143246	0.0588376	0.1150433	0.5244185	0.1614437	0.299637
F	UB	54	0.1374652	0.0969503	0.0485731*			
F	UB	57				0.6321939	0.6157001	0.546599
F	UB	58	0.6563597	0.6696225	0.5799856			
F	UT	31	0.5755494	0.7126253	0.6127645	0.9325401	0.9769117	0.986282

**Table B-1. List of all p-Values for the Tumor Dose Trend Tests – Females (Continued)**

Sex	Tissue Code <sup>a</sup>	Diagnosis Code <sup>b</sup>	P-Value Trend <sup>c</sup> 1,3,4,5	P-Value Trend <sup>c</sup> 2,3,4,5	P-Value Trend <sup>c</sup> 1&2,3,4,5	P-Value Trend <sup>c</sup> 1,6,7,8	P-Value Trend <sup>c</sup> 2,6,7,8	P-Value Trend <sup>c</sup> 1&2,6,7,8
F	UT	46	0.069361	0.0253696*	0.0117453**	0.3552797	0.1514507	0.153785
F	UT	63				0.6575284	0.6725312	0.582508
F	UT	77	0.0808783	0.2494048	0.1447262	0.5143896	0.8239028	0.594449
F	VA	21				0.3936654	0.6692911	0.495456
F	VA	24		0.0497178*	0.2241135	0.6533533	0.1614437	0.48585
F	VA	30	0.6529	0.1938173	0.3241861	0.6507533	0.2131425	0.339292
F	VA	57	0.1820395	0.190995	0.0948785			
F	VA	64				0.6260302	0.6260302	0.548896
F	ZY	57	0.1868363	0.1754122	0.2270545	0.1778754	0.1618099	0.214653

\*  $p \leq 0.05$ .\*\*  $p \leq 0.0167$ .

a. Tissue codes are defined in Table B-3.

b. Diagnosis codes are defined in Table B-4.

c. Blank cells indicated a lack of variability among the groups involved in the trend tests; statistical analysis cannot be performed if the cell entries are same. These cells can be regarded as having a p-value of 1.

Table B-2. List of all p-Values for the Tumor Dose Trend Tests – Males

Sex	Tissue Code <sup>a</sup>	Diagnosis Code <sup>b</sup>	P-Value Trend <sup>c</sup> 1,3,4,5	P-Value Trend <sup>c</sup> 2,3,4,5	P-Value Trend <sup>c</sup> 1&2,3,4,5	P-Value Trend <sup>c</sup> 1,6,7,8	P-Value Trend <sup>c</sup> 2,6,7,8	P-Value Trend <sup>c</sup> 1&2,6,7,8
M	AD	6	0.6783782	0.6958991	0.606223			
M	AD	17	0.6783782	0.5801523	0.8310587		0.1413945	0.2521157
M	AD	29	0.0291381*	0.0779141	0.0280154*	0.0272032*	0.0658387	0.0486635*
M	AD	38				0.2999651	0.2490555	0.1940437
M	BM	38	0.2482131	0.2482131	0.1076889	0.0935441	0.0803907	0.036363*
M	BM	63				0.6492944	0.6492944	0.5656676
M	BO	19	0.1746154		0.379041	0.1860623		0.3982564
M	BO	27	0.1746154		0.379041	0.1860623		0.3982564
M	BO	38				0.2999651	0.2490555	0.1940437
M	BO	71		0.1678471	0.3797566		0.16989	0.383421
M	BR	19	0.8354767	0.2348535	0.4625246	0.1860623		0.3982564
M	BR	38				0.2999651	0.2490555	0.1940437
M	BR	39	0.41983	0.3810481	0.4074065	0.0553083	0.053624	0.0873548
M	EP	69	0.0235588*	0.0252965*	0.0045476**	0.9513822	0.7808396	0.8317044
M	EYE	38				0.2999651	0.2490555	0.1940437
M	HG	1	0.6373391	0.6148384	0.5480816			
M	HG	38				0.2999651	0.2490555	0.1940437
M	HT	33				0.5551981	0.5258916	0.43141
M	JE	41	0.6373391	0.6148384	0.5480816			
M	K	13				0.4871331	0.5084321	0.3927687
M	K	25				0.1882615	0.1942054	0.098273
M	K	38				0.1673606	0.1723209	0.0824086
M	LI	8				0.162626	0.1675631	0.0781928
M	LI	38				0.2999651	0.2490555	0.1940437
M	LI	63				0.8526837	0.8526837	0.7381666
M	LNMAN	38				0.2999651	0.2490555	0.1940437
M	LNMED	38				0.2999651	0.2490555	0.1940437
M	LNMED	66				0.1442921	0.2635525	0.0644064
M	LNMES	21				0.9959692	0.8978425	0.9087974
M	LNMES	38				0.2999651	0.2490555	0.1940437
M	LNMES	62	0.3055599	0.7069349	0.3948428	0.5502428	0.1924151	0.2568748
M	LNMES	63				0.8526837	0.8526837	0.7381666
M	LNO	38				0.2999651	0.2490555	0.1940437
M	LU	4	0.1746154		0.379041	0.4687862	0.9892324	0.6440819
M	LU	38				0.2999651	0.2490555	0.1940437
M	LU	49		0.2482131	0.4717298		0.2652054	0.51913
M	LU	50	0.1933348	0.198826	0.1027676			
M	LU	53				0.2999651	0.2490555	0.1940437
M	LU	69				0.6240703	0.6409502	0.5464798
M	LU	74		0.3710934	0.5730641		0.1948351	0.2940719
M	MA	1	0.1933348	0.3810481	0.9409672	0.3232468	0.7230584	0.7655903
M	ME	69				0.9513822	0.7808396	0.8317044
M	NO	1				0.6773266	0.6546331	0.5787696
M	OC	57	0.9671777	0.9362394	0.9512955			
M	P	67				0.6660376	0.6493816	0.5731535
M	PA	22	0.8878425	0.7244647	0.7697754	0.7024046	0.6589982	0.6395215
M	PA	38				0.2999651	0.2490555	0.1940437
M	PA	51	1	1	0.7994953			
M	PI	10	0.0334173*	0.1730568	0.0532884	0.2173503	0.793893	0.3788936
M	PI	11	0.0644747	0.6148384	0.1712949	0.7594615	0.3589534	0.7820405
M	PI	38				0.2999651	0.2490555	0.1940437

Table B-2. List of all p-Values for the Tumor Dose Trend Tests – Males (Continued)

Sex	Tissue Code <sup>a</sup>	Diagnosis Code <sup>b</sup>	P-Value Trend <sup>c</sup> 1,3,4,5	P-Value Trend <sup>c</sup> 2,3,4,5	P-Value Trend <sup>c</sup> 1&2,3,4,5	P-Value Trend <sup>c</sup> 1,6,7,8	P-Value Trend <sup>c</sup> 2,6,7,8	P-Value Trend <sup>c</sup> 1&2,6,7,8
M	PI	55	0.1626235	0.198826	0.6123088	0.4945211	0.1905286	0.8764369
M	PI	56				0.162626	0.1675631	0.0781928
M	PRE	43				0.162626	0.1675631	0.0781928
M	PRO	1				0.6240703	0.6409502	0.5464798
M	PRO	38				0.2999651	0.2490555	0.1940437
M	PRO	44				0.6357032	0.6438995	0.5555603
M	PTHY	1	0.1746154		0.379041	0.1860623		0.3982564
M	R	24				0.6240703	0.6409502	0.5464798
M	SA	32				0.6240703	0.6409502	0.5464798
M	SA	38				0.2999651	0.2490555	0.1940437
M	SC	60	0.657434	0.6609956	0.5755873			
M	SK	2	0.1746154	0.1623474	0.2125628	0.2630846	0.2469818	0.1923334
M	SK	12		0.1623474	0.379041		0.1735008	0.3982564
M	SK	19				0.6773266	0.6546331	0.5787696
M	SK	23				0.6240703	0.6409502	0.5464798
M	SK	25	0.1746154		0.379041	0.1860623		0.3982564
M	SK	28	0.6783782	0.6958991	0.606223			
M	SK	37				0.6240703	0.6409502	0.5464798
M	SK	38	0.1903474	0.1891511	0.0972585			
M	SK	48	0.1746154	0.178598	0.2204124	0.9838939	0.9866301	0.9997408
M	SK	61	0.6783782	0.6958991	0.606223	0.162626	0.1675631	0.0781928
M	SK	78		0.1623474	0.379041		0.1735008	0.3982564
M	SM	75		0.1623474	0.379041		0.1735008	0.3982564
M	SP	21	0.1933348	0.9365385	0.5941991		0.1735008	0.3982564
M	SP	38	0.6547208	0.6582374	0.5721718	0.2999651	0.2490555	0.1940437
M	SP	62		0.1623474	0.379041		0.1735008	0.3982564
M	TE	9	0.1797416	0.2058349	0.1156224	0.5952943	0.6314618	0.5644214
M	TE	64				0.5337374	0.5374432	0.4308169
M	TE	69	0.2239762	0.2348535	0.1281929	0.9513822	0.7808396	0.8317044
M	TE	76				0.1831182	0.1843026	0.0936926
M	THG	5	0.156193	0.7334487	0.5333626	0.2825365	0.6327091	0.6348172
M	THG	7	0.1146405	0.0869707	0.076109	0.010398**	0.0104615**	0.0078204**
M	THG	52	0.3773506	0.9937884	0.7087368	0.6240703	0.5258916	0.8640189
M	THY	38		0.1623474	0.379041	0.0397054*	0.228756	0.0707953
M	THY	80	0.967914	0.198826	0.5941991	0.1860623		0.3982564
M	TO	57				0.6639584	0.6639584	0.5797958
M	UB	58	0.6783782	0.5015598	0.8185545		0.1797125	0.3942459
M	ZY	57	0.2164713	0.2304345	0.1227225	0.643002	0.6470203	0.5613725

\* p ≤ 0.05.

\*\* p ≤ 0.0167.

a. Tissue codes are defined in Table B-3.

b. Diagnosis codes are defined in Table B-4.

c. Blank cells indicated a lack of variability among the groups involved in the trend tests; statistical analysis cannot be performed if the cell entries are same. These cells can be treated as having a p-value of 1.

**Table B-3. Tissue Codes Used for Statistical Analyses**

<b>Tissue Code</b>	<b>Tissue</b>
AD	ADRENAL GLAND
BO	BONE
BM	BONE MARROW
BR	BRAIN
CE	CECUM
CL	CLITORAL GLAND
EP	EPIDIDYIMIDES
EYE	EYE
HG	HARDERIAN GLAND
HT	HEART
JE	JEJUNUM
K	KIDNEY
LI	LIVER
LNMAN	LYMPH NODE, MANDIBULAR
LNMED	LYMPH NODE, MEDIASTINAL
LNMES	LYMPH NODE, MESENTERIC
LNO	LYMPH NODE, OTHER
LU	LUNG
MA	MAMMARY GLAND
ME	MESENTERY
NO	NOSE/TURBINATES
OC	ORAL MUCOSA
OV	OVARY
PA	PANCREAS
PTHY	PARATHYROID
P	PENIS
PI	PITUITARY GLAND
PRE	PREPUTIAL GLAND
PRO	PROSTATE
R	RECTUM
SA	SALIVARY GLAND
SM	SKELETAL MUSCLE
SK	SKIN
SC	SPINAL CORD
SP	SPLEEN
STE	STERNUM

**Table B-3. Tissue Codes Used for Statistical Analyses (Continued)**

<b>Tissue Code</b>	<b>Tissue</b>
ST	STOMACH
TE	TESTES
THY	THYMUS
THG	THYROID GLAND
TO	TONGUE
UB	URINARY BLADDER
UT	UTERUS
VA	VAGINA
ZY	ZYMBAL'S GLAND

**Table B-4. Diagnosis Codes Used for Statistical Analyses**

<b>Diagnosis Code</b>	<b>Tumor Diagnosis</b>
1	B-ADENOMA
2	B-ADENOMA, BASAL CELL
3	B-ADENOMA, BILIARY
4	B-ADENOMA, BRONCHIOLAR-ALVEOLAR
5	B-ADENOMA, C-CELL
6	B-ADENOMA, CORTICAL
7	B-ADENOMA, FOLLICULAR CELL
8	B-ADENOMA, HEPATOCELLULAR
9	B-ADENOMA, INTERSTITIAL CELL
10	B-ADENOMA, PARS DISTALIS
11	B-ADENOMA, PARS INTERMEDIA
12	B-ADENOMA, SEBACEOUS GLAND
13	B-ADENOMA, TUBULAR
14	B-DYSGERMINOMA
15	B-FIBROMA
16	B-FIBROPAPILLOMA
17	B-GANGLIONEUROMA
18	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED
19	B-GRANULAR CELL TUMOR
20	B-GRANULOSA CELL TUMOR
21	B-HEMANGIOMA
22	B-ISLET CELL TUMOR
23	B-KERATOACANTHOMA
24	B-LEIOMYOMA
25	B-LIPOMA
26	B-LUTEOMA
27	B-OSTEOMA
28	B-PAPILLOMA, SQUAMOUS CELL
29	B-PHEOCHROMOCYTOMA
30	B-POLYP
31	B-POLYP, ENDOMETRIAL STROMAL
32	B-SCHWANNOMA
33	B-SCHWANNOMA, ENDOCARDIAL
34	B-SCHWANNOMA, OPTIC NERVE

**Table B-4. Diagnosis Codes Used for Statistical Analyses (Continued)**

<b>Diagnosis Code</b>	<b>Tumor Diagnosis</b>
35	B-SERTOLI CELL TUMOR
36	B-THECOMA
37	B-TRICHOEPITHELIOMA
38	F-LYMPHOMA
39	M-ASTROCYTOMA
40	M-CARCINOMA [clitoral gland] <sup>a</sup>
41	M-CARCINOMA [jejunum] <sup>a</sup>
42	M-CARCINOMA [mammary gland] <sup>a</sup>
43	M-CARCINOMA [preputial gland] <sup>a</sup>
44	M-CARCINOMA [prostate] <sup>a</sup>
45	M-CARCINOMA [salivary gland] <sup>a</sup>
46	M-CARCINOMA [uterus] <sup>a</sup>
47	M-CARCINOMA, APOCRINE GLAND
48	M-CARCINOMA, BASAL CELL
49	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)
50	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR
51	M-CARCINOMA, EXOCRINE
52	M-CARCINOMA, FOLLICULAR CELL
53	M-CARCINOMA, METASTATIC (SKIN)
54	M-CARCINOMA, METASTATIC (UTERUS)
55	M-CARCINOMA, PARS DISTALIS
56	M-CARCINOMA, PARS INTERMEDIA
57	M-CARCINOMA, SQUAMOUS CELL
58	M-CARCINOMA, TRANSITIONAL CELL
59	M-CARCINOSARCOMA
60	M-EPENDYMOMA, ANAPLASTIC
61	M-FIBROSARCOMA
62	M-HEMANGIOSARCOMA
63	M-HISTIOCYTIC SARCOMA
64	M-LEIOMYOSARCOMA
65	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)
66	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)
67	M-LYMPHOMA, EPITHELIOTROPIC
68	M-MEDULLOBLASTOMA



**Table B-4. Diagnosis Codes Used for Statistical Analyses (Continued)**

<b>Diagnosis Code</b>	<b>Tumor Diagnosis</b>
69	M-MESOTHELIOMA
70	M-OLIGODENDROGLIOMA
71	M-OSTEOSARCOMA
72	M-OSTEOSARCOMA, EXTRASKELETAL
73	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)
74	M-OSTEOSARCOMA, METASTATIC (BONE)
75	M-RHABDOMYOSARCOMA
76	M-SARCOMA
77	M-SARCOMA, STROMAL
78	M-SCWANNOMA
79	M-STROMAL SARCOMA, METASTATIC (UTERUS)
80	M-THYMOMA
81	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)
82	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)
83	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)
84	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LUNG)
85	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LYMPH NODE, MEDIASTINAL)
86	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LYMPH NODE, MESENTERIC)
87	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LYMPH NODE, OTHER)
88	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)
89	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)
90	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (SPLEEN)

a. Entries in brackets clarify the tissue site and are assigned unique codes to designate discrete tumor types, but they are not included in the raw microscopic data in order to avoid redundancy.

**APPENDIX C**  
**DATA SET FOR TUMOR INCIDENCE AND**  
**SURVIVAL STATISTICAL ANALYSIS**

**Table C-1. Data Set for Tumor Incidence and Survival Analyses**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1121	F	1	458	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1121	F	1	458	U2	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1121	F	1	458	U2	UTERUS		INFLAMMATION		
1122	F	1	603	U2	HEART		CARDIOMYOPATHY		
1122	F	1	603	U2	KIDNEY		CYST(S), TUBULAR		
1122	F	1	603	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1122	F	1	603	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1122	F	1	603	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1123	F	1	464	U2	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1123	F	1	464	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1123	F	1	464	U2	KIDNEY		INFLAMMATION		
1123	F	1	464	U2	LUNG	LU	M-OSTEOSARCOMA, METASTATIC (SKELETAL MUSCLE)	73	I
1123	F	1	464	U2	SKELETAL MUSCLE	SM	M-OSTEOSARCOMA, EXTRASKELETAL	72	F
1123	F	1	464	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1123	F	1	464	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1124	F	1	612	U2	BRAIN	BR	M-OLIGODENDROGLIOMA	70	F
1124	F	1	612	U2	KIDNEY		NEPHROPATHY		
1124	F	1	612	U2	OVARY		CYST(S)		
1124	F	1	612	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1124	F	1	612	U2	SPLEEN		ATROPHY, LYMPHOID		
1124	F	1	612	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
1124	F	1	612	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1125	F	1	729	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1125	F	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1125	F	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1125	F	1	729	FS	KIDNEY		NEPHROPATHY		
1125	F	1	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1125	F	1	729	FS	LUNG		INFLAMMATION		
1125	F	1	729	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1125	F	1	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1126	F	1	729	FS	LUNG		INFLAMMATION		
1126	F	1	729	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1126	F	1	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
1126	F	1	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1127	F	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1127	F	1	729	FS	HEART		CARDIOMYOPATHY		
1127	F	1	729	FS	KIDNEY		INFLAMMATION		
1127	F	1	729	FS	KIDNEY		NEPHROPATHY		
1127	F	1	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1127	F	1	729	FS	LUNG		INFLAMMATION		
1127	F	1	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1127	F	1	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1128	F	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1128	F	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1128	F	1	729	FS	HEART		CARDIOMYOPATHY		
1128	F	1	729	FS	LIVER		CYST(S), BILE DUCTS		
1128	F	1	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
1128	F	1	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1128	F	1	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1128	F	1	729	FS	UTERUS	UT	M-SARCOMA, STROMAL	77	M
1129	F	1	596	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1129	F	1	596	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1129	F	1	596	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
1130	F	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1130	F	1	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1130	F	1	731	FS	HEART		CARDIOMYOPATHY		
1130	F	1	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1130	F	1	731	FS	OVARY		CYST(S)		
1130	F	1	731	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1131	F	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1131	F	1	731	FS	HEART		CARDIOMYOPATHY		
1131	F	1	731	FS	OVARY		CYST(S)		
1131	F	1	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1131	F	1	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1132	F	1	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1132	F	1	731	FS	OVARY		CYST(S)		
1132	F	1	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1132	F	1	731	FS	STOMACH		MINERALIZATION		
1133	F	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1133	F	1	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1133	F	1	731	FS	KIDNEY		NEPHROPATHY		
1133	F	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1133	F	1	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1134	F	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1134	F	1	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1134	F	1	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1134	F	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1135	F	1	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1135	F	1	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1136	F	1	400	U2	KIDNEY		NEPHROPATHY		
1136	F	1	400	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1136	F	1	400	U2	SKIN	SK	M-CARCINOMA, BASAL CELL	48	F
1137	F	1	731	FS	KIDNEY		NEPHROPATHY		
1137	F	1	731	FS	LIVER		DILATATION, BILE DUCT		
1137	F	1	731	FS	SPLEEN		FIBROSIS		
1137	F	1	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1138	F	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1139	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1139	F	1	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1139	F	1	735	FS	HEART		CARDIOMYOPATHY		
1139	F	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
1139	F	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1139	F	1	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1139	F	1	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1140	F	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1140	F	1	735	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1140	F	1	735	FS	LIVER		CYST(S), BILE DUCTS		
1140	F	1	735	FS	LIVER		FOCUS, EOSINOPHILIC		
1140	F	1	735	FS	LIVER		LIPIDOSIS, DIFFUSE		
1140	F	1	735	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1140	F	1	735	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1140	F	1	735	FS	STOMACH		ULCER, NON-GLANDULAR		
1140	F	1	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1140	F	1	735	FS	VAGINA	VA	B-POLYP	30	M
1141	F	1	540	U2	HEART		CARDIOMYOPATHY		
1141	F	1	540	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1141	F	1	540	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1141	F	1	540	U2	THYMUS	THY	M-THYMOMA	80	F
1142	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1142	F	1	735	FS	KIDNEY		NEPHROPATHY		
1142	F	1	735	FS	LIVER		FIBROSIS		
1142	F	1	735	FS	LIVER		HEMOSIDERIN PIGMENT		
1142	F	1	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1142	F	1	735	FS	LIVER		TELANGIECTASIS		
1142	F	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1142	F	1	735	FS	SKIN		ULCER, EPIDERMIS		
1142	F	1	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1142	F	1	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1143	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1143	F	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1143	F	1	735	FS	KIDNEY		NEPHROPATHY		
1143	F	1	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1143	F	1	735	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1143	F	1	735	FS	MAMMARY GLAND		HYPERPLASIA		
1143	F	1	735	FS	OVARY		CYST(S)		
1143	F	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1143	F	1	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1144	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1144	F	1	735	FS	HEART		CARDIOMYOPATHY		
1144	F	1	735	FS	KIDNEY	K	B-LIPOMA	25	M
1144	F	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
1144	F	1	735	FS	OVARY		CYST(S)		
1144	F	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1144	F	1	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1145	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1145	F	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1145	F	1	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1145	F	1	735	FS	HEART		CARDIOMYOPATHY		
1145	F	1	735	FS	KIDNEY		HYDRONEPHROSIS		
1145	F	1	735	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1145	F	1	735	FS	KIDNEY		INFLAMMATION		
1145	F	1	735	FS	KIDNEY		NEPHROPATHY		
1145	F	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1145	F	1	735	FS	PANCREAS		ATROPHY, ACINAR CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1145	F	1	735	FS	PANCREAS		LIPOMATOSIS		
1145	F	1	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1145	F	1	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1146	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1146	F	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1146	F	1	735	FS	HEART		CARDIOMYOPATHY		
1146	F	1	735	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1146	F	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1146	F	1	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1146	F	1	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1146	F	1	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1147	F	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1147	F	1	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1147	F	1	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1147	F	1	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
1147	F	1	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1148	F	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1148	F	1	737	FS	HEART		CARDIOMYOPATHY		
1148	F	1	737	FS	KIDNEY		NEPHROPATHY		
1148	F	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1148	F	1	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1149	F	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1149	F	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1149	F	1	737	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1149	F	1	737	FS	SKIN	SK	B-PAPILLOMA, SQUAMOUS CELL	28	M
1149	F	1	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1150	F	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1150	F	1	737	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1150	F	1	737	FS	KIDNEY		NEPHROPATHY		
1150	F	1	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1150	F	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1150	F	1	737	FS	TRACHEA		INFLAMMATION		
1151	F	1	737	FS	CLITORAL GLAND		INFLAMMATION		
1151	F	1	737	FS	HEART		CARDIOMYOPATHY		
1151	F	1	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1151	F	1	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1151	F	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1151	F	1	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1152	F	1	703	U2	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1152	F	1	703	U2	KIDNEY		HYDRONEPHROSIS		
1152	F	1	703	U2	KIDNEY		NEPHROPATHY		
1152	F	1	703	U2	LN-MESENTERIC	LNMES	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1152	F	1	703	U2	LN-OTHER	LNO	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1152	F	1	703	U2	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1152	F	1	703	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1152	F	1	703	U2	UTERUS	UT	M-CARCINOMA	46	F
1152	F	1	703	U2	UTERUS		INFLAMMATION		
1153	F	1	737	FS	LIVER		LIPIDOSIS, FOCAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1153	F	1	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1153	F	1	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1154	F	1	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1154	F	1	741	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1154	F	1	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1154	F	1	741	FS	PANCREAS		LIPOMATOSIS		
1155	F	1	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1155	F	1	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1155	F	1	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1155	F	1	741	FS	PANCREAS		ATROPHY, ACINAR CELL		
1155	F	1	741	FS	PANCREAS		LIPOMATOSIS		
1155	F	1	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1156	F	1	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1156	F	1	741	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1156	F	1	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1156	F	1	741	FS	LIVER		INFLAMMATION		
1156	F	1	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1156	F	1	741	FS	RECTUM		METAZOAN PARASITE(S)		
1156	F	1	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1157	F	1	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1157	F	1	741	FS	HEART		CARDIOMYOPATHY		
1157	F	1	741	FS	KIDNEY		NEPHROPATHY		
1157	F	1	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1158	F	1	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1158	F	1	741	FS	KIDNEY		NEPHROPATHY		
1158	F	1	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1158	F	1	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1159	F	1	741	FS	HEART		CARDIOMYOPATHY		
1159	F	1	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1159	F	1	741	FS	OVARY		CYST(S)		
1159	F	1	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1159	F	1	741	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1160	F	1	680	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1160	F	1	680	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1160	F	1	680	U2	EYE		INFLAMMATION, OCULAR		
1160	F	1	680	U2	KIDNEY		INFLAMMATION		
1160	F	1	680	U2	KIDNEY		NEPHROPATHY		
1160	F	1	680	U2	LIVER		CYST(S), BILE DUCTS		
1160	F	1	680	U2	NOSE/TURBINATES		INFLAMMATION		
1160	F	1	680	U2	ORAL MUCOSA	OC	M-CARCINOMA, SQUAMOUS CELL	57	F
1160	F	1	680	U2	PANCREAS		ATROPHY, ACINAR CELL		
1160	F	1	680	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1160	F	1	680	U2	SKIN	SK	M-CARCINOMA, BASAL CELL	48	I
1160	F	1	680	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1160	F	1	680	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1161	F	1	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1161	F	1	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1161	F	1	741	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1161	F	1	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1161	F	1	741	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1161	F	1	741	FS	MAMMARY GLAND		INFLAMMATION		
1161	F	1	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1161	F	1	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1162	F	1	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1162	F	1	741	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1162	F	1	741	FS	LIVER	LI	B-ADENOMA, HEPATOCELLULAR	8	M
1162	F	1	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1162	F	1	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1163	F	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1163	F	1	743	FS	EYE	EYE	B-SCHWANNOMA, OPTIC NERVE	34	M
1163	F	1	743	FS	EYE		ATROPHY, RETINA		
1164	F	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1164	F	1	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1164	F	1	743	FS	HEART		CARDIOMYOPATHY		
1164	F	1	743	FS	KIDNEY		NEPHROPATHY		
1164	F	1	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1164	F	1	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1165	F	1	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1165	F	1	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1165	F	1	743	FS	LUNG		INFLAMMATION		
1165	F	1	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1165	F	1	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1165	F	1	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1166	F	1	743	FS	HEART		CARDIOMYOPATHY		
1166	F	1	743	FS	KIDNEY		NEPHROPATHY		
1166	F	1	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1166	F	1	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1166	F	1	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1167	F	1	743	FS	HEART		CARDIOMYOPATHY		
1167	F	1	743	FS	KIDNEY		NEPHROPATHY		
1167	F	1	743	FS	LIVER		FOCUS, CLEAR CELL		
1167	F	1	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1167	F	1	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1167	F	1	743	FS	SKIN	SK	M-CARCINOMA, BASAL CELL	48	M
1167	F	1	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1167	F	1	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1167	F	1	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1168	F	1	591	U1	HEART		INFLAMMATION		
1168	F	1	591	U1	KIDNEY		INFLAMMATION		
1168	F	1	591	U1	LUNG		INFLAMMATION		
1168	F	1	591	U1	NOSE/TURBINATES		INFLAMMATION		
1168	F	1	591	U1	OVARY		CYST(S)		
1169	F	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1169	F	1	743	FS	KIDNEY		MINERALIZATION		
1169	F	1	743	FS	KIDNEY		NEPHROPATHY		
1169	F	1	743	FS	LIVER		FOCUS, BASOPHILIC CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1169	F	1	743	FS	LIVER		FOCUS, EOSINOPHILIC		
1169	F	1	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1169	F	1	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1169	F	1	743	FS	OVARY		CYST(S)		
1170	F	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1170	F	1	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1170	F	1	743	FS	HEART		CARDIOMYOPATHY		
1170	F	1	743	FS	KIDNEY		NEPHROPATHY		
1170	F	1	743	FS	LN-MANDIBULAR		CYSTIC DEGENERATION		
1170	F	1	743	FS	LN-MESENTERIC		CYSTIC DEGENERATION		
1170	F	1	743	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1170	F	1	743	FS	SPLEEN		CYST(S)		
1170	F	1	743	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1170	F	1	743	FS	TONGUE		HYPERPLASIA, MUCOSAL EPITHELIUM		
1170	F	1	743	FS	TONGUE		INFLAMMATION, CHRONIC		
1171	F	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1171	F	1	743	FS	HEART		CARDIOMYOPATHY		
1171	F	1	743	FS	KIDNEY		NEPHROPATHY		
1171	F	1	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1171	F	1	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1171	F	1	743	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1171	F	1	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1171	F	1	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1172	F	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1172	F	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1172	F	1	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1172	F	1	745	FS	HEART		CARDIOMYOPATHY		
1172	F	1	745	FS	KIDNEY		NEPHROPATHY		
1172	F	1	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1172	F	1	745	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1172	F	1	745	FS	OVARY		CYST(S)		
1172	F	1	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1172	F	1	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1173	F	1	720	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1173	F	1	720	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1173	F	1	720	U2	MAMMARY GLAND		HYPERPLASIA		
1173	F	1	720	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1174	F	1	744	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1174	F	1	744	U2	MAMMARY GLAND		CYST(S), DUCTAL		
1174	F	1	744	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1174	F	1	744	U2	SKIN	SK	M-CARCINOMA, BASAL CELL	48	F
1174	F	1	744	U2	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	I
1175	F	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1175	F	1	745	FS	EYE		ULCER, CORNEA		
1175	F	1	745	FS	HEART		CARDIOMYOPATHY		
1175	F	1	745	FS	KIDNEY		NEPHROPATHY		
1175	F	1	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1175	F	1	745	FS	NOSE/TURBINATES	NO	M-CARCINOMA, SQUAMOUS CELL	57	M



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1175	F	1	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1176	F	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1176	F	1	745	FS	OVARY		CYST(S)		
1176	F	1	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1176	F	1	745	FS	SPLEEN		ATROPHY, LYMPHOID		
1176	F	1	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1176	F	1	745	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1177	F	1	735	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1177	F	1	735	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1177	F	1	735	U2	KIDNEY		INFARCT, CHRONIC		
1177	F	1	735	U2	KIDNEY		NEPHROPATHY		
1177	F	1	735	U2	OVARY		ATROPHY		
1177	F	1	735	U2	STOMACH		ULCER, NON-GLANDULAR		
1177	F	1	735	U2	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1178	F	1	546	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1178	F	1	546	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1178	F	1	546	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1179	F	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1179	F	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1179	F	1	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1179	F	1	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1179	F	1	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1180	F	1	549	U2	KIDNEY	K	F-LYMPHOMA	38	I
1180	F	1	549	U2	LIVER	LI	F-LYMPHOMA	38	I

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1180	F	1	549	U2	LUNG	LU	F-LYMPHOMA	38	I
1180	F	1	549	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1180	F	1	549	U2	MAMMARY GLAND	MA	F-LYMPHOMA	38	I
1180	F	1	549	U2	OVARY		CYST(S)		
1180	F	1	549	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1180	F	1	549	U2	SKIN		ULCER, EPIDERMIS		
1180	F	1	549	U2	SPLEEN	SP	F-LYMPHOMA	38	I
1180	F	1	549	U2	STOMACH	ST	F-LYMPHOMA	38	I
1180	F	1	549	U2	THYMUS	THY	F-LYMPHOMA	38	I
1201	F	2	715	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1201	F	2	715	U2	KIDNEY		MINERALIZATION		
1201	F	2	715	U2	LIVER	LI	B-ADENOMA, BILIARY	3	I
1201	F	2	715	U2	LIVER		FOCUS, BASOPHILIC CELL		
1201	F	2	715	U2	LIVER		LIPIDOSIS, FOCAL		
1201	F	2	715	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1201	F	2	715	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1201	F	2	715	U2	STOMACH	ST	B-FIBROPAPILLOMA	16	I
1201	F	2	715	U2	UTERUS	UT	M-SARCOMA, STROMAL	77	I
1202	F	2	729	FS	KIDNEY		CYST(S), TUBULAR		
1202	F	2	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1202	F	2	729	FS	MAMMARY GLAND	MA	B-LIPOMA, INFILTRATIVE	25	M
1202	F	2	729	FS	MAMMARY GLAND		FIBROSIS, PERIDUCTAL		
1202	F	2	729	FS	MAMMARY GLAND		HYPERPLASIA		
1202	F	2	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1202	F	2	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1202	F	2	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1203	F	2	512	U2	KIDNEY		NEPHROPATHY		
1203	F	2	512	U2	LIVER		FOCUS, BASOPHILIC CELL		
1203	F	2	512	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1203	F	2	512	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	I
1203	F	2	512	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1204	F	2	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1204	F	2	729	FS	HEART		CARDIOMYOPATHY		
1204	F	2	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1204	F	2	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1205	F	2	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1205	F	2	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1205	F	2	729	FS	OVARY		CYST(S)		
1205	F	2	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1206	F	2	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1206	F	2	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1206	F	2	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1206	F	2	729	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1206	F	2	729	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1206	F	2	729	FS	RECTUM		METAZOAN PARASITE(S)		
1206	F	2	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1206	F	2	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1207	F	2	486	U2	CLITORAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1207	F	2	486	U2	LIVER		FOCUS, BASOPHILIC CELL		
1207	F	2	486	U2	SKELETAL MUSCLE	SM	M-RHABDOMYOSARCOMA	75	F
1207	F	2	486	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1207	F	2	486	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1207	F	2	486	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1208	F	2	365	U2	LIVER		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1208	F	2	365	U2	LUNG	LU	M-STROMAL SARCOMA, METASTATIC (UTERUS)	79	I
1208	F	2	365	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1208	F	2	365	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1208	F	2	365	U2	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1209	F	2	729	FS	HEART		CARDIOMYOPATHY		
1209	F	2	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1209	F	2	729	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1209	F	2	729	FS	PARATHYROID	PTHY	B-ADENOMA	1	M
1209	F	2	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1209	F	2	729	FS	SKIN		FIBROSIS, DERMIS		
1210	F	2	731	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1210	F	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1210	F	2	731	FS	MESENTERY		NECROSIS, MESENTERIC FAT		
1210	F	2	731	FS	OVARY		CYST(S)		
1210	F	2	731	FS	PANCREAS		INFLAMMATION		
1210	F	2	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1211	F	2	731	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1211	F	2	731	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1211	F	2	731	FS	KIDNEY		NEPHROPATHY		
1211	F	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1211	F	2	731	FS	OVARY		CYST(S)		
1211	F	2	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1211	F	2	731	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1211	F	2	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1211	F	2	731	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1211	F	2	731	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1211	F	2	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1212	F	2	511	U2	LIVER		FOCUS, BASOPHILIC CELL		
1212	F	2	511	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1212	F	2	511	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1212	F	2	511	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1213	F	2	693	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1213	F	2	693	U2	HEART		CARDIOMYOPATHY		
1213	F	2	693	U2	LIVER		FOCUS, BASOPHILIC CELL		
1213	F	2	693	U2	LIVER		LIPIDOSIS, FOCAL		
1213	F	2	693	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1213	F	2	693	U2	OVARY	OV	B-SERTOLI CELL TUMOR	35	I
1213	F	2	693	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1213	F	2	693	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1213	F	2	693	U2	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1213	F	2	693	U2	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	F
1214	F	2	647	U1	EYE		INFLAMMATION, OCULAR		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1214	F	2	647	U1	LIVER		FOCUS, BASOPHILIC CELL		
1214	F	2	647	U1	MAMMARY GLAND	MA	B-ADENOMA	1	I
1214	F	2	647	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1214	F	2	647	U1	THYROID GLAND		HYPERPLASIA, C-CELL		
1215	F	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1215	F	2	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1215	F	2	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1216	F	2	609	U2	CLITORAL GLAND		INFLAMMATION		
1216	F	2	609	U2	HEART		CARDIOMYOPATHY		
1216	F	2	609	U2	LUNG		INFLAMMATION		
1216	F	2	609	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1217	F	2	731	FS	JEJUNUM		DIVERTICULUM		
1217	F	2	731	FS	JEJUNUM		INFLAMMATION		
1217	F	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1217	F	2	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1217	F	2	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1217	F	2	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
1218	F	2	552	U1	ESOPHAGUS		DILATATION, LUMEN		
1218	F	2	552	U1	LUNG		INFLAMMATION		
1219	F	2	735	FS	HEART		CARDIOMYOPATHY		
1219	F	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1219	F	2	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1220	F	2	735	FS	HEART		CARDIOMYOPATHY		
1220	F	2	735	FS	MAMMARY GLAND		CYST(S), DUCTAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1220	F	2	735	FS	OVARY	OV	B-THECOMA	36	M
1220	F	2	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
1220	F	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1220	F	2	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1221	F	2	735	FS	HEART		CARDIOMYOPATHY		
1221	F	2	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1221	F	2	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1221	F	2	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1221	F	2	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1221	F	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1221	F	2	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1222	F	2	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1222	F	2	735	FS	HEART		CARDIOMYOPATHY		
1222	F	2	735	FS	KIDNEY		MINERALIZATION		
1222	F	2	735	FS	KIDNEY		NEPHROPATHY		
1222	F	2	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1222	F	2	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1222	F	2	735	FS	MAMMARY GLAND		HYPERPLASIA		
1222	F	2	735	FS	ORAL MUCOSA	OC	M-CARCINOMA, SQUAMOUS CELL	57	M
1222	F	2	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
1222	F	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1223	F	2	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1223	F	2	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1223	F	2	735	FS	VAGINA	VA	B-LEIOMYOMA	24	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1224	F	2	499	U2	ADRENAL GLAND	AD	F-LYMPHOMA	38	I
1224	F	2	499	U2	LIVER	LI	F-LYMPHOMA	38	I
1224	F	2	499	U2	LUNG	LU	F-LYMPHOMA	38	I
1224	F	2	499	U2	PANCREAS	PA	F-LYMPHOMA	38	I
1224	F	2	499	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1224	F	2	499	U2	STOMACH	ST	F-LYMPHOMA	38	F
1225	F	2	720	U2	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	I
1225	F	2	720	U2	HEART		CARDIOMYOPATHY		
1225	F	2	720	U2	KIDNEY		INFLAMMATION		
1225	F	2	720	U2	LIVER		FOCUS, BASOPHILIC CELL		
1225	F	2	720	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1225	F	2	720	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1225	F	2	720	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1225	F	2	720	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1226	F	2	735	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1226	F	2	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1226	F	2	735	FS	RECTUM		METAZOAN PARASITE(S)		
1227	F	2	735	FS	HEART		CARDIOMYOPATHY		
1227	F	2	735	FS	KIDNEY		NEPHROPATHY		
1227	F	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1227	F	2	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1227	F	2	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1227	F	2	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1228	F	2	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1228	F	2	737	FS	CLITORAL GLAND		INFLAMMATION		
1228	F	2	737	FS	KIDNEY		HYDRONEPHROSIS		
1228	F	2	737	FS	KIDNEY		NEPHROPATHY		
1228	F	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1228	F	2	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1228	F	2	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1228	F	2	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1229	F	2	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1229	F	2	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1229	F	2	737	FS	KIDNEY		NEPHROPATHY		
1229	F	2	737	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1229	F	2	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
1229	F	2	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1229	F	2	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1230	F	2	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1230	F	2	737	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1230	F	2	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1230	F	2	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
1230	F	2	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1230	F	2	737	FS	THYMUS	THY	M-THYMOMA	80	M
1231	F	2	737	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1231	F	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1231	F	2	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1231	F	2	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1231	F	2	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1232	F	2	737	FS	HEART		CARDIOMYOPATHY		
1232	F	2	737	FS	KIDNEY		NEPHROPATHY		
1232	F	2	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1232	F	2	737	FS	SKIN		ULCER, EPIDERMIS		
1232	F	2	737	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1232	F	2	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1233	F	2	737	FS	KIDNEY		CYST(S), TUBULAR		
1233	F	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1233	F	2	737	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1234	F	2	741	FS	HEART		CARDIOMYOPATHY		
1234	F	2	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1234	F	2	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1234	F	2	741	FS	OVARY		CYST(S)		
1234	F	2	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1234	F	2	741	FS	THYMUS	THY	M-THYMOMA	80	M
1234	F	2	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1235	F	2	683	U2	HEART		CARDIOMYOPATHY		
1235	F	2	683	U2	KIDNEY		NEPHROPATHY		
1235	F	2	683	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1235	F	2	683	U2	RECTUM		METAZOAN PARASITE(S)		
1235	F	2	683	U2	SALIVARY GLAND		INFLAMMATION		
1235	F	2	683	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1236	F	2	741	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1236	F	2	741	FS	KIDNEY		MINERALIZATION		
1236	F	2	741	FS	KIDNEY		NEPHROPATHY		
1236	F	2	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1236	F	2	741	FS	TONGUE		HYPERPLASIA, MUCOSAL EPITHELIUM		
1237	F	2	741	FS	KIDNEY		NEPHROPATHY		
1237	F	2	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1237	F	2	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1238	F	2	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1238	F	2	741	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1238	F	2	741	FS	HEART		CARDIOMYOPATHY		
1238	F	2	741	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1238	F	2	741	FS	KIDNEY		ATROPHY		
1238	F	2	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1238	F	2	741	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1238	F	2	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1239	F	2	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1239	F	2	741	FS	HEART		CARDIOMYOPATHY		
1239	F	2	741	FS	KIDNEY		INFLAMMATION		
1239	F	2	741	FS	KIDNEY		MINERALIZATION		
1239	F	2	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1239	F	2	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1239	F	2	741	FS	NOSE/TURBINATES		INFLAMMATION		
1239	F	2	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1240	F	2	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1240	F	2	741	FS	HEART		CARDIOMYOPATHY		
1240	F	2	741	FS	KIDNEY		HYDRONEPHROSIS		
1240	F	2	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1240	F	2	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1240	F	2	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1240	F	2	741	FS	VAGINA	VA	B-LEIOMYOMA	24	M
1241	F	2	499	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1241	F	2	499	U2	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1241	F	2	499	U2	KIDNEY		HYDRONEPHROSIS		
1241	F	2	499	U2	KIDNEY		MINERALIZATION		
1241	F	2	499	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1242	F	2	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1242	F	2	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1242	F	2	741	FS	HEART		CARDIOMYOPATHY		
1242	F	2	741	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1242	F	2	741	FS	KIDNEY		NEPHROPATHY		
1242	F	2	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1242	F	2	741	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1242	F	2	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1242	F	2	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1242	F	2	741	FS	SPLEEN		HYPERPLASIA, LYMPHOID		
1243	F	2	672	U1	KIDNEY		HYDRONEPHROSIS		
1243	F	2	672	U1	MAMMARY GLAND	MA	B-ADENOMA	1	F
1244	F	2	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1244	F	2	743	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1244	F	2	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1245	F	2	384	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1245	F	2	384	U2	LIVER		FOCUS, BASOPHILIC CELL		
1245	F	2	384	U2	SKIN	SK	M-CARCINOMA, APOCRINE GLAND	47	F
1245	F	2	384	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	I
1245	F	2	384	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1246	F	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1246	F	2	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1246	F	2	743	FS	LN-MANDIBULAR		HYPERPLASIA, PLASMA CELL		
1246	F	2	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1246	F	2	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1246	F	2	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1246	F	2	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1246	F	2	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1246	F	2	743	FS	TONGUE		HYPERPLASIA, MUCOSAL EPITHELIUM		
1247	F	2	715	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1247	F	2	715	U2	BRAIN	BR	M-OLIGODENDROGLIOMA	70	F
1247	F	2	715	U2	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1247	F	2	715	U2	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1248	F	2	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1248	F	2	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1248	F	2	743	FS	LIVER		FOCUS, EOSINOPHILIC		
1248	F	2	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1248	F	2	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1248	F	2	743	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1248	F	2	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1248	F	2	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1249	F	2	672	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1249	F	2	672	U2	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1249	F	2	672	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1249	F	2	672	U2	UTERUS		HEMORRHAGE		
1249	F	2	672	U2	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1250	F	2	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1250	F	2	743	FS	CLITORAL GLAND		INFLAMMATION		
1250	F	2	743	FS	KIDNEY		CYST(S), TUBULAR		
1250	F	2	743	FS	LIVER		LIPIDOSIS; FOCAL		
1250	F	2	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1250	F	2	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1250	F	2	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1251	F	2	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1251	F	2	743	FS	LUNG		INFLAMMATION		
1252	F	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1252	F	2	745	FS	KIDNEY		NEPHROPATHY		
1252	F	2	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1253	F	2	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1253	F	2	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1253	F	2	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1254	F	2	745	FS	KIDNEY		NEPHROPATHY		
1254	F	2	745	FS	LUNG		FIBROSIS, INTERSTITIAL		
1255	F	2	745	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1255	F	2	745	FS	KIDNEY		INFLAMMATION		
1255	F	2	745	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1255	F	2	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1256	F	2	745	FS	HEART		CARDIOMYOPATHY		
1256	F	2	745	FS	KIDNEY		NEPHROPATHY		
1256	F	2	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1256	F	2	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1256	F	2	745	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1257	F	2	647	U1	LN-MEDIASTINAL	LNMED	M-HISTIOCYTIC SARCOMA	63	I
1257	F	2	647	U1	LN-MESENTERIC	LNMES	M-HISTIOCYTIC SARCOMA	63	I
1257	F	2	647	U1	MAMMARY GLAND	MA	F-LYMPHOMA	38	I
1257	F	2	647	U1	MESENTERY	ME	M-HISTIOCYTIC SARCOMA	63	I
1257	F	2	647	U1	SKELETAL MUSCLE	SM	M-RHABDOMYOSARCOMA	75	F
1258	F	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1258	F	2	745	FS	HEART		CARDIOMYOPATHY		
1258	F	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1258	F	2	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1259	F	2	720	U2	BONE	BO	M-OSTEOSARCOMA	71	F
1259	F	2	720	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1259	F	2	720	U2	KIDNEY		INFLAMMATION		
1259	F	2	720	U2	OVARY		CYST(S)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1259	F	2	720	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1259	F	2	720	U2	URINARY BLADDER		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1259	F	2	720	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1260	F	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1260	F	2	745	FS	HEART		CARDIOMYOPATHY		
1260	F	2	745	FS	KIDNEY		NEPHROPATHY		
1260	F	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1260	F	2	745	FS	LIVER		FOCUS, CLEAR CELL		
1260	F	2	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1260	F	2	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1321	F	3	703	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1321	F	3	703	U1	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1321	F	3	703	U1	HEART		CARDIOMYOPATHY		
1321	F	3	703	U1	KIDNEY		NEPHROPATHY		
1321	F	3	703	U1	LIVER		FOCUS, BASOPHILIC CELL		
1321	F	3	703	U1	LIVER		HYPERPLASIA, BILE DUCT		
1321	F	3	703	U1	LIVER		INFLAMMATION		
1321	F	3	703	U1	MAMMARY GLAND	MA	B-ADENOMA	1	I
1321	F	3	703	U1	NOSE/TURBINATES		INFLAMMATION		
1321	F	3	703	U1	PANCREAS	PA	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1321	F	3	703	U1	SPLEEN		INFARCT		
1321	F	3	703	U1	STOMACH		INFLAMMATION, GLANDULAR		
1321	F	3	703	U1	UTERUS	UT	M-CARCINOMA	46	F
1321	F	3	703	U1	VAGINA		INFLAMMATION		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1322	F	3	729	FS	HEART		CARDIOMYOPATHY		
1322	F	3	729	FS	KIDNEY		CYST(S), TUBULAR		
1322	F	3	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1322	F	3	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1322	F	3	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1322	F	3	729	FS	RECTUM		METAZOAN PARASITE(S)		
1323	F	3	689	U2	ADRENAL GLAND		DEGENERATION, CYSTIC		
1323	F	3	689	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1323	F	3	689	U2	UTERUS		HEMORRHAGE		
1324	F	3	652	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1324	F	3	652	U2	KIDNEY		NEPHROPATHY		
1324	F	3	652	U2	LIVER		HYPERPLASIA, BILE DUCT		
1324	F	3	652	U2	LIVER		NECROSIS, HEPATOCYTE		
1324	F	3	652	U2	MESENTERY	ME	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1324	F	3	652	U2	PANCREAS	PA	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1324	F	3	652	U2	UTERUS	UT	M-CARCINOMA	46	F
1325	F	3	710	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1325	F	3	710	U2	CLITORAL GLAND		INFLAMMATION		
1325	F	3	710	U2	HEART		CARDIOMYOPATHY		
1325	F	3	710	U2	KIDNEY		HYDRONEPHROSIS		
1325	F	3	710	U2	KIDNEY		NEPHROPATHY		
1325	F	3	710	U2	LUNG		INFLAMMATION		
1325	F	3	710	U2	MAMMARY GLAND	MA	M-CARCINOSARCOMA	59	I
1325	F	3	710	U2	MAMMARY GLAND		HYPERPLASIA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1325	F	3	710	U2	OVARY		ATROPHY		
1325	F	3	710	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1325	F	3	710	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1325	F	3	710	U2	UTERUS		INFLAMMATION		
1326	F	3	631	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1326	F	3	631	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1326	F	3	631	U2	LIVER		FOCUS, BASOPHILIC CELL		
1326	F	3	631	U2	LIVER		FOCUS, CLEAR CELL		
1326	F	3	631	U2	LIVER		HYPERPLASIA, BILE DUCT		
1326	F	3	631	U2	LIVER		LIPIDOSIS, MULTIFOCAL		
1326	F	3	631	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	F
1326	F	3	631	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1326	F	3	631	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1327	F	3	729	FS	KIDNEY		NEPHROPATHY		
1327	F	3	729	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1328	F	3	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1328	F	3	729	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1328	F	3	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1329	F	3	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1330	F	3	731	FS	HEART		CARDIOMYOPATHY		
1330	F	3	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1330	F	3	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1330	F	3	731	FS	THYMUS	THY	M-THYMOMA	80	M
1331	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1331	F	3	731	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1332	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1332	F	3	731	FS	HEART		CARDIOMYOPATHY		
1332	F	3	731	FS	KIDNEY		CYST(S), TUBULAR		
1332	F	3	731	FS	PARATHYROID		HYPERPLASIA		
1332	F	3	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1332	F	3	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1333	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1333	F	3	731	FS	HEART		CARDIOMYOPATHY		
1333	F	3	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1333	F	3	731	FS	LIVER		TELANGIECTASIS		
1334	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1334	F	3	731	FS	KIDNEY		NEPHROPATHY		
1334	F	3	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1334	F	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1335	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1335	F	3	731	FS	HEART		CARDIOMYOPATHY		
1335	F	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1335	F	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
1336	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1336	F	3	731	FS	CLITORAL GLAND		INFLAMMATION		
1336	F	3	731	FS	HEART		CARDIOMYOPATHY		
1336	F	3	731	FS	KIDNEY		NEPHROPATHY		
1336	F	3	731	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1336	F	3	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1336	F	3	731	FS	OVARY		CYST(S)		
1336	F	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1336	F	3	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1336	F	3	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1337	F	3	553	U2	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1337	F	3	553	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1337	F	3	553	U2	MAMMARY GLAND		CYST(S), DUCTAL		
1337	F	3	553	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1338	F	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1338	F	3	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1338	F	3	731	FS	HEART		CARDIOMYOPATHY		
1338	F	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1339	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1339	F	3	735	FS	HEART		CARDIOMYOPATHY		
1339	F	3	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1339	F	3	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1340	F	3	512	U2	KIDNEY		NEPHROPATHY		
1340	F	3	512	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1341	F	3	311	U2	PARATHYROID		HYPERPLASIA		
1341	F	3	311	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1341	F	3	311	U2	SKIN	SK	M-HISTIOCYTIC SARCOMA	63	F
1341	F	3	311	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1341	F	3	311	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1342	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1342	F	3	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
1342	F	3	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1343	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1343	F	3	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1343	F	3	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1344	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1344	F	3	735	FS	HEART		CARDIOMYOPATHY		
1344	F	3	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1344	F	3	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1344	F	3	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1344	F	3	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1344	F	3	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1344	F	3	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1345	F	3	651	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1345	F	3	651	U1	UTERUS	UT	M-CARCINOMA	46	F
1346	F	3	735	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
1346	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1346	F	3	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1346	F	3	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1347	F	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1347	F	3	735	FS	KIDNEY		NEPHROPATHY		
1347	F	3	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1347	F	3	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1347	F	3	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1348	F	3	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1348	F	3	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1348	F	3	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1349	F	3	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1349	F	3	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1349	F	3	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1349	F	3	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1350	F	3	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
1350	F	3	737	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1351	F	3	737	FS	LIVER		CYST(S), BILE DUCTS		
1351	F	3	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1351	F	3	737	FS	OVARY		CYST(S)		
1351	F	3	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1352	F	3	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1352	F	3	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1352	F	3	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1353	F	3	737	FS	ADRENAL GLAND		ATROPHY		
1353	F	3	737	FS	KIDNEY		NEPHROPATHY		
1353	F	3	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1354	F	3	741	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1354	F	3	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1354	F	3	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1354	F	3	741	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1354	F	3	741	FS	LIVER		HYPERPLASIA, NODULAR, HEPATOCYTE		
1354	F	3	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1354	F	3	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1354	F	3	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1355	F	3	526	U2	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	I
1355	F	3	526	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1355	F	3	526	U2	LIVER		LIPIDOSIS, DIFFUSE		
1355	F	3	526	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1355	F	3	526	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1355	F	3	526	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
1356	F	3	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1356	F	3	741	FS	HEART		CARDIOMYOPATHY		
1356	F	3	741	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1356	F	3	741	FS	OVARY		CYST(S)		
1356	F	3	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1356	F	3	741	FS	UTERUS		INFLAMMATION		
1357	F	3	735	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1357	F	3	735	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1357	F	3	735	U2	KIDNEY		NEPHROPATHY		
1357	F	3	735	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1358	F	3	563	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1358	F	3	563	U2	LIVER		FOCUS, BASOPHILIC CELL		
1358	F	3	563	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1359	F	3	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1359	F	3	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1359	F	3	741	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
1359	F	3	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1360	F	3	741	FS	CLITORAL GLAND		INFLAMMATION		
1360	F	3	741	FS	HEART		CARDIOMYOPATHY		
1360	F	3	741	FS	KIDNEY		NEPHROPATHY		
1360	F	3	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1360	F	3	741	FS	LUNG		INFLAMMATION		
1361	F	3	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1361	F	3	741	FS	HEART		CARDIOMYOPATHY		
1361	F	3	741	FS	KIDNEY		NEPHROPATHY		
1361	F	3	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1361	F	3	741	FS	SKIN	SK	B-PAPILLOMA, SQUAMOUS CELL	28	M
1362	F	3	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1362	F	3	741	FS	OVARY		CYST(S)		
1362	F	3	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1363	F	3	743	FS	CLITORAL GLAND		INFLAMMATION		
1363	F	3	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1363	F	3	743	FS	LIVER		FOCUS, CLEAR CELL		
1363	F	3	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1363	F	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1363	F	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
1363	F	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1364	F	3	742	U1	MAMMARY GLAND	MA	B-ADENOMA	1	F



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1364	F	3	742	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1364	F	3	742	U1	SPLEEN		ATROPHY, LYMPHOID		
1364	F	3	742	U1	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	I
1365	F	3	720	U2	ADRENAL GLAND		DEGENERATION, CYSTIC		
1365	F	3	720	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1365	F	3	720	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1365	F	3	720	U2	SKIN	SK	M-CARCINOMA, SQUAMOUS CELL	57	F
1366	F	3	680	U2	HEART		CARDIOMYOPATHY		
1366	F	3	680	U2	LIVER		FOCUS, BASOPHILIC CELL		
1366	F	3	680	U2	LIVER		HYPERPLASIA, BILE DUCT		
1366	F	3	680	U2	MAMMARY GLAND		CYST(S), DUCTAL		
1366	F	3	680	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1366	F	3	680	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1366	F	3	680	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1367	F	3	743	FS	OVARY		CYST(S)		
1367	F	3	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1367	F	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1367	F	3	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1368	F	3	743	FS	LIVER		CYST(S), BILE DUCTS		
1368	F	3	743	FS	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	M
1368	F	3	743	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1368	F	3	743	FS	OVARY		CYST(S)		
1368	F	3	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1368	F	3	743	FS	THYROID GLAND	THG	M-CARCINOMA, FOLLICULAR CELL	52	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1368	F	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1368	F	3	743	FS	UTERUS	UT	M-CARCINOMA	46	M
1369	F	3	743	FS	CLITORAL GLAND		INFLAMMATION		
1369	F	3	743	FS	HEART		CARDIOMYOPATHY		
1369	F	3	743	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1369	F	3	743	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1369	F	3	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1369	F	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1370	F	3	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1370	F	3	743	FS	LIVER		FOCUS, CLEAR CELL		
1370	F	3	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1370	F	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1370	F	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1371	F	3	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1371	F	3	743	FS	CLITORAL GLAND		CYSTIC DUCT		
1371	F	3	743	FS	KIDNEY		INFLAMMATION		
1371	F	3	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1371	F	3	743	FS	OVARY		CYST(S)		
1371	F	3	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1371	F	3	743	FS	UTERUS	UT	M-CARCINOMA	46	M
1372	F	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1372	F	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1373	F	3	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1373	F	3	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1373	F	3	745	FS	KIDNEY		INFARCT, CHRONIC		
1373	F	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1374	F	3	745	FS	HEART		CARDIOMYOPATHY		
1374	F	3	745	FS	PARATHYROID		FIBROSIS		
1374	F	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1374	F	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1375	F	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1375	F	3	745	FS	UTERUS		DYSPLASIA, SMOOTH MUSCLE		
1376	F	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1376	F	3	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1376	F	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1376	F	3	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1377	F	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1377	F	3	745	FS	LIVER		FOCUS, EOSINOPHILIC		
1377	F	3	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1377	F	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1377	F	3	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1378	F	3	652	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1379	F	3	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1379	F	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1379	F	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1379	F	3	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1379	F	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1379	F	3	745	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1380	F	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1380	F	3	745	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1421	F	4	729	FS	HEART		CARDIOMYOPATHY		
1421	F	4	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1421	F	4	729	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1421	F	4	729	FS	OVARY		CYST(S)		
1421	F	4	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1422	F	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1422	F	4	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
1422	F	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1422	F	4	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1423	F	4	693	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1423	F	4	693	U2	HEART	HT	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (HEART)	81	I
1423	F	4	693	U2	KIDNEY	K	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (KIDNEY)	82	I
1423	F	4	693	U2	KIDNEY		HYDRONEPHROSIS		
1423	F	4	693	U2	KIDNEY		NEPHROPATHY		
1423	F	4	693	U2	LIVER	LI	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LIVER)	83	I
1423	F	4	693	U2	LIVER		HYPERPLASIA, BILE DUCT		
1423	F	4	693	U2	LN-MEDIASTINAL	LNMED	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MEDIASTINAL)	85	I
1423	F	4	693	U2	LN-MESENTERIC	LNMES	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-MESENTERIC)	86	I
1423	F	4	693	U2	LN-OTHER	LNO	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LN-OTHER)	87	I
1423	F	4	693	U2	LUNG	LU	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (LUNG)	84	I

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1423	F	4	693	U2	MESENTERY	ME	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (MESENTERY)	88	I
1423	F	4	693	U2	PANCREAS	PA	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (PANCREAS)	89	I
1423	F	4	693	U2	PANCREAS		ATROPHY, ACINAR CELL		
1423	F	4	693	U2	SPLEEN	SP	M-TRANSITIONAL CELL CARCINOMA, METASTATIC (SPLEEN)	90	I
1423	F	4	693	U2	URINARY BLADDER	UB	M-CARCINOMA, TRANSITIONAL CELL	58	F
1423	F	4	693	U2	UTERUS	UT	M-CARCINOMA	46	I
1423	F	4	693	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1424	F	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1424	F	4	729	FS	HEART		CARDIOMYOPATHY		
1424	F	4	729	FS	KIDNEY		NEPHROPATHY		
1424	F	4	729	FS	OVARY		CYST(S)		
1424	F	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1424	F	4	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1425	F	4	729	FS	KIDNEY		NEPHROPATHY		
1425	F	4	729	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1425	F	4	729	FS	UTERUS	UT	M-CARCINOMA	46	M
1426	F	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1426	F	4	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1426	F	4	729	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1426	F	4	729	FS	HEART		CARDIOMYOPATHY		
1426	F	4	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1426	F	4	729	FS	LUNG		INFLAMMATION		
1426	F	4	729	FS	OVARY		CYST(S)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1426	F	4	729	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1427	F	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1427	F	4	729	FS	HEART		CARDIOMYOPATHY		
1427	F	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1428	F	4	729	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
1428	F	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1428	F	4	729	FS	KIDNEY		NEPHROPATHY		
1428	F	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1428	F	4	729	FS	RECTUM		METAZOAN PARASITE(S)		
1428	F	4	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1429	F	4	532	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1429	F	4	532	U2	LIVER		LIPIDOSIS, DIFFUSE		
1429	F	4	532	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1429	F	4	532	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1429	F	4	532	U2	STOMACH		ULCER, NON-GLANDULAR		
1429	F	4	532	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1430	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1430	F	4	731	FS	KIDNEY		NEPHROPATHY		
1430	F	4	731	FS	LIVER		LIPIDOSIS, FOCAL		
1430	F	4	731	FS	OVARY		CYST(S)		
1430	F	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1430	F	4	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1431	F	4	731	FS	HEART		CARDIOMYOPATHY		
1431	F	4	731	FS	HEART		HYPERPLASIA, ENDOTHELIUM		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1431	F	4	731	FS	KIDNEY		NEPHROPATHY		
1431	F	4	731	FS	PANCREAS		ATROPHY, ACINAR CELL		
1431	F	4	731	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1431	F	4	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1432	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1432	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1432	F	4	731	FS	HEART		CARDIOMYOPATHY		
1432	F	4	731	FS	KIDNEY		NEPHROPATHY		
1432	F	4	731	FS	OVARY		CYST(S)		
1432	F	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1432	F	4	731	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1433	F	4	637	UI	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1434	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1434	F	4	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1434	F	4	731	FS	HEART		CARDIOMYOPATHY		
1434	F	4	731	FS	KIDNEY		NEPHROPATHY		
1434	F	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1435	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1435	F	4	731	FS	KIDNEY		NEPHROPATHY		
1435	F	4	731	FS	OVARY		CYST(S)		
1435	F	4	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1435	F	4	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1435	F	4	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1436	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1436	F	4	731	FS	HEART		CARDIOMYOPATHY		
1436	F	4	731	FS	KIDNEY		NEPHROPATHY		
1436	F	4	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1436	F	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1437	F	4	331	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1438	F	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1438	F	4	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1438	F	4	731	FS	KIDNEY		NEPHROPATHY		
1438	F	4	731	FS	LIVER		DILATATION, BILE DUCT		
1438	F	4	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1438	F	4	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1438	F	4	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1439	F	4	682	U2	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1439	F	4	682	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1439	F	4	682	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1439	F	4	682	U2	KIDNEY		NEPHROPATHY		
1439	F	4	682	U2	LIVER		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1439	F	4	682	U2	LIVER		INFLAMMATION		
1439	F	4	682	U2	LN-MESENTERIC	LNMES	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	65	I
1439	F	4	682	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1439	F	4	682	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1439	F	4	682	U2	STOMACH	ST	M-LEIOMYOSARCOMA	64	F
1439	F	4	682	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1439	F	4	682	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	I



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1439	F	4	682	U2	ZYMBAL'S GLAND		HYPERPLASIA		
1440	F	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1440	F	4	735	FS	HEART		CARDIOMYOPATHY		
1440	F	4	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1440	F	4	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1440	F	4	735	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
1440	F	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1441	F	4	434	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1441	F	4	434	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1441	F	4	434	U2	KIDNEY		NEPHROPATHY		
1441	F	4	434	U2	LIVER		LIPIDOSIS, DIFFUSE		
1441	F	4	434	U2	LUNG		INFLAMMATION		
1441	F	4	434	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1441	F	4	434	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1442	F	4	609	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1442	F	4	609	U2	ORAL MUCOSA	OC	M-CARCINOMA, SQUAMOUS CELL	57	F
1443	F	4	735	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1443	F	4	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1443	F	4	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1443	F	4	735	FS	LIVER		INFLAMMATION		
1443	F	4	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1443	F	4	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1443	F	4	735	FS	RECTUM		METAZOAN PARASITE(S)		
1444	F	4	631	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1444	F	4	631	U2	CLITORAL GLAND		INFLAMMATION		
1444	F	4	631	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1445	F	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1445	F	4	735	FS	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	M
1445	F	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1446	F	4	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1446	F	4	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1446	F	4	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1446	F	4	735	FS	OVARY		CYST(S)		
1446	F	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1446	F	4	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1446	F	4	735	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1447	F	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1447	F	4	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1447	F	4	735	FS	KIDNEY		NEPHROPATHY		
1447	F	4	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1447	F	4	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1447	F	4	735	FS	OVARY		CYST(S)		
1447	F	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1448	F	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1448	F	4	737	FS	KIDNEY		NEPHROPATHY		
1448	F	4	737	FS	LIVER		DILATATION, BILE DUCT		
1448	F	4	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1448	F	4	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1448	F	4	737	FS	OVARY		CYST(S)		
1448	F	4	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1448	F	4	737	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1449	F	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1449	F	4	737	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1450	F	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1450	F	4	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1450	F	4	737	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1450	F	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1450	F	4	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1450	F	4	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1451	F	4	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1451	F	4	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1451	F	4	737	FS	KIDNEY		NEPHROPATHY		
1451	F	4	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1451	F	4	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1451	F	4	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1451	F	4	737	FS	LUNG		INFLAMMATION		
1451	F	4	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1451	F	4	737	FS	OVARY		CYST(S)		
1451	F	4	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1452	F	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1452	F	4	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1452	F	4	737	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1452	F	4	737	FS	KIDNEY		NEPHROPATHY		
1452	F	4	737	FS	LIVER		INFLAMMATION		
1452	F	4	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1452	F	4	737	FS	SKELETAL MUSCLE		INFLAMMATION		
1452	F	4	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1453	F	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1453	F	4	737	FS	HEART		CARDIOMYOPATHY		
1453	F	4	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1454	F	4	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1454	F	4	741	FS	HEART		CARDIOMYOPATHY		
1454	F	4	741	FS	OVARY		CYST(S)		
1454	F	4	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1454	F	4	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1455	F	4	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1455	F	4	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1455	F	4	741	FS	OVARY		CYST(S)		
1455	F	4	741	FS	PANCREAS		ATROPHY, ACINAR CELL		
1455	F	4	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1455	F	4	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1456	F	4	689	U2	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	F
1457	F	4	475	U2	KIDNEY		NEPHROPATHY		
1457	F	4	475	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1457	F	4	475	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1457	F	4	475	U2	VAGINA	VA	B-POLYP	30	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1457	F	4	475	U2	VAGINA		PROLAPSE		
1458	F	4	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1458	F	4	741	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1458	F	4	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1458	F	4	741	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1458	F	4	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1458	F	4	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1458	F	4	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1458	F	4	741	FS	OVARY		CYST(S)		
1458	F	4	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1459	F	4	720	U2	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1459	F	4	720	U2	KIDNEY		NEPHROPATHY		
1459	F	4	720	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1459	F	4	720	U2	SKIN	SK	M-FIBROSARCOMA	61	F
1459	F	4	720	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1460	F	4	448	U2	KIDNEY		NEPHROPATHY		
1460	F	4	448	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1460	F	4	448	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1461	F	4	546	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1461	F	4	546	U2	LIVER		HYPERPLASIA, BILE DUCT		
1461	F	4	546	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1461	F	4	546	U2	SPLEEN		ATROPHY, LYMPHOID		
1462	F	4	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1462	F	4	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1462	F	4	741	FS	CLITORAL GLAND		CYSTIC DUCT		
1462	F	4	741	FS	HARDERIAN GLAND		INFLAMMATION		
1462	F	4	741	FS	KIDNEY		HYDRONEPHROSIS		
1462	F	4	741	FS	KIDNEY		NEPHROPATHY		
1462	F	4	741	FS	LN-MANDIBULAR		HYPERPLASIA, PLASMA CELL		
1462	F	4	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1462	F	4	741	FS	LUNG		DYSPLASIA, BRONCHIOLAR		
1462	F	4	741	FS	NOSE/TURBINATES		INFLAMMATION		
1462	F	4	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1462	F	4	741	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1463	F	4	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1463	F	4	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1463	F	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1463	F	4	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1463	F	4	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1464	F	4	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1464	F	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1464	F	4	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1464	F	4	743	FS	KIDNEY		NEPHROPATHY		
1464	F	4	743	FS	OVARY		CYST(S)		
1464	F	4	743	FS	SKIN	SK	B-FIBROMA	15	M
1465	F	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1465	F	4	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1465	F	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1466	F	4	609	U2	LIVER		CYST(S), BILE DUCTS		
1466	F	4	609	U2	OVARY		CYST(S)		
1466	F	4	609	U2	PANCREAS		ATROPHY, ACINAR CELL		
1466	F	4	609	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1466	F	4	609	U2	VAGINA	VA	B-POLYP	30	F
1467	F	4	664	U1	NOSE/TURBINATES		INFLAMMATION		
1467	F	4	664	U1	OVARY		INFLAMMATION		
1467	F	4	664	U1	PHARYNX		INFLAMMATION		
1467	F	4	664	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1467	F	4	664	U1	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1468	F	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1468	F	4	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1469	F	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1469	F	4	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1469	F	4	743	FS	HEART		CARDIOMYOPATHY		
1469	F	4	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1470	F	4	731	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1470	F	4	731	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1470	F	4	731	U2	ADRENAL GLAND		INFARCT		
1470	F	4	731	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1470	F	4	731	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	I
1470	F	4	731	U2	PARATHYROID		FIBROSIS		
1470	F	4	731	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1471	F	4	598	U1	UTERUS	UT	M-CARCINOMA	46	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1472	F	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1472	F	4	745	FS	HEART		CARDIOMYOPATHY		
1472	F	4	745	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1473	F	4	745	FS	HEART		CARDIOMYOPATHY		
1473	F	4	745	FS	KIDNEY		HYDRONEPHROSIS		
1473	F	4	745	FS	KIDNEY		NEPHROPATHY		
1473	F	4	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1473	F	4	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1473	F	4	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1474	F	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1474	F	4	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1474	F	4	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1475	F	4	745	FS	HEART		CARDIOMYOPATHY		
1475	F	4	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1475	F	4	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1475	F	4	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1475	F	4	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1475	F	4	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1475	F	4	745	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1476	F	4	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1476	F	4	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1476	F	4	745	FS	STERNUM	STE	M-OSTEOSARCOMA	71	M
1477	F	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1477	F	4	745	FS	HEART		CARDIOMYOPATHY		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1477	F	4	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1477	F	4	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1477	F	4	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1478	F	4	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1478	F	4	745	FS	LIVER		LIPIDOSIS, FOCAL		
1478	F	4	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1478	F	4	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1479	F	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1479	F	4	745	FS	HEART		CARDIOMYOPATHY		
1479	F	4	745	FS	KIDNEY		INFLAMMATION		
1479	F	4	745	FS	KIDNEY		NEPHROPATHY		
1479	F	4	745	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1479	F	4	745	FS	OVARY		CYST(S)		
1479	F	4	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1480	F	4	598	U2	OVARY		CYST(S)		
1480	F	4	598	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1480	F	4	598	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	I
1480	F	4	598	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1521	F	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1521	F	5	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1521	F	5	729	FS	BRAIN	BR	B-GRANULAR CELL TUMOR	19	M
1521	F	5	729	FS	HEART		CARDIOMYOPATHY		
1521	F	5	729	FS	KIDNEY		NEPHROPATHY		
1521	F	5	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1521	F	5	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1521	F	5	729	FS	UTERUS		THROMBOSIS		
1522	F	5	729	FS	OVARY	OV	B-THECOMA	36	M
1522	F	5	729	FS	OVARY		CYST(S)		
1523	F	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1523	F	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1523	F	5	729	FS	ADRENAL GLAND		THROMBOSIS		
1523	F	5	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1523	F	5	729	FS	UTERUS		INFLAMMATION		
1524	F	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1524	F	5	729	FS	HEART		CARDIOMYOPATHY		
1524	F	5	729	FS	KIDNEY		NEPHROPATHY		
1524	F	5	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1524	F	5	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1525	F	5	729	FS	HEART		CARDIOMYOPATHY		
1525	F	5	729	FS	KIDNEY		NEPHROPATHY		
1525	F	5	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1525	F	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1525	F	5	729	FS	OVARY		CYST(S)		
1525	F	5	729	FS	UTERUS	UT	M-CARCINOMA	46	M
1526	F	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1526	F	5	729	FS	OVARY		CYST(S)		
1526	F	5	729	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1527	F	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1527	F	5	729	FS	LUNG		INFLAMMATION		
1527	F	5	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1527	F	5	729	FS	SKIN		HYPERPLASIA, EPIDERMIS		
1527	F	5	729	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1528	F	5	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1528	F	5	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
1528	F	5	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1528	F	5	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1529	F	5	729	FS	KIDNEY		NEPHROPATHY		
1529	F	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1529	F	5	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1529	F	5	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1530	F	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1530	F	5	731	FS	HEART		CARDIOMYOPATHY		
1530	F	5	731	FS	KIDNEY		NEPHROPATHY		
1530	F	5	731	FS	LIVER		INFLAMMATION		
1530	F	5	731	FS	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	M
1530	F	5	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1530	F	5	731	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1530	F	5	731	FS	UTERUS	UT	M-CARCINOMA	46	M
1530	F	5	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1531	F	5	693	U1					
1532	F	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1532	F	5	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1532	F	5	731	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1533	F	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1533	F	5	731	FS	HEART		CARDIOMYOPATHY		
1533	F	5	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1533	F	5	731	FS	OVARY		CYST(S)		
1533	F	5	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1534	F	5	546	U1	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1534	F	5*	546	U1	HEART		CARDIOMYOPATHY		
1534	F	5	546	U1	KIDNEY		NEPHROPATHY		
1534	F	5	546	U1	LIVER		HYPERPLASIA, BILE DUCT		
1534	F	5	546	U1	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1534	F	5	546	U1	PHARYNX		HYPERPLASIA, MUCOSAL EPITHELIUM		
1534	F	5	546	U1	PHARYNX		INFLAMMATION		
1534	F	5	546	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1534	F	5	546	U1	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	I
1534	F	5	546	U1	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1535	F	5	731	FS	HEART		CARDIOMYOPATHY		
1535	F	5	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1535	F	5	731	FS	OVARY		CYST(S)		
1535	F	5	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1536	F	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1536	F	5	731	FS	ADRENAL GLAND		THROMBOSIS		
1536	F	5	731	FS	CLITORAL GLAND		INFLAMMATION		
1536	F	5	731	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1536	F	5	731	FS	KIDNEY		NEPHROPATHY		
1536	F	5	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1536	F	5	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1536	F	5	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1536	F	5	731	FS	MESENTERY	ME	M-MESOTHELIOMA	69	M
1536	F	5	731	FS	OVARY	OV	M-MESOTHELIOMA	69	M
1536	F	5	731	FS	OVARY		CYST(S)		
1536	F	5	731	FS	PANCREAS		ATROPHY, ACINAR CELL		
1537	F	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1537	F	5	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1537	F	5	731	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1537	F	5	731	FS	MAMMARY GLAND		INFLAMMATION		
1537	F	5	731	FS	OVARY		CYST(S)		
1537	F	5	731	FS	PANCREAS		ATROPHY, ACINAR CELL		
1537	F	5	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1537	F	5	731	FS	SALIVARY GLAND		INFLAMMATION		
1537	F	5	731	FS	SKIN		ULCER, EPIDERMIS		
1537	F	5	731	FS	VAGINA	VA	M-CARCINOMA, SQUAMOUS CELL	57	M
1538	F	5	574	U2	LIVER		HYPERPLASIA, BILE DUCT		
1538	F	5	574	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1538	F	5	574	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1538	F	5	574	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1538	F	5	574	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	F
1539	F	5	665	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1539	F	5	665	U1	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1539	F	5	665	U1	HEART		CARDIOMYOPATHY		
1539	F	5	665	U1	LIVER		HYPERPLASIA, BILE DUCT		
1539	F	5	665	U1	LIVER		THROMBOSIS		
1539	F	5	665	U1	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1539	F	5	665	U1	MESENTERY	ME	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1539	F	5	665	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1539	F	5	665	U1	URINARY BLADDER	UB	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1539	F	5	665	U1	UTERUS	UT	M-CARCINOMA	46	F
1539	F	5	665	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1540	F	5	735	FS	HEART		CARDIOMYOPATHY		
1540	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1540	F	5	735	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1540	F	5	735	FS	OVARY		CYST(S)		
1540	F	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1540	F	5	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1541	F	5	735	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1541	F	5	735	FS	HEART		CARDIOMYOPATHY		
1541	F	5	735	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1541	F	5	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1541	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1541	F	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1541	F	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
1541	F	5	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1541	F	5	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1542	F	5	735	FS	HEART		CARDIOMYOPATHY		
1542	F	5	735	FS	KIDNEY		NEPHROPATHY		
1542	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1542	F	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1543	F	5	735	FS	HEART		CARDIOMYOPATHY		
1543	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1544	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1544	F	5	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
1544	F	5	735	FS	SKIN	SK	M-CARCINOMA, BASAL CELL	48	M
1545	F	5	735	FS	COLON		METAZOAN PARASITE, LUMEN		
1545	F	5	735	FS	LIVER		FOCUS, MIXED CELL		
1545	F	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1545	F	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1546	F	5	735	FS	HEART		CARDIOMYOPATHY		
1546	F	5	735	FS	KIDNEY		NEPHROPATHY		
1546	F	5	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1547	F	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1547	F	5	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1547	F	5	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1547	F	5	735	FS	LIVER		DILATATION, BILE DUCT		
1547	F	5	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1548	F	5	720	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1548	F	5	720	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1548	F	5	720	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1548	F	5	720	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	F
1548	F	5	720	U2	OVARY		CYST(S)		
1548	F	5	720	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	I
1548	F	5	720	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1548	F	5	720	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1549	F	5	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1549	F	5	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1549	F	5	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1549	F	5	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1550	F	5	548	U2	KIDNEY	K	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1550	F	5	548	U2	LN-MEDIASTINAL	LNMED	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1550	F	5	548	U2	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1550	F	5	548	U2	PANCREAS	PA	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1550	F	5	548	U2	SKELETAL MUSCLE	SM	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1550	F	5	548	U2	UTERUS	UT	M-CARCINOMA	46	F
1550	F	5	548	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1551	F	5	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1552	F	5	490	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1552	F	5	490	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1552	F	5	490	U2	VAGINA	VA	B-POLYP	30	F
1553	F	5	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1554	F	5	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1554	F	5	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1554	F	5	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1554	F	5	741	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1554	F	5	741	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1555	F	5	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1555	F	5	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1555	F	5	741	FS	HEART		CARDIOMYOPATHY		
1555	F	5	741	FS	KIDNEY		HYDRONEPHROSIS		
1555	F	5	741	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1555	F	5	741	FS	KIDNEY		NEPHROPATHY		
1555	F	5	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1555	F	5	741	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1555	F	5	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1555	F	5	741	FS	PANCREAS		ATROPHY, ACINAR CELL		
1555	F	5	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1555	F	5	741	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1556	F	5	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1556	F	5	741	FS	UTERUS	UT	M-CARCINOMA	46	M
1557	F	5	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1557	F	5	741	FS	HEART		CARDIOMYOPATHY		
1557	F	5	741	FS	LIVER		FOCUS, MIXED CELL		
1557	F	5	741	FS	LIVER		LIPIDOSIS, FOCAL		
1557	F	5	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1557	F	5	741	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1557	F	5	741	FS	OVARY		CYST(S)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1557	F	5	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1557	F	5	741	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1558	F	5	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1558	F	5	741	FS	CLITORAL GLAND		INFLAMMATION		
1558	F	5	741	FS	LUNG		INFLAMMATION		
1558	F	5	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1558	F	5	741	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1559	F	5	532	U2	BRAIN	BR	M-MEDULLOBLASTOMA	68	F
1559	F	5	532	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1560	F	5	532	U2	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1560	F	5	532	U2	HEART		CARDIOMYOPATHY		
1560	F	5	532	U2	KIDNEY		NEPHROPATHY		
1560	F	5	532	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	F
1560	F	5	532	U2	PANCREAS		ATROPHY, ACINAR CELL		
1560	F	5	532	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1561	F	5	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1561	F	5	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1561	F	5	741	FS	UTERUS	UT	M-CARCINOMA	46	M
1562	F	5	741	FS	OVARY		CYST(S)		
1562	F	5	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1563	F	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1563	F	5	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1563	F	5	743	FS	OVARY		CYST(S)		
1563	F	5	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1564	F	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1564	F	5	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1564	F	5	743	FS	MAMMARY GLAND		HYPERPLASIA		
1564	F	5	743	FS	OVARY		CYST(S)		
1564	F	5	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1565	F	5	451	U2	KIDNEY		INFLAMMATION		
1565	F	5	451	U2	LIVER		FOCUS, BASOPHILIC CELL		
1565	F	5	451	U2	LIVER		HYPERPLASIA, BILE DUCT		
1565	F	5	451	U2	MAMMARY GLAND		CYST(S), DUCTAL		
1565	F	5	451	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1566	F	5	743	FS	KIDNEY		NEPHROPATHY		
1566	F	5	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1566	F	5	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1566	F	5	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1567	F	5	743	FS	HEART		CARDIOMYOPATHY		
1567	F	5	743	FS	KIDNEY		NEPHROPATHY		
1567	F	5	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1567	F	5	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1567	F	5	743	FS	STOMACH	ST	B-FIBROPAPILLOMA	16	M
1567	F	5	743	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
1567	F	5	743	FS	STOMACH		INFLAMMATION, NON-GLANDULAR		
1567	F	5	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1568	F	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1568	F	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1568	F	5	743	FS	LIVER		DILATATION, BILE DUCT		
1568	F	5	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1569	F	5	743	FS	KIDNEY		NEPHROPATHY		
1569	F	5	743	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1569	F	5	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1570	F	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1570	F	5	743	FS	CLITORAL GLAND	CL	M-CARCINOMA	40	M
1570	F	5	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1570	F	5	743	FS	NOSE/TURBINATES		INFLAMMATION		
1570	F	5	743	FS	OVARY		CYST(S)		
1570	F	5	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1571	F	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1571	F	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1571	F	5	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1571	F	5	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1572	F	5	745	FS	CLITORAL GLAND		INFLAMMATION		
1572	F	5	745	FS	HEART		CARDIOMYOPATHY		
1572	F	5	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1572	F	5	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1572	F	5	745	FS	OVARY		CYST(S)		
1572	F	5	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1573	F	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1573	F	5	745	FS	OVARY		CYST(S)		
1573	F	5	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1573	F	5	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1574	F	5	451	U2	BRAIN	BR	M-ASTROCYTOMA	39	F
1574	F	5	451	U2	LIVER		FOCUS, BASOPHILIC CELL		
1575	F	5	651	U1	HEART		CARDIOMYOPATHY		
1575	F	5	651	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1575	F	5	651	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1576	F	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1576	F	5	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1576	F	5	745	FS	HEART		CARDIOMYOPATHY		
1576	F	5	745	FS	MAMMARY GLAND		HYPERPLASIA		
1576	F	5	745	FS	OVARY		CYST(S)		
1576	F	5	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1577	F	5	693	U1	CLITORAL GLAND		INFLAMMATION		
1577	F	5	693	U1	HEART		CARDIOMYOPATHY		
1577	F	5	693	U1	KIDNEY		HYDRONEPHROSIS		
1577	F	5	693	U1	MESENTERY	ME	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1577	F	5	693	U1	UTERUS	UT	M-CARCINOMA	46	F
1578	F	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1578	F	5	745	FS	LIVER		CYST(S), BILE DUCTS		
1579	F	5	745	FS	HEART		CARDIOMYOPATHY		
1579	F	5	745	FS	OVARY		CYST(S)		
1579	F	5	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1579	F	5	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1580	F	5	745	FS					

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1621	F	6	729	FS	KIDNEY		NEPHROPATHY		
1621	F	6	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1621	F	6	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1621	F	6	729	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1621	F	6	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1621	F	6	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1621	F	6	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1622	F	6	729	FS	KIDNEY		NEPHROPATHY		
1622	F	6	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1622	F	6	729	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1622	F	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1623	F	6	729	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1623	F	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1623	F	6	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1623	F	6	729	FS	HEART		CARDIOMYOPATHY		
1623	F	6	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1623	F	6	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1623	F	6	729	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1623	F	6	729	FS	OVARY		CYST(S)		
1623	F	6	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
1623	F	6	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1623	F	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1624	F	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1624	F	6	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1624	F	6	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1624	F	6	729	FS	HEART		CARDIOMYOPATHY		
1624	F	6	729	FS	KIDNEY		NEPHROPATHY		
1624	F	6	729	FS	LIVER		DILATATION, BILE DUCT		
1624	F	6	729	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1624	F	6	729	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1624	F	6	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1624	F	6	729	FS	RECTUM		METAZOAN PARASITE(S)		
1624	F	6	729	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1625	F	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1625	F	6	729	FS	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	M
1625	F	6	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1625	F	6	729	FS	OVARY		CYST(S)		
1625	F	6	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1625	F	6	729	FS	SKIN		ULCER, EPIDERMIS		
1625	F	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1626	F	6	612	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1626	F	6	612	U2	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1626	F	6	612	U2	KIDNEY		NEPHROPATHY		
1626	F	6	612	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1626	F	6	612	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1627	F	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1627	F	6	729	FS	CLITORAL GLAND		INFLAMMATION		
1627	F	6	729	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1627	F	6	729	FS	KIDNEY		NEPHROPATHY		
1627	F	6	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1627	F	6	729	FS	MAMMARY GLAND		HYPERPLASIA		
1627	F	6	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1627	F	6	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1627	F	6	729	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1628	F	6	631	U1	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	I
1628	F	6	631	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1628	F	6	631	U1	LIVER		FOCUS, BASOPHILIC CELL		
1628	F	6	631	U1	MAMMARY GLAND	MA	B-ADENOMA	1	I
1628	F	6	631	U1	MAMMARY GLAND		CYST(S), DUCTAL		
1628	F	6	631	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1628	F	6	631	U1	VAGINA	VA	B-HEMANGIOMA	21	I
1629	F	6	729	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1629	F	6	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1629	F	6	729	FS	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	M
1630	F	6	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1630	F	6	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1630	F	6	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1630	F	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1630	F	6	731	FS	LIVER		LIPIDOSIS, FOCAL		
1630	F	6	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1631	F	6	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1631	F	6	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1632	F	6	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1632	F	6	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1633	F	6	612	U2	HEART		CARDIOMYOPATHY		
1633	F	6	612	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1633	F	6	612	U2	VAGINA	VA	M-LEIOMYOSARCOMA	64	F
1634	F	6	675	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1634	F	6	675	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1634	F	6	675	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1634	F	6	675	U2	KIDNEY		NEPHROPATHY		
1634	F	6	675	U2	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	I
1634	F	6	675	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1634	F	6	675	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1634	F	6	675	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1634	F	6	675	U2	SPLEEN		HYPERPLASIA, LYMPHOID		
1634	F	6	675	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1635	F	6	496	U1	HEART		CARDIOMYOPATHY		
1635	F	6	496	U1	LIVER		HYPERPLASIA, BILE DUCT		
1635	F	6	496	U1	LIVER		INFLAMMATION		
1635	F	6	496	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1635	F	6	496	U1	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1636	F	6	731	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1636	F	6	731	FS	HEART		CARDIOMYOPATHY		
1636	F	6	731	FS	KIDNEY		NEPHROPATHY		
1636	F	6	731	FS	LIVER		FOCUS, BASOPHILIC CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1636	F	6	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1636	F	6	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1636	F	6	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1636	F	6	731	FS	RECTUM		METAZOAN PARASITE(S)		
1636	F	6	731	FS	SKIN		ULCER, EPIDERMIS		
1636	F	6	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1637	F	6	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1637	F	6	731	FS	HEART		CARDIOMYOPATHY		
1637	F	6	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1637	F	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1637	F	6	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1637	F	6	731	FS	LUNG		INFLAMMATION		
1637	F	6	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1637	F	6	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1638	F	6	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1638	F	6	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1638	F	6	731	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1638	F	6	731	FS	KIDNEY		NEPHROPATHY		
1638	F	6	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1638	F	6	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1639	F	6	676	U2	KIDNEY		HYDRONEPHROSIS		
1639	F	6	676	U2	KIDNEY		INFARCT, CHRONIC		
1639	F	6	676	U2	KIDNEY		INFLAMMATION		
1639	F	6	676	U2	LIVER		FOCUS, MIXED CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1639	F	6	676	U2	URINARY BLADDER	UB	M-CARCINOMA, SQUAMOUS CELL	57	F
1640	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1640	F	6	735	FS	HEART		CARDIOMYOPATHY		
1640	F	6	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1641	F	6	735	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1641	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1641	F	6	735	FS	HEART		CARDIOMYOPATHY		
1641	F	6	735	FS	KIDNEY		NEPHROPATHY		
1641	F	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1641	F	6	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1641	F	6	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1641	F	6	735	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1641	F	6	735	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1641	F	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1641	F	6	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1642	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1642	F	6	735	FS	HEART		HYPERPLASIA, ENDOTHELIUM		
1642	F	6	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1642	F	6	735	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		
1643	F	6	735	FS	HEART		CARDIOMYOPATHY		
1643	F	6	735	FS	KIDNEY		NEPHROPATHY		
1643	F	6	735	FS	LIVER		CYST(S), BILE DUCTS		
1643	F	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1643	F	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1644	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1644	F	6	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1644	F	6	735	FS	HEART		CARDIOMYOPATHY		
1644	F	6	735	FS	KIDNEY		NEPHROPATHY		
1644	F	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1644	F	6	735	FS	STOMACH		MINERALIZATION		
1644	F	6	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1644	F	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1645	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1645	F	6	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1645	F	6	735	FS	KIDNEY		NEPHROPATHY		
1645	F	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1645	F	6	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
1645	F	6	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1645	F	6	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1646	F	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1646	F	6	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1646	F	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1646	F	6	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1647	F	6	533	U2	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1647	F	6	533	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1647	F	6	533	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1647	F	6	533	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1648	F	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1648	F	6	737	FS	KIDNEY		NEPHROPATHY		
1648	F	6	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1648	F	6	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1648	F	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1649	F	6	737	FS	KIDNEY		NEPHROPATHY		
1649	F	6	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1649	F	6	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1649	F	6	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1650	F	6	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1650	F	6	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1650	F	6	737	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1650	F	6	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1650	F	6	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1651	F	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1651	F	6	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1651	F	6	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1651	F	6	737	FS	KIDNEY		NEPHROPATHY		
1651	F	6	737	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
1651	F	6	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1651	F	6	737	FS	MAMMARY GLAND		HYPERPLASIA		
1651	F	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1651	F	6	737	FS	THYMUS	THY	F-LYMPHOMA	38	M
1651	F	6	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1652	F	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1652	F	6	737	FS	HEART		CARDIOMYOPATHY		
1652	F	6	737	FS	KIDNEY		NEPHROPATHY		
1652	F	6	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1652	F	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1652	F	6	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1652	F	6	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1653	F	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1653	F	6	737	FS	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	M
1653	F	6	737	FS	KIDNEY		NEPHROPATHY		
1653	F	6	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1653	F	6	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1653	F	6	737	FS	OVARY		CYST(S)		
1653	F	6	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1653	F	6	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1654	F	6	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1654	F	6	741	FS	HEART		CARDIOMYOPATHY		
1654	F	6	741	FS	KIDNEY		NEPHROPATHY		
1654	F	6	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1654	F	6	741	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1654	F	6	741	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1655	F	6	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1655	F	6	741	FS	CLITORAL GLAND		INFLAMMATION		
1655	F	6	741	FS	HEART		CARDIOMYOPATHY		
1655	F	6	741	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1655	F	6	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1655	F	6	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1656	F	6	685	U1	KIDNEY		HYDRONEPHROSIS		
1656	F	6	685	U1	OVARY	OV	B-ADENOMA	1	I
1656	F	6	685	U1	OVARY		CYST(S)		
1656	F	6	685	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1656	F	6	685	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1657	F	6	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1657	F	6	741	FS	HEART		CARDIOMYOPATHY		
1657	F	6	741	FS	KIDNEY		NEPHROPATHY		
1657	F	6	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1657	F	6	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1657	F	6	741	FS	LIVER		INFLAMMATION		
1657	F	6	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1657	F	6	741	FS	LUNG		INFLAMMATION		
1657	F	6	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1657	F	6	741	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1658	F	6	652	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1658	F	6	652	U2	LIVER		HYPERPLASIA, BILE DUCT		
1658	F	6	652	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1658	F	6	652	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1659	F	6	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1659	F	6	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1659	F	6	741	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1659	F	6	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1659	F	6	741	FS	LIVER		INFLAMMATION		
1659	F	6	741	FS	LIVER		LIPIDOSIS, DIFFUSE		
1659	F	6	741	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1659	F	6	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1660	F	6	703	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1660	F	6	703	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1660	F	6	703	U2	CECUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1660	F	6	703	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1660	F	6	703	U2	KIDNEY		NEPHROPATHY		
1660	F	6	703	U2	PANCREAS		ATROPHY, ACINAR CELL		
1660	F	6	703	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1660	F	6	703	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1661	F	6	741	FS	KIDNEY		NEPHROPATHY		
1661	F	6	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1661	F	6	741	FS	LIVER		HYPERPLASIA, BILE DUCT		
1661	F	6	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1662	F	6	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1662	F	6	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1662	F	6	741	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
1663	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1663	F	6	743	FS	HEART		CARDIOMYOPATHY		
1663	F	6	743	FS	KIDNEY		NEPHROPATHY		
1663	F	6	743	FS	LIVER		HYPERPLASIA, BILE DUCT		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1663	F	6	743	FS	MAMMARY GLAND		HYPERPLASIA		
1663	F	6	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1663	F	6	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1664	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1664	F	6	743	FS	HEART		CARDIOMYOPATHY		
1664	F	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1664	F	6	743	FS	UTERUS		SQUAMOUS METAPLASIA, ENDOMETRIUM		
1665	F	6	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1665	F	6	743	FS	MAMMARY GLAND		FIBROSIS, PERIDUCTAL		
1665	F	6	743	FS	OVARY		CYST(S)		
1665	F	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1666	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1666	F	6	743	FS	HEART		CARDIOMYOPATHY		
1666	F	6	743	FS	KIDNEY		HYPERPLASIA, TUBULAR		
1666	F	6	743	FS	KIDNEY		NEPHROPATHY		
1666	F	6	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1666	F	6	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1666	F	6	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1666	F	6	743	FS	OVARY		CYST(S)		
1666	F	6	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1666	F	6	743	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1666	F	6	743	FS	UTERUS		INFLAMMATION		
1666	F	6	743	FS	UTERUS		SQUAMOUS METAPLASIA, ENDOMETRIUM		
1667	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1667	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1667	F	6	743	FS	KIDNEY		NEPHROPATHY		
1667	F	6	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1667	F	6	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1667	F	6	743	FS	RECTUM		METAZOAN PARASITE(S)		
1667	F	6	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1668	F	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1668	F	6	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1668	F	6	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1668	F	6	743	FS	KIDNEY		HYDRONEPHROSIS		
1668	F	6	743	FS	KIDNEY		INFLAMMATION		
1668	F	6	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1668	F	6	743	FS	LIVER		FOCUS, EOSINOPHILIC		
1668	F	6	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1668	F	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1668	F	6	743	FS	STOMACH		HYPERPLASIA, MUCOSA, GLANDULAR		
1669	F	6	743	FS	CLITORAL GLAND		INFLAMMATION		
1669	F	6	743	FS	HEART		CARDIOMYOPATHY		
1669	F	6	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1669	F	6	743	FS	PANCREAS		BASOPHILIC FOCUS, ACINAR CELL		
1669	F	6	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1669	F	6	743	FS	STOMACH		MINERALIZATION		
1670	F	6	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
1670	F	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1670	F	6	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1670	F	6	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1670	F	6	743	FS	UTERUS	UT	M-CARCINOMA	46	M
1671	F	6	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1671	F	6	743	FS	KIDNEY		NEPHROPATHY		
1671	F	6	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1671	F	6	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1671	F	6	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1672	F	6	666	U1	HEART		CARDIOMYOPATHY		
1672	F	6	666	U1	KIDNEY		CYST(S), TUBULAR		
1672	F	6	666	U1	OVARY		INFLAMMATION		
1672	F	6	666	U1	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	I
1672	F	6	666	U1	UTERUS	UT	M-CARCINOMA	46	F
1672	F	6	666	U1	UTERUS		INFLAMMATION		
1673	F	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1673	F	6	745	FS	HEART		CARDIOMYOPATHY		
1673	F	6	745	FS	KIDNEY		NEPHROPATHY		
1673	F	6	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1674	F	6	745	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1674	F	6	745	FS	KIDNEY		NEPHROPATHY		
1674	F	6	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1674	F	6	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1675	F	6	700	U1	HEART		CARDIOMYOPATHY		
1676	F	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1676	F	6	745	FS	KIDNEY		NEPHROPATHY		
1676	F	6	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1676	F	6	745	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1676	F	6	745	FS	OVARY		CYST(S)		
1676	F	6	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1676	F	6	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1677	F	6	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1677	F	6	745	FS	HEART		CARDIOMYOPATHY		
1677	F	6	745	FS	KIDNEY		NEPHROPATHY		
1677	F	6	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1677	F	6	745	FS	MAMMARY GLAND		HYPERPLASIA		
1677	F	6	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1677	F	6	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1678	F	6	745	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1678	F	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1678	F	6	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1678	F	6	745	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1679	F	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1679	F	6	745	FS	HEART		CARDIOMYOPATHY		
1679	F	6	745	FS	KIDNEY		NEPHROPATHY		
1679	F	6	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1679	F	6	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1679	F	6	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1680	F	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1680	F	6	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1680	F	6	745	FS	HEART		CARDIOMYOPATHY		
1680	F	6	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1680	F	6	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1680	F	6	745	FS	OVARY		CYST(S)		
1680	F	6	745	FS	UTERUS	UT	M-CARCINOMA	46	M
1721	F	7	729	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1721	F	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1721	F	7	729	FS	OVARY		CYST(S)		
1721	F	7	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1722	F	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1722	F	7	729	FS	OVARY		CYST(S)		
1722	F	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1722	F	7	729	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1723	F	7	729	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1723	F	7	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1723	F	7	729	FS	HEART		CARDIOMYOPATHY		
1723	F	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1723	F	7	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1723	F	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1724	F	7	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1724	F	7	729	FS	SKIN	SK	B-LIPOMA	25	M
1724	F	7	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1724	F	7	729	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1725	F	7	616	U1	ADRENAL GLAND		DEGENERATION, CYSTIC		
1725	F	7	616	U1	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1725	F	7	616	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1726	F	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
1726	F	7	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1726	F	7	729	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1727	F	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1727	F	7	729	FS	HEART		CARDIOMYOPATHY		
1727	F	7	729	FS	KIDNEY		NEPHROPATHY		
1727	F	7	729	FS	OVARY		CYST(S)		
1727	F	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1727	F	7	729	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1727	F	7	729	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1728	F	7	540	U1	HARDERIAN GLAND		INFLAMMATION		
1728	F	7	540	U1	HEART		CARDIOMYOPATHY		
1728	F	7	540	U1	LIVER	LI	M-HISTIOCYTIC SARCOMA	63	I
1728	F	7	540	U1	LN-OTHER	LNO	M-HISTIOCYTIC SARCOMA	63	I
1728	F	7	540	U1	LUNG	LU	M-HISTIOCYTIC SARCOMA	63	I
1728	F	7	540	U1	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1728	F	7	540	U1	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1728	F	7	540	U1	LUNG		INFLAMMATION		
1728	F	7	540	U1	THYMUS		INFLAMMATION		
1728	F	7	540	U1	UTERUS	UT	M-HISTIOCYTIC SARCOMA	63	F
1729	F	7	661	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1729	F	7	661	U1	HEART		CARDIOMYOPATHY		
1729	F	7	661	U1	KIDNEY		HYDRONEPHROSIS		
1729	F	7	661	U1	KIDNEY		NEPHROPATHY		
1729	F	7	661	U1	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	I
1729	F	7	661	U1	UTERUS	UT	M-SARCOMA, STROMAL	77	F
1730	F	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1730	F	7	731	FS	HEART		CARDIOMYOPATHY		
1730	F	7	731	FS	KIDNEY		NEPHROPATHY		
1730	F	7	731	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1730	F	7	731	FS	LUNG		INFLAMMATION		
1730	F	7	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1730	F	7	731	FS	MAMMARY GLAND		HYPERPLASIA		
1730	F	7	731	FS	OVARY		CYST(S)		
1730	F	7	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1730	F	7	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1731	F	7	450	U1	CLITORAL GLAND		INFLAMMATION		
1731	F	7	450	U1	HEART		CARDIOMYOPATHY		
1731	F	7	450	U1	LUNG	LU	F-LYMPHOMA	38	F
1731	F	7	450	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1732	F	7	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1732	F	7	731	FS	LUNG		INFLAMMATION		
1732	F	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1732	F	7	731	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1732	F	7	731	FS	VAGINA	VA	B-POLYP	30	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1733	F	7	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1733	F	7	731	FS	HEART		CARDIOMYOPATHY		
1733	F	7	731	FS	KIDNEY		NEPHROPATHY		
1733	F	7	731	FS	LIVER	LI	B-ADENOMA, BILIARY	3	M
1733	F	7	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1733	F	7	731	FS	SPLEEN	SP	B-HEMANGIOMA	21	M
1733	F	7	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1734	F	7	731	FS	KIDNEY		NEPHROPATHY		
1734	F	7	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1734	F	7	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1734	F	7	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1734	F	7	731	FS	OVARY		CYST(S)		
1735	F	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1735	F	7	731	FS	DUODENUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1735	F	7	731	FS	LIVER		DILATATION, BILE DUCT		
1735	F	7	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1735	F	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1735	F	7	731	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1736	F	7	731	FS	LIVER		DILATATION, BILE DUCT		
1737	F	7	703	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1737	F	7	703	U2	BRAIN	BR	B-GRANULAR CELL TUMOR	19	F
1737	F	7	703	U2	HEART		CARDIOMYOPATHY		
1737	F	7	703	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1737	F	7	703	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1737	F	7	703	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1738	F	7	731	FS	CECUM	CE	F-LYMPHOMA	38	M
1738	F	7	731	FS	HEART		CARDIOMYOPATHY		
1738	F	7	731	FS	LN-MESENTERIC	LNMES	F-LYMPHOMA	38	M
1738	F	7	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1738	F	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1738	F	7	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1738	F	7	731	FS	UTERUS	UT	M-SARCOMA, STROMAL	77	M
1738	F	7	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1738	F	7	731	FS	VAGINA	VA	B-POLYP	30	M
1739	F	7	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1739	F	7	735	FS	OVARY		CYST(S)		
1740	F	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1740	F	7	735	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1740	F	7	735	FS	KIDNEY		MINERALIZATION		
1740	F	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1740	F	7	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
1740	F	7	735	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1741	F	7	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1741	F	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1741	F	7	735	FS	OVARY		CYST(S)		
1741	F	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1741	F	7	735	FS	RECTUM		METAZOAN PARASITE(S)		
1742	F	7	486	U1	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1742	F	7	486	U1	KIDNEY		HYDRONEPHROSIS		
1742	F	7	486	U1	THYMUS	THY	M-HISTIOCYTIC SARCOMA	63	I
1743	F	7	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1743	F	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1744	F	7	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1744	F	7	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1745	F	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1745	F	7	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1745	F	7	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1746	F	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1746	F	7	735	FS	OVARY		CYST(S)		
1746	F	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1746	F	7	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1747	F	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1747	F	7	735	FS	KIDNEY		INFLAMMATION		
1747	F	7	735	FS	OVARY		CYST(S)		
1747	F	7	735	FS	SKIN		INFLAMMATION		
1747	F	7	735	FS	SKIN		ULCER, EPIDERMIS		
1747	F	7	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1748	F	7	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1748	F	7	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1748	F	7	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1748	F	7	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1748	F	7	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1748	F	7	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1749	F	7	737	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1749	F	7	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1749	F	7	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1749	F	7	737	FS	HEART		CARDIOMYOPATHY		
1749	F	7	737	FS	MAMMARY GLAND		HYPERPLASIA		
1749	F	7	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1749	F	7	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1750	F	7	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1750	F	7	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1750	F	7	737	FS	HEART		CARDIOMYOPATHY		
1750	F	7	737	FS	LIVER		CYST(S), BILE DUCTS		
1750	F	7	737	FS	LIVER		DILATATION, BILE DUCT		
1750	F	7	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1750	F	7	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1750	F	7	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1750	F	7	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1751	F	7	737	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1751	F	7	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1751	F	7	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1751	F	7	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1751	F	7	737	FS	KIDNEY		CYST(S), TUBULAR		
1751	F	7	737	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1751	F	7	737	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1751	F	7	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1751	F	7	737	FS	SKIN		INFLAMMATION		
1751	F	7	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1752	F	7	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1752	F	7	737	FS	KIDNEY		NEPHROPATHY		
1752	F	7	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1752	F	7	737	FS	MAMMARY GLAND		HYPERPLASIA		
1752	F	7	737	FS	OVARY		CYST(S)		
1752	F	7	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1752	F	7	737	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1753	F	7	737	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1753	F	7	737	FS	KIDNEY		INFLAMMATION		
1753	F	7	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1754	F	7	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1754	F	7	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1754	F	7	741	FS	HEART		CARDIOMYOPATHY		
1754	F	7	741	FS	KIDNEY		NEPHROPATHY		
1754	F	7	741	FS	PANCREAS		ATROPHY, ACINAR CELL		
1754	F	7	741	FS	ZYMBAL'S GLAND		DUCTAL CYST		
1755	F	7	741	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1755	F	7	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1755	F	7	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1755	F	7	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1755	F	7	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1756	F	7	719	U1	MAMMARY GLAND	MA	B-ADENOMA	1	F
1756	F	7	719	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1757	F	7	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1757	F	7	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1757	F	7	741	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1757	F	7	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1757	F	7	741	FS	VAGINA	VA	B-LEIOMYOMA	24	M
1758	F	7	741	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1758	F	7	741	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1758	F	7	741	FS	HEART		CARDIOMYOPATHY		
1758	F	7	741	FS	LIVER		CYST(S), BILE DUCTS		
1758	F	7	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1758	F	7	741	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1758	F	7	741	FS	VAGINA		FIBROSIS, SUBMUCOSA		
1759	F	7	598	U2	HEART		CARDIOMYOPATHY		
1759	F	7	598	U2	LIVER		FOCUS, BASOPHILIC CELL		
1759	F	7	598	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	F
1759	F	7	598	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1760	F	7	741	FS	HEART		CARDIOMYOPATHY		
1760	F	7	741	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1761	F	7	741	FS	HEART		CARDIOMYOPATHY		
1761	F	7	741	FS	LIVER		FOCUS, BASOPHILIC CELL		
1761	F	7	741	FS	LIVER		FOCUS, MIXED CELL		
1761	F	7	741	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1761	F	7	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1762	F	7	741	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1762	F	7	741	FS	HEART		CARDIOMYOPATHY		
1762	F	7	741	FS	LIVER		FOCUS, EOSINOPHILIC		
1762	F	7	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1762	F	7	741	FS	OVARY		CYST(S)		
1762	F	7	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1762	F	7	741	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
1762	F	7	741	FS	UTERUS	UT	M-SARCOMA, STROMAL	77	M
1763	F	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1763	F	7	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1763	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1763	F	7	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1764	F	7	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1764	F	7	743	FS	CLITORAL GLAND		INFLAMMATION		
1764	F	7	743	FS	LIVER		FOCUS, EOSINOPHILIC		
1764	F	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1764	F	7	743	FS	OVARY		CYST(S)		
1764	F	7	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1765	F	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1765	F	7	743	FS	HEART		CARDIOMYOPATHY		
1765	F	7	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1765	F	7	743	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
1765	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1765	F	7	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1766	F	7	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1766	F	7	743	FS	HEART		CARDIOMYOPATHY		
1766	F	7	743	FS	OVARY	OV	B-LUTEOMA	26	M
1766	F	7	743	FS	OVARY	OV	B-SERTOLI CELL TUMOR	35	M
1766	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1766	F	7	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1766	F	7	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1767	F	7	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1767	F	7	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1767	F	7	743	FS	HEART		CARDIOMYOPATHY		
1767	F	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1767	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1767	F	7	743	FS	THYMUS	THY	M-THYMOMA	80	M
1767	F	7	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1768	F	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1768	F	7	743	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
1768	F	7	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1768	F	7	743	FS	OVARY		CYST(S)		
1768	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1768	F	7	743	FS	STOMACH		MINERALIZATION		
1769	F	7	710	U2	ADRENAL GLAND		DEGENERATION, CYSTIC		
1769	F	7	710	U2	KIDNEY		NEPHROPATHY		
1769	F	7	710	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1769	F	7	710	U2	MAMMARY GLAND	MA	B-ADENOMA	1	I
1769	F	7	710	U2	OVARY	OV	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	18	I
1769	F	7	710	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1769	F	7	710	U2	RECTUM		METAZOAN PARASITE(S)		
1769	F	7	710	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1769	F	7	710	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	I
1770	F	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1770	F	7	743	FS	KIDNEY		NEPHROPATHY		
1770	F	7	743	FS	OVARY	OV	B-GONADAL STROMAL TUMOR, UNDIFFERENTIATED	18	M
1770	F	7	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
1770	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1770	F	7	743	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1771	F	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1771	F	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1771	F	7	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1771	F	7	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1772	F	7	628	U1	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	F
1772	F	7	628	U1	SPLEEN		ATROPHY, LYMPHOID		
1772	F	7	628	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1773	F	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1773	F	7	745	FS	HEART		CARDIOMYOPATHY		
1773	F	7	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1773	F	7	745	FS	LUNG	LU	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	4	M



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1773	F	7	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1773	F	7	745	FS	SPLEEN	SP	M-HEMANGIOSARCOMA	62	M
1773	F	7	745	FS	THYMUS	THY	F-LYMPHOMA	38	M
1773	F	7	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1774	F	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1774	F	7	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1774	F	7	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1775	F	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1776	F	7	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1777	F	7	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1777	F	7	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1778	F	7	693	U2	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1778	F	7	693	U2	KIDNEY		MINERALIZATION		
1778	F	7	693	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1778	F	7	693	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
1779	F	7	493	U2	MAMMARY GLAND		CYST(S), DUCTAL		
1779	F	7	493	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1780	F	7	745	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
1780	F	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1780	F	7	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1780	F	7	745	FS	KIDNEY		NEPHROPATHY		
1780	F	7	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1780	F	7	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1821	F	8	729	FS	CLITORAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1822	F	8	729	FS	KIDNEY		NEPHROPATHY		
1822	F	8	729	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1823	F	8	729	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1823	F	8	729	FS	KIDNEY		NEPHROPATHY		
1823	F	8	729	FS	OVARY		CYST(S)		
1823	F	8	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1824	F	8	729	FS	HEART		CARDIOMYOPATHY		
1824	F	8	729	FS	KIDNEY		NEPHROPATHY		
1824	F	8	729	FS	OVARY		CYST(S)		
1825	F	8	729	FS	HEART		CARDIOMYOPATHY		
1825	F	8	729	FS	KIDNEY		NEPHROPATHY		
1825	F	8	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
1825	F	8	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1825	F	8	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1825	F	8	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
1826	F	8	729	FS	EYE		CATARACT		
1826	F	8	729	FS	HARDERIAN GLAND		INFLAMMATION		
1826	F	8	729	FS	KIDNEY		NEPHROPATHY		
1826	F	8	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1827	F	8	729	FS	HEART		CARDIOMYOPATHY		
1827	F	8	729	FS	KIDNEY		HYDRONEPHROSIS		
1827	F	8	729	FS	KIDNEY		NEPHROPATHY		
1828	F	8	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1828	F	8	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1829	F	8	729	FS	HEART		CARDIOMYOPATHY		
1829	F	8	729	FS	OVARY		CYST(S)		
1829	F	8	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1829	F	8	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1830	F	8	689	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1830	F	8	689	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1830	F	8	689	U2	KIDNEY		NEPHROPATHY		
1830	F	8	689	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	I
1830	F	8	689	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1831	F	8	731	FS	HEART		CARDIOMYOPATHY		
1831	F	8	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1831	F	8	731	FS	LIVER		FOCUS, EOSINOPHILIC		
1831	F	8	731	FS	LIVER		FOCUS, MIXED CELL		
1831	F	8	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1831	F	8	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1832	F	8	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1832	F	8	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1832	F	8	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1832	F	8	731	FS	HEART		CARDIOMYOPATHY		
1832	F	8	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1832	F	8	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1832	F	8	731	FS	OVARY		CYST(S)		
1832	F	8	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1832	F	8	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1833	F	8	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1833	F	8	731	FS	THYMUS		CYST(S)		
1834	F	8	731	FS	KIDNEY		CYST(S), TUBULAR		
1834	F	8	731	FS	KIDNEY		NEPHROPATHY		
1834	F	8	731	FS	LUNG		INFLAMMATION		
1834	F	8	731	FS	PITUITARY GLAND		CYST(S), PARS DISTALIS		
1834	F	8	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1835	F	8	731	FS	KIDNEY		NEPHROPATHY		
1835	F	8	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
1835	F	8	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
1835	F	8	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1835	F	8	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1836	F	8	731	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1836	F	8	731	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1837	F	8	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1837	F	8	731	FS	OVARY		CYST(S)		
1837	F	8	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1837	F	8	731	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1838	F	8	720	U2	ADRENAL GLAND		DEGENERATION, CYSTIC		
1838	F	8	720	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1838	F	8	720	U2	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1838	F	8	720	U2	MAMMARY GLAND	MA	B-ADENOMA	1	F
1839	F	8	735	FS	KIDNEY		NEPHROPATHY		
1839	F	8	735	FS	OVARY		CYST(S)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1839	F	8	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1839	F	8	735	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		
1839	F	8	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1840	F	8	716	U1	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1840	F	8	716	U1	CLITORAL GLAND		INFLAMMATION		
1840	F	8	716	U1	LIVER	LI	F-LYMPHOMA	38	I
1840	F	8	716	U1	LN-MEDIASTINAL	LNMED	F-LYMPHOMA	38	I
1840	F	8	716	U1	LN-MESENTERIC	LNMES	F-LYMPHOMA	38	I
1840	F	8	716	U1	LN-OTHER	LNO	F-LYMPHOMA	38	I
1840	F	8	716	U1	LUNG	LU	F-LYMPHOMA	38	I
1840	F	8	716	U1	OVARY		CYST(S)		
1840	F	8	716	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1840	F	8	716	U1	SPLEEN	SP	F-LYMPHOMA	38	F
1841	F	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1841	F	8	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1841	F	8	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1841	F	8	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1841	F	8	735	FS	MAMMARY GLAND	MA	M-CARCINOMA	42	M
1841	F	8	735	FS	OVARY		CYST(S)		
1841	F	8	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1842	F	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1842	F	8	735	FS	KIDNEY		NEPHROPATHY		
1842	F	8	735	FS	LIVER		CYST(S), BILE DUCTS		
1842	F	8	735	FS	LIVER		DILATATION, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1842	F	8	735	FS	LIVER		FOCUS, CLEAR CELL		
1842	F	8	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1842	F	8	735	FS	LUNG		INFLAMMATION		
1842	F	8	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1842	F	8	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1843	F	8	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1843	F	8	735	FS	KIDNEY		HYDRONEPHROSIS		
1843	F	8	735	FS	KIDNEY		NEPHROPATHY		
1843	F	8	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1843	F	8	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
1843	F	8	735	FS	PANCREAS		LIPOMATOSIS		
1843	F	8	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1843	F	8	735	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1844	F	8	735	FS	LIVER		CYST(S), BILE DUCTS		
1844	F	8	735	FS	LIVER		DILATATION, BILE DUCT		
1844	F	8	735	FS	VAGINA	VA	B-POLYP	30	M
1845	F	8	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
1845	F	8	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
1845	F	8	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1845	F	8	735	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1846	F	8	735	FS	HEART		CARDIOMYOPATHY		
1846	F	8	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
1846	F	8	735	FS	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	M
1847	F	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1847	F	8	735	FS	LIVER	LI	M-LEIOMYOSARCOMA, METASTATIC (STOMACH)	65	M
1847	F	8	735	FS	LIVER		FIBROSIS		
1847	F	8	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1847	F	8	735	FS	OVARY		CYST(S)		
1847	F	8	735	FS	RECTUM		METAZOAN PARASITE(S)		
1847	F	8	735	FS	STOMACH	ST	M-LEIOMYOSARCOMA	64	M
1848	F	8	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
1848	F	8	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1848	F	8	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1848	F	8	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1849	F	8	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1849	F	8	737	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
1849	F	8	737	FS	KIDNEY		NEPHROPATHY		
1849	F	8	737	FS	LIVER		LIPIDOSIS, FOCAL		
1849	F	8	737	FS	OVARY		CYST(S)		
1849	F	8	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
1849	F	8	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1849	F	8	737	FS	SALIVARY GLAND	SA	M-CARCINOMA	45	M
1849	F	8	737	FS	THYMUS		CYST(S)		
1849	F	8	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1850	F	8	737	FS	KIDNEY		NEPHROPATHY		
1850	F	8	737	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1850	F	8	737	FS	OVARY	OV	B-GRANULOSA CELL TUMOR	20	M
1850	F	8	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1850	F	8	737	FS	THYMUS		INFLAMMATION		
1851	F	8	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1851	F	8	737	FS	CLITORAL GLAND		INFLAMMATION		
1851	F	8	737	FS	HEART		CARDIOMYOPATHY		
1851	F	8	737	FS	KIDNEY		NEPHROPATHY		
1851	F	8	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
1851	F	8	737	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1851	F	8	737	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
1851	F	8	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1851	F	8	737	FS	UTERUS	UT	M-CARCINOMA	46	M
1852	F	8	663	U1	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1852	F	8	663	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	F
1853	F	8	737	FS	KIDNEY		HYDRONEPHROSIS		
1853	F	8	737	FS	KIDNEY		NEPHROPATHY		
1853	F	8	737	FS	OVARY		CYST(S)		
1853	F	8	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1853	F	8	737	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1854	F	8	741	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
1854	F	8	741	FS	KIDNEY		NEPHROPATHY		
1854	F	8	741	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
1854	F	8	741	FS	OVARY		CYST(S)		
1854	F	8	741	FS	PANCREAS		ATROPHY, ACINAR CELL		
1854	F	8	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1855	F	8	715	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1856	F	8	741	FS	KIDNEY		HYDRONEPHROSIS		
1856	F	8	741	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1857	F	8	741	FS	HEART		CARDIOMYOPATHY		
1857	F	8	741	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1857	F	8	741	FS	TONGUE		INFLAMMATION, CHRONIC		
1858	F	8	665	U1	LIVER	LI	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	LN-MESENTERIC	LNMES	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	LN-OTHER	LNO	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	MESENTERY	ME	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	OVARY	OV	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	SKELETAL MUSCLE	SM	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1858	F	8	665	U1	UTERUS	UT	M-CARCINOMA	46	F
1859	F	8	741	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1859	F	8	741	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1859	F	8	741	FS	KIDNEY		NEPHROPATHY		
1859	F	8	741	FS	LN-OTHER	LNO	M-HEMANGIOSARCOMA	62	M
1859	F	8	741	FS	MAMMARY GLAND		CYST(S), DUCTAL		
1859	F	8	741	FS	OVARY		CYST(S)		
1859	F	8	741	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
1860	F	8	652	U2	LIVER		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1860	F	8	652	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1860	F	8	652	U2	UTERUS	UT	B-POLYP, ENDOMETRIAL STROMAL	31	F
1860	F	8	652	U2	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1861	F	8	741	FS	LIVER		FOCUS, BASOPHILIC CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1861	F	8	741	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1862	F	8	683	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1862	F	8	683	U2	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1862	F	8	683	U2	MAMMARY GLAND	MA	M-CARCINOMA	42	I
1862	F	8	683	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1862	F	8	683	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1862	F	8	683	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
1863	F	8	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
1864	F	8	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
1864	F	8	743	FS	UTERUS		HYPERPLASIA, ENDOMETRIUM, ATYPICAL		
1865	F	8	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1865	F	8	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1866	F	8	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1866	F	8	743	FS	KIDNEY		HYDRONEPHROSIS		
1866	F	8	743	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
1866	F	8	743	FS	KIDNEY		NEPHROPATHY		
1867	F	8	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1867	F	8	743	FS	OVARY		CYST(S)		
1867	F	8	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1868	F	8	725	U1	ADRENAL GLAND		ATROPHY		
1868	F	8	725	U1	LIVER		NECROSIS, HEPATOCELLULAR		
1868	F	8	725	U1	LUNG	LU	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1868	F	8	725	U1	OVARY	OV	B-DYSGERMINOMA	14	I
1868	F	8	725	U1	OVARY	OV	M-CARCINOMA, METASTATIC (UTERUS)	54	I

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1868	F	8	725	U1	PANCREAS	PA	M-CARCINOMA, METASTATIC (UTERUS)	54	I
1868	F	8	725	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	I
1868	F	8	725	U1	UTERUS	UT	M-CARCINOMA	46	F
1869	F	8	743	FS	LIVER		HEMOSIDERIN PIGMENT		
1869	F	8	743	FS	STOMACH		MINERALIZATION		
1870	F	8	680	U1	HEART		CARDIOMYOPATHY		
1870	F	8	680	U1	LIVER		FOCUS, BASOPHILIC CELL		
1870	F	8	680	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1871	F	8	743	FS	KIDNEY		NEPHROPATHY		
1871	F	8	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
1871	F	8	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
1871	F	8	743	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
1871	F	8	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1871	F	8	743	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1872	F	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1872	F	8	745	FS	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1873	F	8	476	U1	OVARY		CYST(S)		
1873	F	8	476	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1873	F	8	476	U1	UTERUS		ENDOMETRIAL HYPERPLASIA, CYSTIC (CEH)		
1874	F	8	476	U2	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1874	F	8	476	U2	KIDNEY		NEPHROPATHY		
1874	F	8	476	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1874	F	8	476	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
1874	F	8	476	U2	UTERUS	UT	M-SARCOMA, STROMAL	77	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1875	F	8	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1875	F	8	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
1875	F	8	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1875	F	8	745	FS	OVARY		CYST(S)		
1875	F	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1876	F	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
1876	F	8	745	FS	HEART		CARDIOMYOPATHY		
1876	F	8	745	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
1876	F	8	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
1876	F	8	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
1877	F	8	745	FS	HEART		CARDIOMYOPATHY		
1877	F	8	745	FS	OVARY		CYST(S)		
1877	F	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1877	F	8	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
1878	F	8	698	U1	ADRENAL GLAND		HYPERTROPHY, CORTEX		
1878	F	8	698	U1	HEART		CARDIOMYOPATHY		
1878	F	8	698	U1	LUNG		INFLAMMATION		
1878	F	8	698	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
1878	F	8	698	U1	SPLEEN		ATROPHY, LYMPHOID		
1878	F	8	698	U1	STOMACH		INFLAMMATION, NON-GLANDULAR		
1879	F	8	745	FS	CLITORAL GLAND		INFLAMMATION		
1879	F	8	745	FS	KIDNEY		NEPHROPATHY		
1879	F	8	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
1879	F	8	745	FS	OVARY		CYST(S)		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
1879	F	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
1879	F	8	745	FS	UTERUS	UT	M-CARCINOMA	46	M
1880	F	8	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
1880	F	8	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
1880	F	8	745	FS	OVARY		CYST(S)		
1880	F	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
121	M	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
121	M	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
121	M	1	729	FS	KIDNEY		HYDRONEPHROSIS		
121	M	1	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
121	M	1	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
121	M	1	729	FS	SKIN		INFLAMMATION		
121	M	1	729	FS	SKIN		ULCER, EPIDERMIS		
122	M	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
122	M	1	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
122	M	1	729	FS	HEART		CARDIOMYOPATHY		
122	M	1	729	FS	KIDNEY		NEPHROPATHY		
122	M	1	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
122	M	1	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
122	M	1	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
122	M	1	729	FS	SKIN		INFLAMMATION		
122	M	1	729	FS	SKIN		ULCER, EPIDERMIS		
123	M	1	212	U2	PREPUTIAL GLAND		INFLAMMATION		
124	M	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
124	M	1	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
124	M	1	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
124	M	1	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
124	M	1	729	FS	SKIN		INFLAMMATION		
125	M	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
125	M	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
125	M	1	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
125	M	1	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
125	M	1	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
126	M	1	729	FS	KIDNEY		NEPHROPATHY		
126	M	1	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
126	M	1	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
126	M	1	729	FS	SKIN		INFLAMMATION		
126	M	1	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
126	M	1	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
127	M	1	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
127	M	1	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
127	M	1	729	FS	KIDNEY		NEPHROPATHY		
127	M	1	729	FS	LIVER		INFLAMMATION		
127	M	1	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
127	M	1	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
127	M	1	729	FS	PREPUTIAL GLAND		INFLAMMATION		
127	M	1	729	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
128	M	1	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
128	M	1	729	FS	HEART		CARDIOMYOPATHY		
128	M	1	729	FS	KIDNEY		NEPHROPATHY		
128	M	1	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
128	M	1	729	FS	PREPUTIAL GLAND		INFLAMMATION		
128	M	1	729	FS	SKIN		INFLAMMATION		
129	M	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
129	M	1	731	FS	HEART		CARDIOMYOPATHY		
129	M	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
129	M	1	731	FS	PREPUTIAL GLAND		INFLAMMATION		
129	M	1	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
130	M	1	731	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
130	M	1	731	FS	HEART		CARDIOMYOPATHY		
130	M	1	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
130	M	1	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
130	M	1	731	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
130	M	1	731	FS	PREPUTIAL GLAND		INFLAMMATION		
131	M	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
131	M	1	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
131	M	1	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
131	M	1	731	FS	HEART		CARDIOMYOPATHY		
131	M	1	731	FS	LIVER		CYST(S), BILE DUCTS		
131	M	1	731	FS	LIVER		FOCUS, CLEAR CELL		
131	M	1	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
131	M	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
131	M	1	731	FS	PREPUTIAL GLAND		INFLAMMATION		
131	M	1	731	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
131	M	1	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
131	M	1	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
132	M	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
132	M	1	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
132	M	1	731	FS	HEART		CARDIOMYOPATHY		
132	M	1	731	FS	KIDNEY		NECROSIS, PAPILLARY		
132	M	1	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
132	M	1	731	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
132	M	1	731	FS	PROSTATE		INFLAMMATION		
132	M	1	731	FS	STOMACH		INFLAMMATION, NON-GLANDULAR		
132	M	1	731	FS	STOMACH		ULCER, NON-GLANDULAR		
132	M	1	731	FS	TESTIS		ATROPHY, BILATERAL		
132	M	1	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
133	M	1	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
133	M	1	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
133	M	1	731	FS	HEART		CARDIOMYOPATHY		
133	M	1	731	FS	KIDNEY		CYST(S), TUBULAR		
133	M	1	731	FS	KIDNEY		INFLAMMATION		
133	M	1	731	FS	LN-OTHER		CYSTIC DEGENERATION		
133	M	1	731	FS	LN-OTHER		HYPERPLASIA, PLASMA CELL		
133	M	1	731	FS	PHARYNX		HYPERPLASIA, MUCOSAL EPITHELIUM		
133	M	1	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
133	M	1	731	FS	SKIN		INFLAMMATION		
133	M	1	731	FS	SKIN		ULCER, EPIDERMIS		
133	M	1	731	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
133	M	1	731	FS	TESTIS		ATROPHY, BILATERAL		
134	M	1	578	U2	HEART		CARDIOMYOPATHY		
134	M	1	578	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
134	M	1	578	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
135	M	1	735	FS	HEART		CARDIOMYOPATHY		
135	M	1	735	FS	KIDNEY		NECROSIS, PAPILLARY		
135	M	1	735	FS	KIDNEY		NEPHROPATHY		
135	M	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
135	M	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
135	M	1	735	FS	PREPUTIAL GLAND		INFLAMMATION		
135	M	1	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
136	M	1	735	FS	HEART		CARDIOMYOPATHY		
136	M	1	735	FS	KIDNEY		INFLAMMATION		
136	M	1	735	FS	KIDNEY		NEPHROPATHY		
136	M	1	735	FS	LIVER		FOCUS, CLEAR CELL		
136	M	1	735	FS	LIVER		INFLAMMATION		
136	M	1	735	FS	PARATHYROID	PTHY	B-ADENOMA	1	M
136	M	1	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
136	M	1	735	FS	PROSTATE		INFLAMMATION		
136	M	1	735	FS	SKIN		INFLAMMATION		
136	M	1	735	FS	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
137	M	1	735	FS	HEART		CARDIOMYOPATHY		
137	M	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
137	M	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
137	M	1	735	FS	PROSTATE		INFLAMMATION		
137	M	1	735	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
137	M	1	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
138	M	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
138	M	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
138	M	1	735	FS	HEART		CARDIOMYOPATHY		
138	M	1	735	FS	KIDNEY		INFLAMMATION		
138	M	1	735	FS	KIDNEY		NEPHROPATHY		
138	M	1	735	FS	LIVER		INFLAMMATION		
138	M	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
138	M	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
138	M	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
138	M	1	735	FS	PROSTATE		INFLAMMATION		
138	M	1	735	FS	SKIN		INFLAMMATION		
138	M	1	735	FS	SKIN		ULCER, EPIDERMIS		
138	M	1	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
138	M	1	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
139	M	1	735	FS	HEART		CARDIOMYOPATHY		
139	M	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
139	M	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
139	M	1	735	FS	PROSTATE		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
139	M	1	735	FS	SKIN		INFLAMMATION		
139	M	1	735	FS	SKIN		ULCER, EPIDERMIS		
140	M	1	467	U2	CECUM		INFLAMMATION		
140	M	1	467	U2	HEART		CARDIOMYOPATHY		
140	M	1	467	U2	KIDNEY		NEPHROPATHY		
140	M	1	467	U2	LIVER		HYPERPLASIA, BILE DUCT		
140	M	1	467	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
140	M	1	467	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
140	M	1	467	U2	PROSTATE		INFLAMMATION		
140	M	1	467	U2	SPLEEN		ATROPHY, LYMPHOID		
140	M	1	467	U2	STOMACH		ULCER, NON-GLANDULAR		
141	M	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
141	M	1	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
141	M	1	735	FS	HEART		CARDIOMYOPATHY		
141	M	1	735	FS	KIDNEY		NEPHROPATHY		
141	M	1	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
141	M	1	735	FS	LIVER		FOCUS, CLEAR CELL		
141	M	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
141	M	1	735	FS	SKIN		INFLAMMATION		
141	M	1	735	FS	SKIN		ULCER, EPIDERMIS		
141	M	1	735	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
141	M	1	735	FS	THYMUS	THY	M-THYMOMA	80	M
142	M	1	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
142	M	1	735	FS	BONE	BO	B-OSTEOMA	27	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
142	M	1	735	FS	BRAIN	BR	B-GRANULAR CELL TUMOR	19	M
142	M	1	735	FS	HEART		CARDIOMYOPATHY		
142	M	1	735	FS	KIDNEY		NEPHROPATHY		
142	M	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
142	M	1	735	FS	PANCREAS	PA	B-ISLET CELL TUMOR	22	M
142	M	1	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
142	M	1	735	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
142	M	1	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
142	M	1	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
143	M	1	735	FS	HEART		CARDIOMYOPATHY		
143	M	1	735	FS	KIDNEY		NEPHROPATHY		
143	M	1	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
143	M	1	735	FS	LIVER		FOCUS, CLEAR CELL		
143	M	1	735	FS	LIVER		INFLAMMATION		
143	M	1	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
143	M	1	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
144	M	1	735	FS	HEART		CARDIOMYOPATHY		
144	M	1	735	FS	KIDNEY		CYST(S), TUBULAR		
144	M	1	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
144	M	1	735	FS	NOSE/TURBINATES		INFLAMMATION		
144	M	1	735	FS	PARATHYROID		HYPERPLASIA		
144	M	1	735	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
144	M	1	735	FS	PROSTATE		INFLAMMATION		
144	M	1	735	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
144	M	1	735	FS	RECTUM		METAZOAN PARASITE(S)		
144	M	1	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
144	M	1	735	FS	TOOTH		INFLAMMATION		
145	M	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
145	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
145	M	1	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
145	M	1	737	FS	HEART		CARDIOMYOPATHY		
145	M	1	737	FS	KIDNEY		NEPHROPATHY		
145	M	1	737	FS	LIVER		LIPIDOSIS, DIFFUSE		
145	M	1	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
145	M	1	737	FS	PROSTATE		INFLAMMATION		
145	M	1	737	FS	SKIN	SK	M-CARCINOMA, BASAL CELL	48	M
145	M	1	737	FS	SKIN		ULCER, EPIDERMIS		
146	M	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
146	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
146	M	1	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
146	M	1	737	FS	COLON		METAZOAN PARASITE, LUMEN		
146	M	1	737	FS	KIDNEY		NEPHROPATHY		
146	M	1	737	FS	LIVER		DILATATION, BILE DUCT		
146	M	1	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
146	M	1	737	FS	LIVER		LIPIDOSIS, DIFFUSE		
146	M	1	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
146	M	1	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
147	M	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
147	M	1	737	FS	HEART		CARDIOMYOPATHY		
147	M	1	737	FS	KIDNEY		NEPHROPATHY		
147	M	1	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
147	M	1	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
147	M	1	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
147	M	1	737	FS	SKIN		ULCER, EPIDERMIS		
147	M	1	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
147	M	1	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
148	M	1	653	U2	HEART		CARDIOMYOPATHY		
148	M	1	653	U2	KIDNEY		CYST(S), TUBULAR		
148	M	1	653	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
148	M	1	653	U2	TESTIS		ATROPHY, UNILATERAL		
148	M	1	653	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
149	M	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
149	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
149	M	1	737	FS	KIDNEY		NEPHROPATHY		
149	M	1	737	FS	LIVER		CYST(S), BILE DUCTS		
149	M	1	737	FS	LIVER		INFLAMMATION		
149	M	1	737	FS	PANCREAS		LIPOMATOSIS		
149	M	1	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
149	M	1	737	FS	RECTUM		METAZOAN PARASITE(S)		
149	M	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
150	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
150	M	1	737	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
150	M	1	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
150	M	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
151	M	1	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
151	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
151	M	1	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
151	M	1	737	FS	HEART		CARDIOMYOPATHY		
151	M	1	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
151	M	1	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
151	M	1	737	FS	LIVER		INFLAMMATION, ARTERY		
151	M	1	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
151	M	1	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
151	M	1	737	FS	RECTUM		METAZOAN PARASITE(S)		
151	M	1	737	FS	STOMACH		INFLAMMATION, NON-GLANDULAR		
151	M	1	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
152	M	1	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
152	M	1	737	FS	HEART		CARDIOMYOPATHY		
152	M	1	737	FS	KIDNEY		NEPHROPATHY		
152	M	1	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
152	M	1	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
152	M	1	737	FS	TESTIS		ATROPHY, UNILATERAL		
152	M	1	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
153	M	1	739	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
153	M	1	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
153	M	1	739	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
153	M	1	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
154	M	1	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
154	M	1	739	FS	HEART		CARDIOMYOPATHY		
154	M	1	739	FS	KIDNEY		NEPHROPATHY		
154	M	1	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
154	M	1	739	FS	PANCREAS		LIPOMATOSIS		
154	M	1	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
154	M	1	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
155	M	1	739	FS	HEART		CARDIOMYOPATHY		
155	M	1	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
155	M	1	739	FS	PANCREAS		LIPOMATOSIS		
155	M	1	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
156	M	1	739	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
156	M	1	739	FS	PANCREAS		LIPOMATOSIS		
156	M	1	739	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
156	M	1	739	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
157	M	1	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
157	M	1	739	FS	CECUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
157	M	1	739	FS	HEART		CARDIOMYOPATHY		
157	M	1	739	FS	KIDNEY		CYST(S), TUBULAR		
157	M	1	739	FS	KIDNEY		NEPHROPATHY		
157	M	1	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
157	M	1	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
157	M	1	739	FS	PROSTATE		INFLAMMATION		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
157	M	1	739	FS	STOMACH		INFLAMMATION, NON-GLANDULAR		
157	M	1	739	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
158	M	1	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
158	M	1	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
159	M	1	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
159	M	1	739	FS	KIDNEY		NEPHROPATHY		
159	M	1	739	FS	PANCREAS		BASOPHILIC FOCUS, ACINAR CELL		
159	M	1	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
159	M	1	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
160	M	1	739	FS	KIDNEY		NEPHROPATHY		
160	M	1	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
160	M	1	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
160	M	1	739	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
160	M	1	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
161	M	1	532	U2	HEART		CARDIOMYOPATHY		
161	M	1	532	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
161	M	1	532	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
161	M	1	532	U2	SKIN		HYPERPLASIA, EPIDERMIS		
161	M	1	532	U2	SKIN		INFLAMMATION		
161	M	1	532	U2	TESTIS		ATROPHY, BILATERAL		
162	M	1	301	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
162	M	1	301	U2	BRAIN	BR	M-ASTROCYTOMA	39	F
163	M	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
163	M	1	743	FS	BONE	BO	B-GRANULAR CELL TUMOR	19	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
163	M	1	743	FS	HEART		CARDIOMYOPATHY		
163	M	1	743	FS	KIDNEY		NEPHROPATHY		
163	M	1	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
163	M	1	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
164	M	1	524	U1	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
164	M	1	524	U1	PREPUTIAL GLAND		INFLAMMATION		
164	M	1	524	U1	PROSTATE		INFLAMMATION		
164	M	1	524	U1	SPLEEN		ATROPHY, LYMPHOID		
164	M	1	524	U1	THYROID GLAND		HYPERPLASIA, C-CELL		
165	M	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
165	M	1	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
165	M	1	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
165	M	1	743	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
165	M	1	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
165	M	1	743	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
165	M	1	743	FS	TESTIS		ATROPHY, UNILATERAL		
165	M	1	743	FS	TONGUE		HYPERPLASIA, MUCOSAL EPITHELIUM		
166	M	1	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
166	M	1	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
166	M	1	743	FS	HEART		CARDIOMYOPATHY		
166	M	1	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
166	M	1	743	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
166	M	1	743	FS	SKIN	SK	B-LIPOMA	25	M
166	M	1	743	FS	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
166	M	1	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
167	M	1	623	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
167	M	1	623	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
167	M	1	623	U2	BRAIN	BR	M-ASTROCYTOMA	39	F
167	M	1	623	U2	KIDNEY		NEPHROPATHY		
167	M	1	623	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
167	M	1	623	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	I
167	M	1	623	U2	SKIN		CYST, EPITHELIAL INCLUSION		
167	M	1	623	U2	SKIN		HYPERPLASIA, EPIDERMIS		
167	M	1	623	U2	SKIN		INFLAMMATION		
167	M	1	623	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
168	M	1	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
168	M	1	743	FS	HEART		CARDIOMYOPATHY		
168	M	1	743	FS	LUNG		INFLAMMATION		
168	M	1	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
168	M	1	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
168	M	1	743	FS	PROSTATE		INFLAMMATION		
169	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
169	M	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
169	M	1	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
169	M	1	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
169	M	1	745	FS	KIDNEY		HYDRONEPHROSIS		
169	M	1	745	FS	KIDNEY		NEPHROPATHY		
169	M	1	745	FS	LIVER		FOCUS, CLEAR CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
169	M	1	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
169	M	1	745	FS	PROSTATE		INFLAMMATION		
170	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
170	M	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
170	M	1	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
170	M	1	745	FS	HEART		CARDIOMYOPATHY		
170	M	1	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
170	M	1	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
170	M	1	745	FS	SKIN		HYPERPLASIA, EPIDERMIS		
170	M	1	745	FS	SKIN		ULCER, EPIDERMIS		
170	M	1	745	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
170	M	1	745	FS	TESTIS		ATROPHY, BILATERAL		
170	M	1	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
170	M	1	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
171	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
171	M	1	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
171	M	1	745	FS	HEART		CARDIOMYOPATHY		
171	M	1	745	FS	LUNG	LU	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	4	M
171	M	1	745	FS	SKIN		ULCER, EPIDERMIS		
171	M	1	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
171	M	1	745	FS	TESTIS		ATROPHY, UNILATERAL		
172	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
172	M	1	745	FS	HEART		CARDIOMYOPATHY		
172	M	1	745	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
172	M	1	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
172	M	1	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
172	M	1	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
172	M	1	745	FS	PHARYNX		INFLAMMATION		
172	M	1	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
173	M	1	745	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
173	M	1	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
173	M	1	745	FS	KIDNEY		NEPHROPATHY		
173	M	1	745	FS	PANCREAS		ATROPHY, ACINAR CELL		
173	M	1	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
173	M	1	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
173	M	1	745	FS	SKIN		INFLAMMATION		
174	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
174	M	1	745	FS	HEART		CARDIOMYOPATHY		
174	M	1	745	FS	LIVER		LIPIDOSIS, FOCAL		
174	M	1	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
174	M	1	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
174	M	1	745	FS	SKIN		HYPERPLASIA, EPIDERMIS		
174	M	1	745	FS	SKIN		INFLAMMATION		
174	M	1	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
174	M	1	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
175	M	1	547	MISSING					
176	M	1	547	MISSING					
177	M	1	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
177	M	1	745	FS	HEART		CARDIOMYOPATHY		
177	M	1	745	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
177	M	1	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
178	M	1	732	U2	HEART		CARDIOMYOPATHY		
178	M	1	732	U2	KIDNEY		NEPHROPATHY		
178	M	1	732	U2	PANCREAS		LIPOMATOSIS		
178	M	1	732	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
178	M	1	732	U2	PROSTATE		INFLAMMATION		
178	M	1	732	U2	SKIN		ULCER, EPIDERMIS		
178	M	1	732	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
179	M	1	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
179	M	1	746	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
179	M	1	746	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
179	M	1	746	FS	PROSTATE		INFLAMMATION		
179	M	1	746	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
180	M	1	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
180	M	1	746	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
180	M	1	746	FS	HEART		CARDIOMYOPATHY		
180	M	1	746	FS	LIVER		LIPIDOSIS, DIFFUSE		
180	M	1	746	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
180	M	1	746	FS	SKIN	SK	B-ADENOMA, BASAL CELL	2	M
180	M	1	746	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
201	M	2	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
201	M	2	729	FS	KIDNEY		HYDRONEPHROSIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
201	M	2	729	FS	KIDNEY		NEPHROPATHY		
201	M	2	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
201	M	2	729	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
202	M	2	564	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
202	M	2	564	U2	LIVER		FOCUS, CLEAR CELL		
202	M	2	564	U2	SKIN		ULCER, EPIDERMIS		
203	M	2	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
203	M	2	729	FS	HEART		CARDIOMYOPATHY		
203	M	2	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
203	M	2	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
203	M	2	729	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
204	M	2	593	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
204	M	2	593	U1	PROSTATE		ATROPHY		
204	M	2	593	U1	SEMINAL VESICLE		ATROPHY		
204	M	2	593	U1	TESTIS		ATROPHY, BILATERAL		
204	M	2	593	U1	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
205	M	2	675	U1	KIDNEY		INFLAMMATION		
205	M	2	675	U1	KIDNEY		NEPHROPATHY		
205	M	2	675	U1	PROSTATE		INFLAMMATION		
205	M	2	675	U1	SKIN		ULCER, EPIDERMIS		
206	M	2	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
206	M	2	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
206	M	2	729	FS	SKIN		INFLAMMATION		
206	M	2	729	FS	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
207	M	2	513	U2	HEART		CARDIOMYOPATHY		
207	M	2	513	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
208	M	2	729	FS	HEART		CARDIOMYOPATHY		
208	M	2	729	FS	LIVER		FOCUS, MIXED CELL		
208	M	2	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
208	M	2	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
208	M	2	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
208	M	2	729	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
209	M	2	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
209	M	2	731	FS	HEART		CARDIOMYOPATHY		
209	M	2	731	FS	KIDNEY		NEPHROPATHY		
209	M	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
209	M	2	731	FS	LIVER		FOCUS, MIXED CELL		
209	M	2	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
209	M	2	731	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
210	M	2	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
210	M	2	731	FS	HEART		CARDIOMYOPATHY		
210	M	2	731	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
210	M	2	731	FS	KIDNEY		NEPHROPATHY		
210	M	2	731	FS	NOSE/TURBINATES		SQUAMOUS METAPLASIA (RESPIRATORY EPITHELIUM)		
210	M	2	731	FS	SKIN		ULCER, EPIDERMIS		
210	M	2	731	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
211	M	2	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
211	M	2	731	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
211	M	2	731	FS	KIDNEY		INFLAMMATION		
211	M	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
211	M	2	731	FS	LIVER		TELANGIECTASIS		
211	M	2	731	FS	PREPUTIAL GLAND		INFLAMMATION		
211	M	2	731	FS	SKIN		INFLAMMATION		
211	M	2	731	FS	SKIN		ULCER, EPIDERMIS		
211	M	2	731	FS	STERNUM		FIBROSIS		
211	M	2	731	FS	TESTIS		ATROPHY, BILATERAL		
212	M	2	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
212	M	2	731	FS	HEART		CARDIOMYOPATHY		
212	M	2	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
212	M	2	731	FS	PANCREAS		ATROPHY, ACINAR CELL		
212	M	2	731	FS	STOMACH		INFLAMMATION, GLANDULAR		
212	M	2	731	FS	TESTIS		EDEMA, INTERSTITIUM		
212	M	2	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
213	M	2	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
213	M	2	731	FS	HEART		CARDIOMYOPATHY		
213	M	2	731	FS	KIDNEY		NEPHROPATHY		
213	M	2	731	FS	LIVER		TELANGIECTASIS		
213	M	2	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
213	M	2	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
213	M	2	731	FS	SKIN		ULCER, EPIDERMIS		
213	M	2	731	FS	SPLEEN	SP	B-HEMANGIOMA	21	M
213	M	2	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
214	M	2	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
214	M	2	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
214	M	2	731	FS	DUODENUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
214	M	2	731	FS	HEART		CARDIOMYOPATHY		
214	M	2	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
214	M	2	731	FS	LIVER		FOCUS, CLEAR CELL		
214	M	2	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
214	M	2	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
214	M	2	731	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
214	M	2	731	FS	PROSTATE		INFLAMMATION		
214	M	2	731	FS	RECTUM		METAZOAN PARASITE(S)		
214	M	2	731	FS	TESTIS		EDEMA, INTERSTITIUM		
215	M	2	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
215	M	2	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
215	M	2	735	FS	KIDNEY		NEPHROPATHY		
215	M	2	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
215	M	2	735	FS	RECTUM		METAZOAN PARASITE(S)		
216	M	2	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
216	M	2	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
216	M	2	735	FS	HEART		CARDIOMYOPATHY		
216	M	2	735	FS	KIDNEY		NEPHROPATHY		
216	M	2	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
216	M	2	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
216	M	2	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
216	M	2	735	FS	PROSTATE		INFLAMMATION		
216	M	2	735	FS	SKIN		ULCER, EPIDERMIS		
217	M	2	735	FS	DUODENUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
217	M	2	735	FS	HEART		CARDIOMYOPATHY		
217	M	2	735	FS	KIDNEY		NEPHROPATHY		
217	M	2	735	FS	LIVER		TELANGIECTASIS		
217	M	2	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
217	M	2	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
217	M	2	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
217	M	2	735	FS	RECTUM		METAZOAN PARASITE(S)		
217	M	2	735	FS	SKIN		ULCER, EPIDERMIS		
217	M	2	735	FS	TESTIS		ATROPHY, BILATERAL		
217	M	2	735	FS	TESTIS		EDEMA, INTERSTITIUM		
218	M	2	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
218	M	2	735	FS	HEART		CARDIOMYOPATHY		
218	M	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
218	M	2	735	FS	LIVER		FOCUS, CLEAR CELL		
218	M	2	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
218	M	2	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
218	M	2	735	FS	PREPUTIAL GLAND		INFLAMMATION		
218	M	2	735	FS	TESTIS		EDEMA, INTERSTITIUM		
219	M	2	735	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
219	M	2	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
219	M	2	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
219	M	2	735	FS	HEART		CARDIOMYOPATHY		
219	M	2	735	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
219	M	2	735	FS	LIVER		DILATATION, BILE DUCT		
219	M	2	735	FS	PANCREAS		HYPERPLASIA, ISLET CELL		
219	M	2	735	FS	PREPUTIAL GLAND		INFLAMMATION		
219	M	2	735	FS	RECTUM		METAZOAN PARASITE(S)		
219	M	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
220	M	2	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
220	M	2	735	FS	BRAIN	BR	M-ASTROCYTOMA	39	M
220	M	2	735	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
220	M	2	735	FS	HEART		CARDIOMYOPATHY		
220	M	2	735	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
220	M	2	735	FS	KIDNEY		NEPHROPATHY		
220	M	2	735	FS	LIVER		FOCUS, CLEAR CELL		
220	M	2	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
220	M	2	735	FS	LIVER		THROMBOSIS		
220	M	2	735	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
220	M	2	735	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
220	M	2	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
220	M	2	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
220	M	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
221	M	2	611	U2	BONE	BO	M-OSTEOSARCOMA	71	F
221	M	2	611	U2	KIDNEY		NEPHROPATHY		
221	M	2	611	U2	LIVER		FOCUS, CLEAR CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
221	M	2	611	U2	LUNG	LU	M-OSTEOSARCOMA, METASTATIC (BONE)	74	I
221	M	2	611	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
221	M	2	611	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
221	M	2	611	U2	TESTIS		EDEMA, INTERSTITIUM		
221	M	2	611	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
222	M	2	735	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
222	M	2	735	FS	HEART		CARDIOMYOPATHY		
222	M	2	735	FS	KIDNEY		NEPHROPATHY		
222	M	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
222	M	2	735	FS	LIVER		FOCUS, CLEAR CELL		
222	M	2	735	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
222	M	2	735	FS	NOSE/TURBINATES		INFLAMMATION		
222	M	2	735	FS	PREPUTIAL GLAND		INFLAMMATION		
222	M	2	735	FS	SKIN		ULCER, EPIDERMIS		
222	M	2	735	FS	SPLEEN	SP	M-HEMANGIOSARCOMA	62	M
222	M	2	735	FS	TESTIS		EDEMA, INTERSTITIUM		
222	M	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
223	M	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
223	M	2	735	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
223	M	2	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
223	M	2	735	FS	PREPUTIAL GLAND		INFLAMMATION		
223	M	2	735	FS	PROSTATE		INFLAMMATION		
223	M	2	735	FS	RECTUM		METAZOAN PARASITE(S)		
223	M	2	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
223	M	2	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
224	M	2	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
224	M	2	735	FS	KIDNEY		NEPHROPATHY		
224	M	2	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
224	M	2	735	FS	SKIN		INFLAMMATION		
224	M	2	735	FS	SKIN		ULCER, EPIDERMIS		
225	M	2	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
225	M	2	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
225	M	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
225	M	2	737	FS	LIVER		FOCUS, CLEAR CELL		
225	M	2	737	FS	PREPUTIAL GLAND		INFLAMMATION		
225	M	2	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
225	M	2	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
225	M	2	737	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
226	M	2	737	FS	KIDNEY		NEPHROPATHY		
226	M	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
226	M	2	737	FS	PREPUTIAL GLAND		INFLAMMATION		
226	M	2	737	FS	SKELETAL MUSCLE	SM	M-RHABDOMYOSARCOMA	75	M
227	M	2	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
227	M	2	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
227	M	2	737	FS	HEART		CARDIOMYOPATHY		
227	M	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
227	M	2	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
227	M	2	737	FS	PREPUTIAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
227	M	2	737	FS	RECTUM		METAZOAN PARASITE(S)		
227	M	2	737	FS	SKIN		ULCER, EPIDERMIS		
227	M	2	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
227	M	2	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
228	M	2	688	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
228	M	2	688	U1	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
228	M	2	688	U1	HEART		CARDIOMYOPATHY		
228	M	2	688	U1	KIDNEY		NEPHROPATHY		
228	M	2	688	U1	LIVER		NECROSIS, HEPATOCELLULAR		
228	M	2	688	U1	MESENTERY		NECROSIS		
228	M	2	688	U1	NOSE/TURBINATES		INFLAMMATION		
228	M	2	688	U1	PREPUTIAL GLAND		INFLAMMATION		
229	M	2	737	FS	HEART		CARDIOMYOPATHY		
229	M	2	737	FS	KIDNEY		NEPHROPATHY		
229	M	2	737	FS	LIVER		FOCUS, CLEAR CELL		
229	M	2	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
229	M	2	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
229	M	2	737	FS	PROSTATE		INFLAMMATION		
229	M	2	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
229	M	2	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
230	M	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
230	M	2	737	FS	LIVER		FOCUS, CLEAR CELL		
230	M	2	737	FS	LIVER		FOCUS, MIXED CELL		
230	M	2	737	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
230	M	2	737	FS	MAMMARY GLAND		CYST(S), DUCTAL		
230	M	2	737	FS	PROSTATE		INFLAMMATION		
230	M	2	737	FS	RECTUM		METAZOAN PARASITE(S)		
230	M	2	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
231	M	2	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
231	M	2	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
231	M	2	737	FS	HEART		CARDIOMYOPATHY		
231	M	2	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
232	M	2	737	FS	HEART		CARDIOMYOPATHY		
232	M	2	737	FS	PREPUTIAL GLAND		INFLAMMATION		
232	M	2	737	FS	TESTIS		ATROPHY, BILATERAL		
232	M	2	737	FS	TESTIS		EDEMA, INTERSTITIUM		
232	M	2	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
233	M	2	739	FS	HEART		CARDIOMYOPATHY		
233	M	2	739	FS	LIVER		FOCUS, CLEAR CELL		
233	M	2	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
233	M	2	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
233	M	2	739	FS	RECTUM		METAZOAN PARASITE(S)		
233	M	2	739	FS	TESTIS		ATROPHY, BILATERAL		
233	M	2	739	FS	TESTIS		EDEMA, INTERSTITIUM		
234	M	2	739	FS	HEART		CARDIOMYOPATHY		
234	M	2	739	FS	KIDNEY		NEPHROPATHY		
234	M	2	739	FS	LIVER		FOCUS, CLEAR CELL		
234	M	2	739	FS	LIVER		HYPERPLASIA, BILE DUCT		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
234	M	2	739	FS	PREPUTIAL GLAND		INFLAMMATION		
234	M	2	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
234	M	2	739	FS	SKIN		ULCER, EPIDERMIS		
234	M	2	739	FS	TESTIS		EDEMA, INTERSTITIUM		
234	M	2	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
235	M	2	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
235	M	2	739	FS	HARDERIAN GLAND		INFLAMMATION		
235	M	2	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
236	M	2	538	U2	HEART		CARDIOMYOPATHY		
236	M	2	538	U2	KIDNEY		INFLAMMATION		
236	M	2	538	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
236	M	2	538	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
236	M	2	538	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
237	M	2	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
237	M	2	739	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
237	M	2	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
237	M	2	739	FS	SKIN	SK	M-SCHWANNOMA	78	M
237	M	2	739	FS	TESTIS		ATROPHY, UNILATERAL		
237	M	2	739	FS	TESTIS		EDEMA, INTERSTITIUM		
238	M	2	739	FS	HEART		CARDIOMYOPATHY		
238	M	2	739	FS	KIDNEY		HYDRONEPHROSIS		
238	M	2	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
238	M	2	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
238	M	2	739	FS	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
238	M	2	739	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
239	M	2	739	FS	HEART		CARDIOMYOPATHY		
239	M	2	739	FS	KIDNEY		HYDRONEPHROSIS		
239	M	2	739	FS	LIVER		FOCUS, BASOPHILIC CELL		
239	M	2	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
239	M	2	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
239	M	2	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
239	M	2	739	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		
239	M	2	739	FS	SKIN	SK	B-ADENOMA, SEBACEOUS GLAND	12	M
240	M	2	691	U2	ADRENAL GLAND	AD	B-GANGLIONEUROMA	17	I
240	M	2	691	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
240	M	2	691	U2	HEART		CARDIOMYOPATHY		
240	M	2	691	U2	KIDNEY		INFLAMMATION		
240	M	2	691	U2	KIDNEY		NEPHROPATHY		
240	M	2	691	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
240	M	2	691	U2	PROSTATE		INFLAMMATION		
240	M	2	691	U2	SKIN		ULCER, EPIDERMIS		
240	M	2	691	U2	TESTIS		ATROPHY, BILATERAL		
241	M	2	662	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
241	M	2	662	U1	HEART		CARDIOMYOPATHY		
241	M	2	662	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
241	M	2	662	U1	PROSTATE		INFLAMMATION		
242	M	2	577	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
242	M	2	577	U2	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
243	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
243	M	2	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
243	M	2	743	FS	LIVER		FOCUS, EOSINOPHILIC		
243	M	2	743	FS	SKIN		INFLAMMATION		
243	M	2	743	FS	SKIN		ULCER, EPIDERMIS		
244	M	2	743	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
244	M	2	743	FS	ADRENAL GLAND		HEMORRHAGE		
244	M	2	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
244	M	2	743	FS	HEART		CARDIOMYOPATHY		
244	M	2	743	FS	KIDNEY		INFLAMMATION		
244	M	2	743	FS	KIDNEY		NEPHROPATHY		
244	M	2	743	FS	LIVER		FOCUS, CLEAR CELL		
244	M	2	743	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
244	M	2	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
244	M	2	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
244	M	2	743	FS	TESTIS		ATROPHY, BILATERAL		
244	M	2	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
245	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
245	M	2	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
245	M	2	743	FS	HEART		CARDIOMYOPATHY		
245	M	2	743	FS	KIDNEY		HYDRONEPHROSIS		
245	M	2	743	FS	KIDNEY		NEPHROPATHY		
245	M	2	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
245	M	2	743	FS	PANCREAS	PA	B-ISLET CELL TUMOR	22	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
245	M	2	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
245	M	2	743	FS	PROSTATE		INFLAMMATION		
246	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
246	M	2	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
246	M	2	743	FS	HEART		CARDIOMYOPATHY		
246	M	2	743	FS	KIDNEY		CYST(S), TUBULAR		
246	M	2	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
246	M	2	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
246	M	2	743	FS	SKIN		ULCER, EPIDERMIS		
246	M	2	743	FS	TESTIS		EDEMA, INTERSTITIUM		
247	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
247	M	2	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
247	M	2	743	FS	HEART		CARDIOMYOPATHY		
247	M	2	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
247	M	2	743	FS	SKIN		INFLAMMATION		
247	M	2	743	FS	SKIN		ULCER, EPIDERMIS		
248	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
248	M	2	743	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
248	M	2	743	FS	BRAIN	BR	M-ASTROCYTOMA	39	M
248	M	2	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
248	M	2	743	FS	HEART		CARDIOMYOPATHY		
248	M	2	743	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
248	M	2	743	FS	KIDNEY		NEPHROPATHY		
248	M	2	743	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
248	M	2	743	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
248	M	2	743	FS	SKIN		INFLAMMATION		
248	M	2	743	FS	SKIN		ULCER, EPIDERMIS		
248	M	2	743	FS	TESTIS		ATROPHY, UNILATERAL		
248	M	2	743	FS	TESTIS		EDEMA, INTERSTITIUM		
249	M	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
249	M	2	745	FS	CECUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
249	M	2	745	FS	HEART		CARDIOMYOPATHY		
249	M	2	745	FS	KIDNEY		NEPHROPATHY		
249	M	2	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
249	M	2	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
249	M	2	745	FS	SKIN	SK	B-ADENOMA, BASAL CELL	2	M
250	M	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
250	M	2	745	FS	HEART		CARDIOMYOPATHY		
250	M	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
250	M	2	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
250	M	2	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
250	M	2	745	FS	TESTIS		ATROPHY, UNILATERAL		
250	M	2	745	FS	TESTIS		EDEMA, INTERSTITIUM		
251	M	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
251	M	2	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
251	M	2	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
251	M	2	745	FS	PANCREAS		LIPOMATOSIS		
251	M	2	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
252	M	2	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
252	M	2	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
252	M	2	745	FS	LIVER		DILATATION, BILE DUCT		
252	M	2	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
252	M	2	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
252	M	2	745	FS	SEMINAL VESICLE		HYPERPLASIA, DUCT EPITHELIUM		
252	M	2	745	FS	TESTIS		ATROPHY, UNILATERAL		
252	M	2	745	FS	THYROID GLAND	THG	M-CARCINOMA, FOLLICULAR CELL	52	M
253	M	2	745	FS	HEART		CARDIOMYOPATHY		
253	M	2	745	FS	KIDNEY		HYDRONEPHROSIS		
253	M	2	745	FS	KIDNEY		NEPHROPATHY		
253	M	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
253	M	2	745	FS	LIVER		FOCUS, MIXED CELL		
253	M	2	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
253	M	2	745	FS	SKIN		INFLAMMATION		
253	M	2	745	FS	TESTIS		ATROPHY, BILATERAL		
253	M	2	745	FS	THYMUS	THY	F-LYMPHOMA	38	M
254	M	2	63	U2	HEART		CARDIOMYOPATHY		
254	M	2	63	U2	KIDNEY		HYDRONEPHROSIS		
254	M	2	63	U2	KIDNEY		INFLAMMATION		
254	M	2	63	U2	LIVER		HYPERPLASIA, BILE DUCT		
254	M	2	63	U2	PROSTATE		INFLAMMATION		
254	M	2	63	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
254	M	2	63	U2	URINARY BLADDER	UB	M-CARCINOMA, TRANSITIONAL CELL	58	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
255	M	2	287	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
255	M	2	287	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
256	M	2	745	FS	KIDNEY		INFLAMMATION		
256	M	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
256	M	2	745	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
256	M	2	745	FS	NOSE/TURBINATES		INFLAMMATION		
256	M	2	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
256	M	2	745	FS	SKIN		ULCER, EPIDERMIS		
256	M	2	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
257	M	2	657	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
257	M	2	657	U2	HEART		CARDIOMYOPATHY		
257	M	2	657	U2	KIDNEY		NEPHROPATHY		
257	M	2	657	U2	LIVER		FOCUS, BASOPHILIC CELL		
257	M	2	657	U2	LIVER		LIPIDOSIS, MULTIFOCAL		
257	M	2	657	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
257	M	2	657	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
258	M	2	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
258	M	2	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
258	M	2	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
258	M	2	745	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
258	M	2	745	FS	HEART		CARDIOMYOPATHY		
258	M	2	745	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
258	M	2	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
258	M	2	745	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
258	M	2	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
258	M	2	745	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
259	M	2	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
259	M	2	746	FS	HEART		CARDIOMYOPATHY		
259	M	2	746	FS	KIDNEY		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
259	M	2	746	FS	KIDNEY		INFLAMMATION		
259	M	2	746	FS	KIDNEY		NEPHROPATHY		
259	M	2	746	FS	SKIN		ULCER, EPIDERMIS		
260	M	2	374	U2	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
260	M	2	374	U2	LIVER		TELANGIECTASIS		
260	M	2	374	U2	LUNG	LU	M-CARCINOMA, BASAL CELL, METASTATIC (SKIN)	49	I
260	M	2	374	U2	PROSTATE		INFLAMMATION		
260	M	2	374	U2	SKIN	SK	M-CARCINOMA, BASAL CELL	48	F
260	M	2	374	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
321	M	3	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
321	M	3	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
321	M	3	729	FS	HEART		CARDIOMYOPATHY		
321	M	3	729	FS	SKIN		ULCER, EPIDERMIS		
321	M	3	729	FS	TESTIS		ATROPHY, UNILATERAL		
322	M	3	716	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
322	M	3	716	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
322	M	3	716	U2	KIDNEY		NEPHROPATHY		
322	M	3	716	U2	LIVER		FOCUS, CLEAR CELL		
322	M	3	716	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
322	M	3	716	U2	SPLEEN		ATROPHY, LYMPHOID		
323	M	3	729	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
323	M	3	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
323	M	3	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
324	M	3	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
324	M	3	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
324	M	3	729	FS	HEART		CARDIOMYOPATHY		
324	M	3	729	FS	KIDNEY		NEPHROPATHY		
324	M	3	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
324	M	3	729	FS	LIVER		FOCUS, CLEAR CELL		
324	M	3	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
325	M	3	729	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
325	M	3	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
325	M	3	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
325	M	3	729	FS	HEART		CARDIOMYOPATHY		
325	M	3	729	FS	KIDNEY		NEPHROPATHY		
325	M	3	729	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M
325	M	3	729	FS	RECTUM		METAZOAN PARASITE(S)		
325	M	3	729	FS	TESTIS		ATROPHY, UNILATERAL		
326	M	3	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
326	M	3	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
326	M	3	729	FS	HEART		CARDIOMYOPATHY		
326	M	3	729	FS	KIDNEY		HYDRONEPHROSIS		
326	M	3	729	FS	LIVER		FOCUS, BASOPHILIC CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
326	M	3	729	FS	LIVER		FOCUS, CLEAR CELL		
326	M	3	729	FS	PREPUTIAL GLAND		INFLAMMATION		
326	M	3	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
327	M	3	729	FS	ADRENAL GLAND		ATROPHY		
327	M	3	729	FS	JEJUNUM	JE	M-CARCINOMA	41	M
327	M	3	729	FS	KIDNEY		NEPHROPATHY		
327	M	3	729	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
327	M	3	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
327	M	3	729	FS	PROSTATE		INFLAMMATION		
327	M	3	729	FS	SKIN		INFLAMMATION		
327	M	3	729	FS	STOMACH		INFLAMMATION, GLANDULAR		
327	M	3	729	FS	TESTIS		ATROPHY, BILATERAL		
327	M	3	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
328	M	3	729	FS	HEART		HYPERPLASIA, ENDOTHELIUM		
328	M	3	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
329	M	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
329	M	3	731	FS	HEART		CARDIOMYOPATHY		
329	M	3	731	FS	KIDNEY		NEPHROPATHY		
329	M	3	731	FS	LIVER		FOCUS, CLEAR CELL		
329	M	3	731	FS	PREPUTIAL GLAND		INFLAMMATION		
329	M	3	731	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
330	M	3	731	FS	KIDNEY		HYDRONEPHROSIS		
331	M	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
331	M	3	731	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
332	M	3	469	U2	HEART		CARDIOMYOPATHY		
332	M	3	469	U2	KIDNEY		INFLAMMATION		
332	M	3	469	U2	KIDNEY		NEPHROPATHY		
332	M	3	469	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
332	M	3	469	U2	PROSTATE		INFLAMMATION		
332	M	3	469	U2	SKIN		ULCER, EPIDERMIS		
332	M	3	469	U2	STOMACH		ULCER, GLANDULAR		
333	M	3	731	FS	LIVER		FOCUS, CLEAR CELL		
333	M	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
333	M	3	731	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
333	M	3	731	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
334	M	3	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
334	M	3	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
334	M	3	731	FS	LIVER		FOCUS, CLEAR CELL		
334	M	3	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
334	M	3	731	FS	TESTIS		ATROPHY, UNILATERAL		
335	M	3	735	FS	KIDNEY		NEPHROPATHY		
335	M	3	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
335	M	3	735	FS	SKIN		INFLAMMATION		
335	M	3	735	FS	SKIN		ULCER, EPIDERMIS		
336	M	3	735	FS	HEART		CARDIOMYOPATHY		
336	M	3	735	FS	KIDNEY		NEPHROPATHY		
336	M	3	735	FS	SKIN		INFLAMMATION		
336	M	3	735	FS	SPLEEN		HYPERPLASIA, LYMPHOID		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
336	M	3	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
337	M	3	735	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
337	M	3	735	FS	HEART		CARDIOMYOPATHY		
338	M	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
338	M	3	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
338	M	3	735	FS	HEART		CARDIOMYOPATHY		
338	M	3	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
339	M	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
339	M	3	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
339	M	3	735	FS	KIDNEY		HYDRONEPHROSIS		
339	M	3	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
339	M	3	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
340	M	3	723	U1	ESOPHAGUS		INFLAMMATION		
340	M	3	723	U1	HEART		CARDIOMYOPATHY		
340	M	3	723	U1	JEJUNUM		DIVERTICULUM		
340	M	3	723	U1	LUNG		INFLAMMATION		
340	M	3	723	U1	NOSE/TURBINATES		INFLAMMATION		
340	M	3	723	U1	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
340	M	3	723	U1	TESTIS		ATROPHY, BILATERAL		
340	M	3	723	U1	TRACHEA		INFLAMMATION		
341	M	3	576	U2	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	I
341	M	3	576	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
341	M	3	576	U2	LIVER		ATROPHY		
341	M	3	576	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
341	M	3	576	U2	SKIN		CYST, EPITHELIAL INCLUSION		
341	M	3	576	U2	SKIN		HYPERPLASIA, EPIDERMIS		
341	M	3	576	U2	SKIN		OSSEOUS METAPLASIA		
341	M	3	576	U2	SKIN		ULCER, EPIDERMIS		
341	M	3	576	U2	SPLEEN		HYPERPLASIA, LYMPHOID		
341	M	3	576	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
342	M	3	735	FS	HEART		CARDIOMYOPATHY		
342	M	3	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
342	M	3	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
343	M	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
343	M	3	735	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
344	M	3	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
344	M	3	735	FS	HEART		CARDIOMYOPATHY		
344	M	3	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
344	M	3	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
344	M	3	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
344	M	3	735	FS	SKIN		INFLAMMATION		
344	M	3	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
345	M	3	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
345	M	3	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
345	M	3	737	FS	KIDNEY		INFLAMMATION		
345	M	3	737	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
345	M	3	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
345	M	3	737	FS	PREPUTIAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
346	M	3	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
346	M	3	737	FS	HEART		CARDIOMYOPATHY		
346	M	3	737	FS	KIDNEY		NEPHROPATHY		
346	M	3	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
347	M	3	613	U2	HEART		CARDIOMYOPATHY		
347	M	3	613	U2	KIDNEY		NEPHROPATHY		
347	M	3	613	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
347	M	3	613	U2	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
348	M	3	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
348	M	3	737	FS	KIDNEY		NEPHROPATHY		
348	M	3	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
348	M	3	737	FS	TESTIS		ATROPHY, UNILATERAL		
348	M	3	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
349	M	3	528	U2	LIVER		INFLAMMATION		
349	M	3	528	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
349	M	3	528	U2	STOMACH		ULCER, NON-GLANDULAR		
349	M	3	528	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
350	M	3	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
350	M	3	737	FS	JEJUNUM		DIVERTICULUM		
350	M	3	737	FS	KIDNEY		NEPHROPATHY		
350	M	3	737	FS	NOSE/TURBINATES		INFLAMMATION		
350	M	3	737	FS	SKIN		INFLAMMATION		
350	M	3	737	FS	SKIN		ULCER, EPIDERMIS		
351	M	3	737	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
351	M	3	737	FS	KIDNEY		NEPHROPATHY		
351	M	3	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
351	M	3	737	FS	PROSTATE		INFLAMMATION		
351	M	3	737	FS	SEMINAL VESICLE		ATROPHY		
351	M	3	737	FS	SKIN		INFLAMMATION		
351	M	3	737	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
351	M	3	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
352	M	3	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
352	M	3	737	FS	HEART		CARDIOMYOPATHY		
352	M	3	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
352	M	3	737	FS	LIVER		FOCUS, CLEAR CELL		
352	M	3	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
352	M	3	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
352	M	3	737	FS	RECTUM		METAZOAN PARASITE(S)		
352	M	3	737	FS	SKIN		ULCER, EPIDERMIS		
352	M	3	737	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
353	M	3	653	U1	SKIN		INFLAMMATION		
353	M	3	653	U1	SKIN		ULCER, EPIDERMIS		
354	M	3	711	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
354	M	3	711	U2	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
354	M	3	711	U2	HEART		CARDIOMYOPATHY		
354	M	3	711	U2	LIVER		HEMORRHAGE		
354	M	3	711	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
354	M	3	711	U2	SKIN		CYST, EPITHELIAL INCLUSION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
354	M	3	711	U2	SKIN		INFLAMMATION		
354	M	3	711	U2	SPLEEN		ATROPHY, LYMPHOID		
355	M	3	739	FS	HEART		CARDIOMYOPATHY		
355	M	3	739	FS	TESTIS		EDEMA, INTERSTITIUM		
355	M	3	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
356	M	3	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
356	M	3	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
356	M	3	739	FS	HEART		CARDIOMYOPATHY		
356	M	3	739	FS	KIDNEY		NEPHROPATHY		
356	M	3	739	FS	LIVER		FOCUS, MIXED CELL		
356	M	3	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
356	M	3	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
356	M	3	739	FS	RECTUM		METAZOAN PARASITE(S)		
356	M	3	739	FS	TESTIS		EDEMA, INTERSTITIUM		
357	M	3	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
357	M	3	739	FS	HARDERIAN GLAND	HG	B-ADENOMA	1	M
357	M	3	739	FS	HEART		CARDIOMYOPATHY		
357	M	3	739	FS	LIVER		FOCUS, BASOPHILIC CELL		
357	M	3	739	FS	LIVER		FOCUS, MIXED CELL		
357	M	3	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
357	M	3	739	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
357	M	3	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
358	M	3	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
358	M	3	739	FS	LIVER		FOCUS, BASOPHILIC CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
358	M	3	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
358	M	3	739	FS	PREPUTIAL GLAND		INFLAMMATION		
358	M	3	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
359	M	3	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
359	M	3	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
359	M	3	739	FS	HEART		CARDIOMYOPATHY		
359	M	3	739	FS	KIDNEY		NEPHROPATHY		
359	M	3	739	FS	LIVER		FOCUS, BASOPHILIC CELL		
359	M	3	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
359	M	3	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
359	M	3	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
359	M	3	739	FS	STOMACH		MUCOSAL CYST, NON-GLANDULAR		
359	M	3	739	FS	TESTIS		ATROPHY, UNILATERAL		
360	M	3	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
360	M	3	739	FS	HEART		CARDIOMYOPATHY		
360	M	3	739	FS	KIDNEY		NEPHROPATHY		
360	M	3	739	FS	PREPUTIAL GLAND		INFLAMMATION		
360	M	3	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
361	M	3	743	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
361	M	3	743	FS	HEART		CARDIOMYOPATHY		
361	M	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
362	M	3	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
362	M	3	743	FS	LIVER		FOCUS, CLEAR CELL		
362	M	3	743	FS	LIVER		FOCUS, MIXED CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
362	M	3	743	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
362	M	3	743	FS	STOMACH		ULCER, NON-GLANDULAR		
362	M	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
363	M	3	381	U2	LIVER		HYPERPLASIA, BILE DUCT		
363	M	3	381	U2	LIVER		INFLAMMATION		
363	M	3	381	U2	PANCREAS	PA	M-CARCINOMA, EXOCRINE	51	I
363	M	3	381	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
364	M	3	743	FS	HEART		CARDIOMYOPATHY		
364	M	3	743	FS	LN-OTHER		HYPERPLASIA, PLASMA CELL		
364	M	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
364	M	3	743	FS	SKIN		ULCER, EPIDERMIS		
364	M	3	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
365	M	3	704	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
365	M	3	704	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
365	M	3	704	U2	KIDNEY		NEPHROPATHY		
365	M	3	704	U2	LIVER		FOCUS, CLEAR CELL		
365	M	3	704	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
365	M	3	704	U2	ORAL MUCOSA	OC	M-CARCINOMA, SQUAMOUS CELL	57	F
365	M	3	704	U2	PREPUTIAL GLAND		INFLAMMATION		
365	M	3	704	U2	STOMACH		ULCER, NON-GLANDULAR		
366	M	3	743	FS	HARDERIAN GLAND		ATROPHY		
366	M	3	743	FS	HEART		CARDIOMYOPATHY		
366	M	3	743	FS	KIDNEY		NEPHROPATHY		
366	M	3	743	FS	LIVER		NECROSIS, HEPATOCYTE		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
366	M	3	743	FS	PARATHYROID		FIBROSIS		
366	M	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
367	M	3	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
367	M	3	743	FS	HEART		CARDIOMYOPATHY		
367	M	3	743	FS	KIDNEY		NEPHROPATHY		
367	M	3	743	FS	LIVER		FOCUS, EOSINOPHILIC		
367	M	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
367	M	3	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
367	M	3	743	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
368	M	3	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
368	M	3	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
368	M	3	743	FS	HEART		CARDIOMYOPATHY		
368	M	3	743	FS	KIDNEY		INFLAMMATION		
368	M	3	743	FS	LIVER		FOCUS, CLEAR CELL		
368	M	3	743	FS	LIVER		FOCUS, MIXED CELL		
368	M	3	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
369	M	3	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
369	M	3	745	FS	HEART		CARDIOMYOPATHY		
369	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
369	M	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
369	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
370	M	3	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
370	M	3	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
370	M	3	745	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
370	M	3	745	FS	KIDNEY		NEPHROPATHY		
370	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
370	M	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
370	M	3	745	FS	SKIN		ULCER, EPIDERMIS		
370	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
371	M	3	745	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
371	M	3	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
371	M	3	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
371	M	3	745	FS	HEART		CARDIOMYOPATHY		
371	M	3	745	FS	KIDNEY		NEPHROPATHY		
371	M	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
371	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
371	M	3	745	FS	LIVER		TELANGIECTASIS		
371	M	3	745	FS	LUNG		INFLAMMATION		
371	M	3	745	FS	NOSE/TURBINATES		INFLAMMATION		
371	M	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
371	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
372	M	3	745	FS	HEART		CARDIOMYOPATHY		
372	M	3	745	FS	KIDNEY		NEPHROPATHY		
372	M	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
372	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
373	M	3	745	FS	EYE		INFLAMMATION, OCULAR		
373	M	3	745	FS	HEART		CARDIOMYOPATHY		
373	M	3	745	FS	LIVER		FOCUS, MIXED CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
374	M	3	745	FS	HEART		CARDIOMYOPATHY		
374	M	3	745	FS	LIVER		TELANGIECTASIS		
374	M	3	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
374	M	3	745	FS	SKIN		ULCER, EPIDERMIS		
374	M	3	745	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
374	M	3	745	FS	TESTIS		EDEMA, INTERSTITIUM		
374	M	3	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
374	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
375	M	3	745	FS	HEART		CARDIOMYOPATHY		
375	M	3	745	FS	KIDNEY		INFLAMMATION		
375	M	3	745	FS	KIDNEY		NEPHROPATHY		
375	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
375	M	3	745	FS	RECTUM		METAZOAN PARASITE(S)		
375	M	3	745	FS	TESTIS		ATROPHY, UNILATERAL		
375	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
376	M	3	574	U1					
377	M	3	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
377	M	3	745	FS	HEART		CARDIOMYOPATHY		
377	M	3	745	FS	KIDNEY		INFLAMMATION		
377	M	3	745	FS	KIDNEY		NEPHROPATHY		
377	M	3	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
377	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
377	M	3	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
377	M	3	745	FS	PREPUTIAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
377	M	3	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
378	M	3	745	FS	HEART		CARDIOMYOPATHY		
378	M	3	745	FS	KIDNEY		NEPHROPATHY		
378	M	3	745	FS	LIVER		FOCUS, MIXED CELL		
378	M	3	745	FS	PREPUTIAL GLAND		INFLAMMATION		
379	M	3	746	FS	HEART		CARDIOMYOPATHY		
379	M	3	746	FS	LIVER		FOCUS, BASOPHILIC CELL		
379	M	3	746	FS	LIVER		FOCUS, CLEAR CELL		
379	M	3	746	FS	NOSE/TURBINATES		INFLAMMATION		
379	M	3	746	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
380	M	3	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
380	M	3	746	FS	HEART		CARDIOMYOPATHY		
380	M	3	746	FS	KIDNEY		NEPHROPATHY		
380	M	3	746	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
380	M	3	746	FS	LIVER		TELANGIECTASIS		
380	M	3	746	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
380	M	3	746	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
421	M	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
421	M	4	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
421	M	4	729	FS	HEART		CARDIOMYOPATHY		
421	M	4	729	FS	KIDNEY		NEPHROPATHY		
421	M	4	729	FS	LIVER		FOCUS, CLEAR CELL		
421	M	4	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
421	M	4	729	FS	LIVER		LIPIDOSIS, FOCAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
421	M	4	729	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M
421	M	4	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
422	M	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
422	M	4	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
422	M	4	729	FS	COLON		METAZOAN PARASITE, LUMEN		
422	M	4	729	FS	HEART		CARDIOMYOPATHY		
422	M	4	729	FS	KIDNEY		NEPHROPATHY		
422	M	4	729	FS	LIVER		FOCUS, CLEAR CELL		
422	M	4	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
422	M	4	729	FS	PROSTATE		INFLAMMATION		
422	M	4	729	FS	SALIVARY GLAND		INFLAMMATION		
423	M	4	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
423	M	4	729	FS	HEART		CARDIOMYOPATHY		
423	M	4	729	FS	LIVER		LIPIDOSIS, DIFFUSE		
423	M	4	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
423	M	4	729	FS	PROSTATE		INFLAMMATION		
423	M	4	729	FS	SKIN		INFLAMMATION		
423	M	4	729	FS	SKIN		ULCER, EPIDERMIS		
423	M	4	729	FS	TESTIS		ATROPHY, UNILATERAL		
424	M	4	357	U1	HEART		CARDIOMYOPATHY		
424	M	4	357	U1	HEART		MINERALIZATION		
424	M	4	357	U1	KIDNEY		INFLAMMATION		
424	M	4	357	U1	KIDNEY		MINERALIZATION		
424	M	4	357	U1	PARATHYROID		HYPERPLASIA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
424	M	4	357	U1	PROSTATE		INFLAMMATION		
424	M	4	357	U1	SALIVARY GLAND		NECROSIS		
424	M	4	357	U1	SPLEEN		ATROPHY, LYMPHOID		
424	M	4	357	U1	STOMACH		MINERALIZATION		
424	M	4	357	U1	THYMUS		HEMORRHAGE		
424	M	4	357	U1	URINARY BLADDER		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
425	M	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
425	M	4	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
425	M	4	729	FS	HEART		CARDIOMYOPATHY		
425	M	4	729	FS	KIDNEY		NEPHROPATHY		
425	M	4	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
425	M	4	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
425	M	4	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
425	M	4	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
425	M	4	729	FS	NOSE/TURBINATES		HYPERPLASIA, GLANDULAR EPITHELIUM		
425	M	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
425	M	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
425	M	4	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
426	M	4	729	FS	KIDNEY		NEPHROPATHY		
426	M	4	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
426	M	4	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
427	M	4	729	FS	BRAIN	BR	B-GRANULAR CELL TUMOR	19	M
427	M	4	729	FS	HEART		CARDIOMYOPATHY		
427	M	4	729	FS	LIVER		FOCUS, CLEAR CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
427	M	4	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
427	M	4	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
427	M	4	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
427	M	4	729	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
428	M	4	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
428	M	4	729	FS	HEART		CARDIOMYOPATHY		
428	M	4	729	FS	KIDNEY		NEPHROPATHY		
428	M	4	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
428	M	4	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
428	M	4	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
428	M	4	729	FS	SKIN		INFLAMMATION		
428	M	4	729	FS	SKIN		ULCER, EPIDERMIS		
428	M	4	729	FS	TESTIS		ATROPHY, BILATERAL		
429	M	4	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
429	M	4	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
429	M	4	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
430	M	4	629	U1	HEART		CARDIOMYOPATHY		
430	M	4	629	U1	KIDNEY		NEPHROPATHY		
430	M	4	629	U1	LIVER		HYPERPLASIA, BILE DUCT		
430	M	4	629	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
430	M	4	629	U1	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
430	M	4	629	U1	SKIN		INFLAMMATION		
431	M	4	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
431	M	4	731	FS	LIVER		FOCUS, MIXED CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
431	M	4	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
431	M	4	731	FS	LIVER		TELANGIECTASIS		
431	M	4	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
432	M	4	731	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
432	M	4	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
432	M	4	731	FS	HEART		CARDIOMYOPATHY		
432	M	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
432	M	4	731	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
433	M	4	731	FS	LIVER		INFLAMMATION		
433	M	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
433	M	4	731	FS	SKIN		INFLAMMATION		
433	M	4	731	FS	STOMACH		MUCOSAL CYST, NON-GLANDULAR		
434	M	4	731	FS	ADRENAL GLAND	AD	B-GANGLIONEUROMA	17	M
434	M	4	731	FS	KIDNEY		NEPHROPATHY		
434	M	4	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
434	M	4	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
434	M	4	731	FS	TESTIS		ATROPHY, UNILATERAL		
435	M	4	735	FS	HEART		CARDIOMYOPATHY		
435	M	4	735	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M
435	M	4	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
436	M	4	513	U2	KIDNEY		NEPHROPATHY		
436	M	4	513	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
436	M	4	513	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
437	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
437	M	4	735	FS	KIDNEY		NEPHROPATHY		
437	M	4	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
438	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
439	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
439	M	4	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
439	M	4	735	FS	HEART		CARDIOMYOPATHY		
439	M	4	735	FS	KIDNEY		NEPHROPATHY		
439	M	4	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
439	M	4	735	FS	LIVER		INFLAMMATION		
439	M	4	735	FS	LIVER		NECROSIS, HEPATOCYTE		
439	M	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
440	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
440	M	4	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
440	M	4	735	FS	TESTIS		INFLAMMATION		
441	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
441	M	4	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
441	M	4	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
441	M	4	735	FS	PROSTATE		INFLAMMATION		
441	M	4	735	FS	SKIN		INFLAMMATION		
441	M	4	735	FS	SKIN		ULCER, EPIDERMIS		
441	M	4	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
442	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
442	M	4	735	FS	HEART		CARDIOMYOPATHY		
442	M	4	735	FS	KIDNEY		HYDRONEPHROSIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
442	M	4	735	FS	KIDNEY		NEPHROPATHY		
442	M	4	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
442	M	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
442	M	4	735	FS	PREPUTIAL GLAND		INFLAMMATION		
443	M	4	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
443	M	4	735	FS	HEART		CARDIOMYOPATHY		
443	M	4	735	FS	KIDNEY		INFLAMMATION		
443	M	4	735	FS	KIDNEY		NEPHROPATHY		
443	M	4	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
444	M	4	618	U2	HEART		CARDIOMYOPATHY		
444	M	4	618	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
444	M	4	618	U2	SKIN		ULCER, EPIDERMIS		
444	M	4	618	U2	THYROID GLAND	THG	M-CARCINOMA, FOLLICULAR CELL	52	I
444	M	4	618	U2	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
445	M	4	93	U1	BONE MARROW	BM	F-LYMPHOMA	38	I
445	M	4	93	U1	SPLEEN	SP	F-LYMPHOMA	38	F
446	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
446	M	4	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
446	M	4	737	FS	HEART		CARDIOMYOPATHY		
446	M	4	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
446	M	4	737	FS	LIVER		NECROSIS, HEPATOCYTE		
446	M	4	737	FS	ORAL MUCOSA	OC	M-CARCINOMA, SQUAMOUS CELL	57	M
446	M	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
446	M	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
447	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
447	M	4	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
447	M	4	737	FS	HEART		CARDIOMYOPATHY		
447	M	4	737	FS	KIDNEY		HYDRONEPHROSIS		
447	M	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
448	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
448	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
448	M	4	737	FS	HARDERIAN GLAND		INFLAMMATION		
448	M	4	737	FS	HEART		CARDIOMYOPATHY		
448	M	4	737	FS	LN-MANDIBULAR		CYSTIC DEGENERATION		
448	M	4	737	FS	LN-MANDIBULAR		HYPERPLASIA, PLASMA CELL		
448	M	4	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
448	M	4	737	FS	TESTIS	TE	M-MESOTHELIOMA	69	M
448	M	4	737	FS	TESTIS		ATROPHY, UNILATERAL		
449	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
449	M	4	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
449	M	4	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
450	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
450	M	4	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
450	M	4	737	FS	CECUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
450	M	4	737	FS	CECUM		INFLAMMATION		
450	M	4	737	FS	HEART		CARDIOMYOPATHY		
450	M	4	737	FS	KIDNEY		INFARCT, CHRONIC		
450	M	4	737	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
450	M	4	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
450	M	4	737	FS	LN-MANDIBULAR		CYSTIC DEGENERATION		
450	M	4	737	FS	LN-MANDIBULAR		HYPERPLASIA, PLASMA CELL		
450	M	4	737	FS	LN-MESENTERIC		CYSTIC DEGENERATION		
450	M	4	737	FS	LN-MESENTERIC		HYPERPLASIA, PLASMA CELL		
450	M	4	737	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
450	M	4	737	FS	LN-OTHER		CYSTIC DEGENERATION		
450	M	4	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
450	M	4	737	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
450	M	4	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
450	M	4	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
450	M	4	737	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
450	M	4	737	FS	TESTIS		ATROPHY, BILATERAL		
451	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
451	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
451	M	4	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
451	M	4	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
451	M	4	737	FS	RECTUM		METAZOAN PARASITE(S)		
451	M	4	737	FS	SKIN		INFLAMMATION		
451	M	4	737	FS	SKIN		ULCER, EPIDERMIS		
452	M	4	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
452	M	4	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
452	M	4	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
453	M	4	739	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
453	M	4	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
453	M	4	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
454	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
454	M	4	739	FS	HEART		CARDIOMYOPATHY		
454	M	4	739	FS	KIDNEY		NEPHROPATHY		
454	M	4	739	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
455	M	4	739	FS	JEJUNUM		DIVERTICULUM		
455	M	4	739	FS	LIVER		FOCUS, CLEAR CELL		
455	M	4	739	FS	PROSTATE		INFLAMMATION		
456	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
456	M	4	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
456	M	4	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
457	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
457	M	4	739	FS	KIDNEY		INFLAMMATION		
457	M	4	739	FS	KIDNEY		NEPHROPATHY		
457	M	4	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
457	M	4	739	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
457	M	4	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
458	M	4	739	FS	BONE MARROW		HYPERPLASIA		
458	M	4	739	FS	HEART		CARDIOMYOPATHY		
458	M	4	739	FS	LIVER		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
458	M	4	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
458	M	4	739	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
458	M	4	739	FS	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
459	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
459	M	4	739	FS	KIDNEY		HYDRONEPHROSIS		
459	M	4	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
460	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
460	M	4	739	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
460	M	4	739	FS	HEART		CARDIOMYOPATHY		
460	M	4	739	FS	KIDNEY		NEPHROPATHY		
460	M	4	739	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M
461	M	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
461	M	4	743	FS	HEART		CARDIOMYOPATHY		
461	M	4	743	FS	KIDNEY		NEPHROPATHY		
461	M	4	743	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M
461	M	4	743	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
462	M	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
462	M	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
462	M	4	743	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
462	M	4	743	FS	SKIN		INFLAMMATION		
463	M	4	743	FS	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
463	M	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
463	M	4	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
463	M	4	743	FS	TESTIS		ATROPHY, UNILATERAL		
464	M	4	711	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
464	M	4	711	U2	HEART		CARDIOMYOPATHY		
464	M	4	711	U2	KIDNEY		NEPHROPATHY		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
464	M	4	711	U2	LIVER		LIPIDOSIS, MULTIFOCAL		
464	M	4	711	U2	PANCREAS	PA	B-ISLET CELL TUMOR	22	F
465	M	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
465	M	4	743	FS	HEART		CARDIOMYOPATHY		
465	M	4	743	FS	KIDNEY		NEPHROPATHY		
465	M	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
465	M	4	743	FS	PROSTATE		INFLAMMATION		
466	M	4	743	FS	HEART		CARDIOMYOPATHY		
466	M	4	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
466	M	4	743	FS	SKIN	SK	B-PAPILLOMA, SQUAMOUS CELL	28	M
466	M	4	743	FS	TESTIS		ATROPHY, UNILATERAL		
467	M	4	743	FS	ADRENAL GLAND	AD	B-ADENOMA, CORTICAL	6	M
467	M	4	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
467	M	4	743	FS	HEART		CARDIOMYOPATHY		
467	M	4	743	FS	KIDNEY		INFLAMMATION		
467	M	4	743	FS	KIDNEY		NEPHROPATHY		
467	M	4	743	FS	LIVER		LIPIDOSIS, FOCAL		
467	M	4	743	FS	TESTIS		ATROPHY, BILATERAL		
467	M	4	743	FS	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	M
468	M	4	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
468	M	4	743	FS	HEART		CARDIOMYOPATHY		
468	M	4	743	FS	LIVER		FOCUS, MIXED CELL		
468	M	4	743	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
468	M	4	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
468	M	4	743	FS	RECTUM		METAZOAN PARASITE(S)		
469	M	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
469	M	4	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
469	M	4	745	FS	HEART		CARDIOMYOPATHY		
470	M	4	745	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
470	M	4	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
470	M	4	745	FS	PARATHYROID		HYPERPLASIA		
470	M	4	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
470	M	4	745	FS	PREPUTIAL GLAND		INFLAMMATION		
470	M	4	745	FS	SKIN	SK	M-FIBROSARCOMA	61	M
470	M	4	745	FS	TESTIS		ATROPHY, BILATERAL		
470	M	4	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
471	M	4	294	U2	KIDNEY		HYPERPLASIA, TUBULAR		
471	M	4	294	U2	KIDNEY		NEPHROPATHY		
471	M	4	294	U2	SPINAL CORD	SC	M-EPENDYMOMA, ANAPLASTIC	60	F
472	M	4	513	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
472	M	4	513	U2	HEART		CARDIOMYOPATHY		
472	M	4	513	U2	KIDNEY		NEPHROPATHY		
472	M	4	513	U2	PANCREAS	PA	B-ISLET CELL TUMOR	22	I
472	M	4	513	U2	PARATHYROID		HYPERPLASIA		
472	M	4	513	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
472	M	4	513	U2	PROSTATE		INFLAMMATION		
472	M	4	513	U2	SPLEEN		ATROPHY, LYMPHOID		
473	M	4	745	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
473	M	4	745	FS	PROSTATE		INFLAMMATION		
473	M	4	745	FS	SKIN		CYST, EPITHELIAL INCLUSION		
473	M	4	745	FS	SKIN		HYPERPLASIA, EPIDERMIS		
473	M	4	745	FS	URINARY BLADDER	UB	M-CARCINOMA, TRANSITIONAL CELL	58	M
474	M	4	745	FS	HEART		CARDIOMYOPATHY		
474	M	4	745	FS	KIDNEY		NEPHROPATHY		
474	M	4	745	FS	SEMINAL VESICLE		DUCT ECTASIA		
474	M	4	745	FS	THYROID GLAND	THG	M-CARCINOMA, FOLLICULAR CELL	52	M
475	M	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
475	M	4	745	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
475	M	4	745	FS	KIDNEY		HYDRONEPHROSIS		
475	M	4	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
475	M	4	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
476	M	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
476	M	4	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
476	M	4	745	FS	HEART		CARDIOMYOPATHY		
476	M	4	745	FS	KIDNEY		NEPHROPATHY		
476	M	4	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
476	M	4	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
476	M	4	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
477	M	4	654	U2	HEART		CARDIOMYOPATHY		
477	M	4	654	U2	KIDNEY		NEPHROPATHY		
477	M	4	654	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
477	M	4	654	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
477	M	4	654	U2	SKIN		ULCER, EPIDERMIS		
478	M	4	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
478	M	4	745	FS	HEART		CARDIOMYOPATHY		
478	M	4	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
479	M	4	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
479	M	4	746	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
479	M	4	746	FS	HEART		CARDIOMYOPATHY		
479	M	4	746	FS	JEJUNUM		DIVERTICULUM		
479	M	4	746	FS	JEJUNUM		INFLAMMATION		
479	M	4	746	FS	KIDNEY		CYST(S), TUBULAR		
479	M	4	746	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
479	M	4	746	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
480	M	4	711	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
480	M	4	711	U1	ADRENAL GLAND		NECROSIS, CORTEX		
480	M	4	711	U1	CECUM		INFLAMMATION		
480	M	4	711	U1	EPIDIDYMIS		ATROPHY, UNILATERAL		
480	M	4	711	U1	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
480	M	4	711	U1	HEART		CARDIOMYOPATHY		
480	M	4	711	U1	KIDNEY		NEPHROPATHY		
480	M	4	711	U1	LIVER		HYPERPLASIA, BILE DUCT		
480	M	4	711	U1	LUNG		INFLAMMATION, FOREIGN BODY		
480	M	4	711	U1	PHARYNX		INFLAMMATION		
480	M	4	711	U1	PROSTATE		INFLAMMATION		
480	M	4	711	U1	SEMINAL VESICLE		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
480	M	4	711	U1	TESTIS		ATROPHY, UNILATERAL		
480	M	4	711	U1	TESTIS		EDEMA, INTERSTITIUM		
480	M	4	711	U1	THYROID GLAND		HYPERPLASIA, C-CELL		
480	M	4	711	U1	URINARY BLADDER		INFLAMMATION		
521	M	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
521	M	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
521	M	5	729	FS	BONE MARROW		MARROW LIPOMATOSIS		
521	M	5	729	FS	LIVER		FOCUS, EOSINOPHILIC		
521	M	5	729	FS	LIVER		FOCUS, MIXED CELL		
521	M	5	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
521	M	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
521	M	5	729	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
521	M	5	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
521	M	5	729	FS	PROSTATE		INFLAMMATION		
521	M	5	729	FS	TESTIS		ATROPHY, UNILATERAL		
521	M	5	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
522	M	5	729	FS	COLON		METAZOAN PARASITE, LUMEN		
522	M	5	729	FS	EPIDIDYMIS	EP	M-MESOTHELIOMA	69	M
522	M	5	729	FS	HEART		CARDIOMYOPATHY		
522	M	5	729	FS	LIVER		DILATATION, BILE DUCT		
522	M	5	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
522	M	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
522	M	5	729	FS	TESTIS	TE	M-MESOTHELIOMA	69	M
522	M	5	729	FS	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
523	M	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
523	M	5	729	FS	HEART		CARDIOMYOPATHY		
524	M	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
524	M	5	729	FS	HEART		CARDIOMYOPATHY		
524	M	5	729	FS	KIDNEY		NEPHROPATHY		
524	M	5	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
525	M	5	729	FS	KIDNEY		NEPHROPATHY		
525	M	5	729	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
525	M	5	729	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
526	M	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
526	M	5	729	FS	EYE		CATARACT		
526	M	5	729	FS	EYE		RETINAL DETACHMENT		
526	M	5	729	FS	KIDNEY		NECROSIS, PAPILLARY		
526	M	5	729	FS	LIVER		FOCUS, MIXED CELL		
526	M	5	729	FS	LIVER		INFLAMMATION		
526	M	5	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
526	M	5	729	FS	PARATHYROID		HYPERPLASIA		
526	M	5	729	FS	RECTUM		METAZOAN PARASITE(S)		
527	M	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
527	M	5	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
527	M	5	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
527	M	5	729	FS	HEART		CARDIOMYOPATHY		
527	M	5	729	FS	KIDNEY		NEPHROPATHY		
527	M	5	729	FS	LIVER		LIPIDOSIS, FOCAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
527	M	5	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
527	M	5	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
527	M	5	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
528	M	5	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
528	M	5	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
528	M	5	729	FS	HEART		CARDIOMYOPATHY		
528	M	5	729	FS	KIDNEY		NEPHROPATHY		
528	M	5	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
528	M	5	729	FS	LIVER		FOCUS, CLEAR CELL		
528	M	5	729	FS	LIVER		LIPIDOSIS, FOCAL		
528	M	5	729	FS	LUNG		EOSINOPHILIC CRYSTALS		
528	M	5	729	FS	LUNG		INFLAMMATION		
529	M	5	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
529	M	5	731	FS	HEART		CARDIOMYOPATHY		
529	M	5	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
530	M	5	676	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
530	M	5	676	U2	ADRENAL GLAND		HYPERTROPHY, CORTEX		
530	M	5	676	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
530	M	5	676	U2	BONE MARROW		MARROW LIPOMATOSIS		
530	M	5	676	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
531	M	5	731	FS	ADRENAL GLAND		DEGENERATION, CYSTIC		
531	M	5	731	FS	KIDNEY		HYDRONEPHROSIS		
531	M	5	731	FS	SKIN		ULCER, EPIDERMIS		
532	M	5	534	U2	HARDERIAN GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
532	M	5	534	U2	HEART		CARDIOMYOPATHY		
532	M	5	534	U2	PHARYNX		INFLAMMATION		
532	M	5	534	U2	SKIN	SK	F-LYMPHOMA	38	F
532	M	5	534	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
533	M	5	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
533	M	5	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
533	M	5	731	FS	BONE MARROW		MARROW LIPOMATOSIS		
533	M	5	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
533	M	5	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
534	M	5	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
534	M	5	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
534	M	5	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
534	M	5	731	FS	HEART		CARDIOMYOPATHY		
534	M	5	731	FS	LIVER		DILATATION, BILE DUCT		
534	M	5	731	FS	PARATHYROID		HYPERPLASIA		
534	M	5	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
535	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
535	M	5	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
535	M	5	735	FS	BONE MARROW		MARROW LIPOMATOSIS		
535	M	5	735	FS	KIDNEY		NEPHROPATHY		
535	M	5	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
535	M	5	735	FS	LIVER		FOCUS, CLEAR CELL		
535	M	5	735	FS	LIVER		FOCUS, EOSINOPHILIC		
535	M	5	735	FS	LIVER		FOCUS, MIXED CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
535	M	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
535	M	5	735	FS	LUNG		INFLAMMATION		
535	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
535	M	5	735	FS	SKIN		HYPERPLASIA, EPIDERMIS		
535	M	5	735	FS	SKIN		INFLAMMATION		
535	M	5	735	FS	THYMUS	THY	M-THYMOMA	80	M
535	M	5	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
536	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
536	M	5	735	FS	KIDNEY		INFLAMMATION		
536	M	5	735	FS	KIDNEY		NEPHROPATHY		
536	M	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
536	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
536	M	5	735	FS	SKIN		INFLAMMATION		
536	M	5	735	FS	SKIN		ULCER, EPIDERMIS		
537	M	5	708	U1	HEART		CARDIOMYOPATHY		
537	M	5	708	U1	HEART		THROMBOSIS		
537	M	5	708	U1	LUNG		THROMBOSIS		
537	M	5	708	U1	PROSTATE		INFLAMMATION		
537	M	5	708	U1	SPLEEN		ATROPHY, LYMPHOID		
537	M	5	708	U1	THYROID GLAND		HYPERPLASIA, C-CELL		
538	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
538	M	5	735	FS	HEART		CARDIOMYOPATHY		
538	M	5	735	FS	KIDNEY		NEPHROPATHY		
538	M	5	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
538	M	5	735	FS	PARATHYROID		HYPERPLASIA		
538	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
538	M	5	735	FS	TESTIS		ATROPHY, BILATERAL		
538	M	5	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
539	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
539	M	5	735	FS	HEART		CARDIOMYOPATHY		
539	M	5	735	FS	KIDNEY		NEPHROPATHY		
539	M	5	735	FS	LIVER		INFLAMMATION		
539	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
540	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
540	M	5	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
540	M	5	735	FS	HEART		CARDIOMYOPATHY		
540	M	5	735	FS	KIDNEY		NEPHROPATHY		
540	M	5	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
540	M	5	735	FS	MESENTERY		CYST(S), ECTOPIC EPITHELIUM		
540	M	5	735	FS	MESENTERY		NECROSIS, MESENTERIC FAT		
540	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
540	M	5	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
541	M	5	735	FS	KIDNEY		NEPHROPATHY		
541	M	5	735	FS	LIVER		INFLAMMATION		
541	M	5	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
541	M	5	735	FS	PROSTATE		INFLAMMATION		
541	M	5	735	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
541	M	5	735	FS	TESTIS		ATROPHY, UNILATERAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
542	M	5	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
542	M	5	735	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
543	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
543	M	5	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
543	M	5	735	FS	KIDNEY		NEPHROPATHY		
543	M	5	735	FS	LIVER		DILATATION, BILE DUCT		
543	M	5	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
543	M	5	735	FS	LUNG		INFLAMMATION		
543	M	5	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
544	M	5	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
544	M	5	735	FS	BONE MARROW		MARROW LIPOMATOSIS		
544	M	5	735	FS	LIVER		FIBROSIS		
544	M	5	735	FS	LIVER		FOCUS, CLEAR CELL		
544	M	5	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
545	M	5	737	FS	EYE		ATROPHY, RETINA		
545	M	5	737	FS	EYE		CATARACT		
545	M	5	737	FS	KIDNEY		HYDRONEPHROSIS		
545	M	5	737	FS	LIVER		FOCUS, MIXED CELL		
545	M	5	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
545	M	5	737	FS	SKIN		INFLAMMATION		
545	M	5	737	FS	SKIN		ULCER, EPIDERMIS		
545	M	5	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
545	M	5	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
546	M	5	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
546	M	5	737	FS	KIDNEY		NEPHROPATHY		
546	M	5	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
546	M	5	737	FS	RECTUM		METAZOAN PARASITE(S)		
546	M	5	737	FS	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	M
547	M	5	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
547	M	5	737	FS	HEART		CARDIOMYOPATHY		
547	M	5	737	FS	KIDNEY		NEPHROPATHY		
547	M	5	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
548	M	5	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
548	M	5	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
548	M	5	737	FS	HEART		CARDIOMYOPATHY		
548	M	5	737	FS	KIDNEY		NEPHROPATHY		
548	M	5	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
549	M	5	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
549	M	5	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
549	M	5	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
549	M	5	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
549	M	5	737	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
550	M	5	737	FS	BRAIN	BR	B-GRANULAR CELL TUMOR	19	M
550	M	5	737	FS	HEART		CARDIOMYOPATHY		
550	M	5	737	FS	KIDNEY		NEPHROPATHY		
550	M	5	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
550	M	5	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
550	M	5	737	FS	STOMACH		INFLAMMATION, NON-GLANDULAR		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
550	M	5	737	FS	STOMACH		ULCER, NON-GLANDULAR		
550	M	5	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
551	M	5	737	FS	HEART		CARDIOMYOPATHY		
551	M	5	737	FS	KIDNEY		NEPHROPATHY		
551	M	5	737	FS	PREPUTIAL GLAND		INFLAMMATION		
551	M	5	737	FS	RECTUM		METAZOAN PARASITE(S)		
551	M	5	737	FS	TESTIS		ATROPHY, UNILATERAL		
552	M	5	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
552	M	5	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
552	M	5	737	FS	HEART		CARDIOMYOPATHY		
552	M	5	737	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
553	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
553	M	5	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
553	M	5	739	FS	HEART		CARDIOMYOPATHY		
553	M	5	739	FS	KIDNEY		NEPHROPATHY		
553	M	5	739	FS	LIVER		FOCUS, EOSINOPHILIC		
553	M	5	739	FS	LIVER		LIPIDOSIS, FOCAL		
553	M	5	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
553	M	5	739	FS	PROSTATE		INFLAMMATION		
553	M	5	739	FS	RECTUM		METAZOAN PARASITE(S)		
553	M	5	739	FS	TESTIS		ATROPHY, UNILATERAL		
554	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
554	M	5	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
554	M	5	739	FS	BONE MARROW		MARROW LIPOMATOSIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
554	M	5	739	FS	HEART		CARDIOMYOPATHY		
554	M	5	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
554	M	5	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
555	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
555	M	5	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
555	M	5	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
555	M	5	739	FS	LIVER		LIPIDOSIS, FOCAL		
555	M	5	739	FS	LUNG		INFLAMMATION		
555	M	5	739	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
556	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
556	M	5	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
556	M	5	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
556	M	5	739	FS	EPIDIDYMIS	EP	M-MESOTHELIOMA	69	M
556	M	5	739	FS	HEART		CARDIOMYOPATHY		
556	M	5	739	FS	KIDNEY		NEPHROPATHY		
556	M	5	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
556	M	5	739	FS	PREPUTIAL GLAND		INFLAMMATION		
556	M	5	739	FS	SKIN		INFLAMMATION		
556	M	5	739	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
556	M	5	739	FS	TESTIS		ATROPHY, BILATERAL		
556	M	5	739	FS	TONGUE		HYPERPLASIA, MUCOSAL EPITHELIUM		
557	M	5	739	FS	KIDNEY		INFLAMMATION		
557	M	5	739	FS	LIVER		FOCUS, CLEAR CELL		
557	M	5	739	FS	PANCREAS		HYPERPLASIA, ISLET CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
557	M	5	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
557	M	5	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
558	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
558	M	5	739	FS	HEART		CARDIOMYOPATHY		
558	M	5	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
558	M	5	739	FS	RECTUM		METAZOAN PARASITE(S)		
558	M	5	739	FS	SKIN		ULCER, EPIDERMIS		
558	M	5	739	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
558	M	5	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
559	M	5	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
559	M	5	739	FS	HEART		CARDIOMYOPATHY		
559	M	5	739	FS	KIDNEY		NEPHROPATHY		
559	M	5	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
559	M	5	739	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
559	M	5	739	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
560	M	5	739	FS	EPIDIDYMIS	EP	M-MESOTHELIOMA	69	M
560	M	5	739	FS	HEART		CARDIOMYOPATHY		
560	M	5	739	FS	KIDNEY		NEPHROPATHY		
560	M	5	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
561	M	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
561	M	5	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
561	M	5	743	FS	HEART		CARDIOMYOPATHY		
561	M	5	743	FS	KIDNEY		NEPHROPATHY		
561	M	5	743	FS	LIVER		FIBROSIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
561	M	5	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
561	M	5	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
561	M	5	743	FS	PHARYNX		INFLAMMATION		
562	M	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
562	M	5	743	FS	HEART		CARDIOMYOPATHY		
562	M	5	743	FS	KIDNEY		NEPHROPATHY		
562	M	5	743	FS	LIVER		INFLAMMATION		
562	M	5	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
562	M	5	743	FS	PROSTATE		INFLAMMATION		
563	M	5	672	U2	HEART		CARDIOMYOPATHY		
563	M	5	672	U2	KIDNEY		NEPHROPATHY		
563	M	5	672	U2	LIVER		FOCUS, CLEAR CELL		
563	M	5	672	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
563	M	5	672	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
563	M	5	672	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
564	M	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
564	M	5	743	FS	KIDNEY		NEPHROPATHY		
564	M	5	743	FS	LIVER		FIBROSIS		
564	M	5	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
564	M	5	743	FS	LIVER		INFLAMMATION		
564	M	5	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
565	M	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
565	M	5	743	FS	HEART		CARDIOMYOPATHY		
565	M	5	743	FS	KIDNEY		NEPHROPATHY		

**00000**



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
565	M	5	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
565	M	5	743	FS	LIVER		FOCUS, MIXED CELL		
565	M	5	743	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
565	M	5	743	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
565	M	5	743	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
566	M	5	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
566	M	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
566	M	5	743	FS	HEART		CARDIOMYOPATHY		
566	M	5	743	FS	KIDNEY		NEPHROPATHY		
566	M	5	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
566	M	5	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
566	M	5	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
566	M	5	743	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
566	M	5	743	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
567	M	5	552	U1	HEART		CARDIOMYOPATHY		
567	M	5	552	U1	LIVER		FOCUS, EOSINOPHILIC		
567	M	5	552	U1	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	F
567	M	5	552	U1	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
568	M	5	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
568	M	5	743	FS	HEART		CARDIOMYOPATHY		
568	M	5	743	FS	KIDNEY		HYDRONEPHROSIS		
568	M	5	743	FS	KIDNEY		NEPHROPATHY		
568	M	5	743	FS	LIVER		FOCUS, EOSINOPHILIC		
569	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
569	M	5	745	FS	HEART		CARDIOMYOPATHY		
569	M	5	745	FS	KIDNEY		NEPHROPATHY		
569	M	5	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
569	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
569	M	5	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
569	M	5	745	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
569	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
569	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
570	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
570	M	5	745	FS	HEART		CARDIOMYOPATHY		
570	M	5	745	FS	KIDNEY		NEPHROPATHY		
570	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
570	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
570	M	5	745	FS	PROSTATE		INFLAMMATION		
570	M	5	745	FS	SKIN		INFLAMMATION		
570	M	5	745	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
571	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
571	M	5	745	FS	LIVER		FOCUS, CLEAR CELL		
571	M	5	745	FS	LIVER		FOCUS, MIXED CELL		
571	M	5	745	FS	PARATHYROID		HYPERPLASIA		
571	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
571	M	5	745	FS	SPLEEN	SP	B-HEMANGIOMA	21	M
572	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
572	M	5	745	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
572	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
572	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
573	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
573	M	5	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
573	M	5	745	FS	HEART		CARDIOMYOPATHY		
573	M	5	745	FS	KIDNEY		NEPHROPATHY		
573	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
573	M	5	745	FS	LUNG	LU	M-CARCINOMA, BRONCHIOLAR-ALVEOLAR	50	M
573	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
573	M	5	745	FS	TESTIS		ATROPHY, BILATERAL		
573	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
574	M	5	745	FS	KIDNEY		NEPHROPATHY		
574	M	5	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
574	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
574	M	5	745	FS	PREPUTIAL GLAND		INFLAMMATION		
574	M	5	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
574	M	5	745	FS	TESTIS		ATROPHY, UNILATERAL		
575	M	5	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
575	M	5	745	FS	HEART		CARDIOMYOPATHY		
575	M	5	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
575	M	5	745	FS	LIVER		FOCUS, CLEAR CELL		
575	M	5	745	FS	LIVER		INFLAMMATION		
575	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
575	M	5	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
575	M	5	745	FS	STOMACH		MINERALIZATION		
575	M	5	745	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
575	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
576	M	5	745	FS	HEART		CARDIOMYOPATHY		
576	M	5	745	FS	KIDNEY		NEPHROPATHY		
576	M	5	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
576	M	5	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
576	M	5	745	FS	PROSTATE		INFLAMMATION		
576	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
577	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
577	M	5	745	FS	BRAIN	BR	M-ASTROCYTOMA	39	M
577	M	5	745	FS	KIDNEY		NEPHROPATHY		
577	M	5	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
577	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
577	M	5	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
577	M	5	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
577	M	5	745	FS	STOMACH		MINERALIZATION		
578	M	5	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
578	M	5	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
578	M	5	745	FS	KIDNEY		HYDRONEPHROSIS		
578	M	5	745	FS	KIDNEY		INFLAMMATION		
578	M	5	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
578	M	5	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
578	M	5	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
578	M	5	745	FS	PROSTATE		INFLAMMATION		
578	M	5	745	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
578	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
578	M	5	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
579	M	5	619	U2	EPIDIDYMIS		INFLAMMATION		
579	M	5	619	U2	HEART		CARDIOMYOPATHY		
579	M	5	619	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
579	M	5	619	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
579	M	5	619	U2	TESTIS		ATROPHY, BILATERAL		
580	M	5	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
580	M	5	746	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
580	M	5	746	FS	HEART		CARDIOMYOPATHY		
580	M	5	746	FS	KIDNEY		NEPHROPATHY		
621	M	6	729	FS	HEART		CARDIOMYOPATHY		
621	M	6	729	FS	KIDNEY		INFARCT, CHRONIC		
621	M	6	729	FS	LIVER		TELANGIECTASIS		
621	M	6	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
621	M	6	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
621	M	6	729	FS	TESTIS		ATROPHY, BILATERAL		
621	M	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
622	M	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
622	M	6	729	FS	HEART		CARDIOMYOPATHY		
622	M	6	729	FS	KIDNEY		NEPHROPATHY		
622	M	6	729	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
622	M	6	729	FS	LIVER		INFLAMMATION		
622	M	6	729	FS	RECTUM		METAZOAN PARASITE(S)		
622	M	6	729	FS	SKIN		INFLAMMATION		
622	M	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
622	M	6	729	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
622	M	6	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
623	M	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
623	M	6	729	FS	LIVER		FOCUS, CLEAR CELL		
623	M	6	729	FS	LIVER		FOCUS, MIXED CELL		
623	M	6	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
623	M	6	729	FS	LUNG		INFLAMMATION		
623	M	6	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
624	M	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
624	M	6	729	FS	HEART		CARDIOMYOPATHY		
624	M	6	729	FS	LIVER		LIPIDOSIS, FOCAL		
624	M	6	729	FS	PANCREAS		ATROPHY, ACINAR CELL		
624	M	6	729	FS	PREPUTIAL GLAND		INFLAMMATION		
624	M	6	729	FS	SKIN		INFLAMMATION		
624	M	6	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
625	M	6	513	U2	HEART		CARDIOMYOPATHY		
625	M	6	513	U2	LIVER		HYPERPLASIA, BILE DUCT		
625	M	6	513	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
625	M	6	513	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
625	M	6	513	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
626	M	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
626	M	6	729	FS	HEART		CARDIOMYOPATHY		
626	M	6	729	FS	PREPUTIAL GLAND		INFLAMMATION		
627	M	6	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
627	M	6	729	FS	HEART		CARDIOMYOPATHY		
627	M	6	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
627	M	6	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
628	M	6	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
628	M	6	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
628	M	6	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
628	M	6	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
628	M	6	729	FS	PROSTATE		INFLAMMATION		
629	M	6	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
629	M	6	731	FS	HEART		CARDIOMYOPATHY		
629	M	6	731	FS	KIDNEY		NEPHROPATHY		
629	M	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
629	M	6	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
629	M	6	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
629	M	6	731	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
629	M	6	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
629	M	6	731	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
630	M	6	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
630	M	6	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
630	M	6	731	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
630	M	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
630	M	6	731	FS	TESTIS		ATROPHY, BILATERAL		
630	M	6	731	FS	TESTIS		EDEMA, INTERSTITIUM		
631	M	6	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
631	M	6	731	FS	HEART		CARDIOMYOPATHY		
631	M	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
631	M	6	731	FS	SKIN		ULCER, EPIDERMIS		
632	M	6	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
632	M	6	731	FS	KIDNEY		NEPHROPATHY		
632	M	6	731	FS	NOSE/TURBINATES		INFLAMMATION		
633	M	6	731	FS	HEART		CARDIOMYOPATHY		
633	M	6	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
633	M	6	731	FS	STOMACH		DYSPLASIA, NON-GLANDULAR EPITHELIUM		
633	M	6	731	FS	TESTIS		ATROPHY, UNILATERAL		
633	M	6	731	FS	TESTIS		EDEMA, INTERSTITIUM		
634	M	6	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
634	M	6	731	FS	HEART		CARDIOMYOPATHY		
634	M	6	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
634	M	6	731	FS	LIVER		INFLAMMATION		
634	M	6	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
634	M	6	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
634	M	6	731	FS	RECTUM		METAZOAN PARASITE(S)		
635	M	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
635	M	6	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
635	M	6	735	FS	HEART		CARDIOMYOPATHY		
635	M	6	735	FS	KIDNEY		NEPHROPATHY		
635	M	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
635	M	6	735	FS	LN-MESENTERIC		CYSTIC DEGENERATION		
635	M	6	735	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		
635	M	6	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
635	M	6	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
635	M	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
635	M	6	735	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
636	M	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
636	M	6	735	FS	HEART		CARDIOMYOPATHY		
636	M	6	735	FS	KIDNEY		HYDRONEPHROSIS		
636	M	6	735	FS	KIDNEY		NEPHROPATHY		
636	M	6	735	FS	LIVER		FOCUS, MIXED CELL		
636	M	6	735	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
636	M	6	735	FS	LUNG	LU	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	4	M
636	M	6	735	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
636	M	6	735	FS	RECTUM		METAZOAN PARASITE(S)		
636	M	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
637	M	6	735	FS	KIDNEY		HYDRONEPHROSIS		
637	M	6	735	FS	PREPUTIAL GLAND		INFLAMMATION		
638	M	6	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
638	M	6	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
638	M	6	735	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
638	M	6	735	FS	SKIN		ULCER, EPIDERMIS		
639	M	6	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
639	M	6	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
639	M	6	735	FS	SKIN		ULCER, EPIDERMIS		
640	M	6	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
640	M	6	735	FS	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	M
640	M	6	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
640	M	6	735	FS	SKIN		ULCER, EPIDERMIS		
640	M	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
641	M	6	724	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
641	M	6	724	U1	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
642	M	6	732	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
642	M	6	732	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
642	M	6	732	U2	EYE		ATROPHY/DEGENERATION		
642	M	6	732	U2	EYE		INFLAMMATION, PERIOcular		
642	M	6	732	U2	KIDNEY		NEPHROPATHY		
642	M	6	732	U2	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	F
642	M	6	732	U2	LUNG		INFLAMMATION		
642	M	6	732	U2	PARATHYROID		HYPERPLASIA		
642	M	6	732	U2	SKIN		ULCER, EPIDERMIS		
642	M	6	732	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
642	M	6	732	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
643	M	6	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
643	M	6	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
643	M	6	735	FS	TESTIS		ATROPHY, UNILATERAL		
643	M	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
644	M	6	735	FS	HEART		CARDIOMYOPATHY		
644	M	6	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
644	M	6	735	FS	LIVER		FOCUS, CLEAR CELL		
644	M	6	735	FS	PREPUTIAL GLAND		INFLAMMATION		
644	M	6	735	FS	SKIN	SK	B-ADENOMA, BASAL CELL	2	M
644	M	6	735	FS	TESTIS		ATROPHY, UNILATERAL		
644	M	6	735	FS	TESTIS		EDEMA, INTERSTITIUM		
644	M	6	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
644	M	6	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
645	M	6	737	FS	PREPUTIAL GLAND		INFLAMMATION		
645	M	6	737	FS	TESTIS		ATROPHY, UNILATERAL		
645	M	6	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
646	M	6	420	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
646	M	6	420	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
646	M	6	420	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
646	M	6	420	U2	PROSTATE		INFLAMMATION		
646	M	6	420	U2	SKIN	SK	B-ADENOMA, BASAL CELL	2	I
647	M	6	737	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
647	M	6	737	FS	HEART		CARDIOMYOPATHY		
647	M	6	737	FS	KIDNEY		INFLAMMATION		
647	M	6	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
647	M	6	737	FS	LN-OTHER		CYSTIC DEGENERATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
647	M	6	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
647	M	6	737	FS	NOSE/TURBINATES		INFLAMMATION		
647	M	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
647	M	6	737	FS	SKIN		INFLAMMATION		
647	M	6	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
648	M	6	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
648	M	6	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
648	M	6	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
648	M	6	737	FS	SKIN		INFLAMMATION		
649	M	6	691	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
649	M	6	691	U2	KIDNEY		HYDRONEPHROSIS		
649	M	6	691	U2	KIDNEY		NEPHROPATHY		
649	M	6	691	U2	PENIS	P	M-LYMPHOMA, EPITHELIOTROPIC	67	F
649	M	6	691	U2	PENIS		INFLAMMATION		
649	M	6	691	U2	SKIN		ULCER, EPIDERMIS		
649	M	6	691	U2	TESTIS		ATROPHY, UNILATERAL		
650	M	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
650	M	6	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
650	M	6	737	FS	HEART		CARDIOMYOPATHY		
650	M	6	737	FS	LIVER		DILATATION, BILE DUCT		
650	M	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
650	M	6	737	FS	PREPUTIAL GLAND		INFLAMMATION		
651	M	6	737	FS	HEART		CARDIOMYOPATHY		
651	M	6	737	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
651	M	6	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
651	M	6	737	FS	SKIN		ULCER, EPIDERMIS		
651	M	6	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
652	M	6	737	FS	ADRENAL GLAND		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
652	M	6	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
652	M	6	737	FS	HEART		CARDIOMYOPATHY		
652	M	6	737	FS	KIDNEY		HYDRONEPHROSIS		
652	M	6	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
652	M	6	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
652	M	6	737	FS	SKIN		ULCER, EPIDERMIS		
652	M	6	737	FS	TESTIS		ATROPHY, UNILATERAL		
652	M	6	737	FS	TESTIS		EDEMA, INTERSTITIUM		
652	M	6	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
653	M	6	739	FS	KIDNEY		NEPHROPATHY		
653	M	6	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
653	M	6	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
654	M	6	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
654	M	6	739	FS	HEART		CARDIOMYOPATHY		
654	M	6	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
654	M	6	739	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
654	M	6	739	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
654	M	6	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
654	M	6	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
654	M	6	739	FS	SKIN		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
655	M	6	739	FS	ADRENAL GLAND	AD	B-PHEOCHROMOCYTOMA	29	M
655	M	6	739	FS	HEART		CARDIOMYOPATHY		
655	M	6	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
656	M	6	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
656	M	6	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
656	M	6	739	FS	JEJUNUM		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
656	M	6	739	FS	JEJUNUM		INFLAMMATION		
656	M	6	739	FS	JEJUNUM		ULCER		
656	M	6	739	FS	KIDNEY		NEPHROPATHY		
656	M	6	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
656	M	6	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
656	M	6	739	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
656	M	6	739	FS	SPLEEN		HYPERPLASIA, PLASMA CELL		
657	M	6	739	FS	HEART		CARDIOMYOPATHY		
657	M	6	739	FS	NOSE/TURBINATES		INFLAMMATION		
657	M	6	739	FS	PANCREAS	PA	B-ISLET CELL TUMOR	22	M
657	M	6	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
657	M	6	739	FS	SKIN		ULCER, EPIDERMIS		
657	M	6	739	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
658	M	6	739	FS	HEART		CARDIOMYOPATHY		
658	M	6	739	FS	KIDNEY		NEPHROPATHY		
658	M	6	739	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
658	M	6	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
658	M	6	739	FS	PREPUTIAL GLAND		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
658	M	6	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
659	M	6	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
659	M	6	739	FS	HEART		CARDIOMYOPATHY		
659	M	6	739	FS	KIDNEY		NEPHROPATHY		
659	M	6	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
659	M	6	739	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
659	M	6	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
660	M	6	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
660	M	6	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
660	M	6	739	FS	HEART		CARDIOMYOPATHY		
660	M	6	739	FS	KIDNEY		NEPHROPATHY		
660	M	6	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
660	M	6	739	FS	SKIN		ULCER, EPIDERMIS		
660	M	6	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
661	M	6	681	U2	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
661	M	6	681	U2	HEART		CARDIOMYOPATHY		
661	M	6	681	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
661	M	6	681	U2	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	I
662	M	6	87	U2					
663	M	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
663	M	6	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
663	M	6	743	FS	HEART		CARDIOMYOPATHY		
663	M	6	743	FS	KIDNEY		NEPHROPATHY		
663	M	6	743	FS	LIVER		FOCUS, CLEAR CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
663	M	6	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
663	M	6	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
664	M	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
664	M	6	743	FS	HEART		CARDIOMYOPATHY		
664	M	6	743	FS	JEJUNUM		DIVERTICULUM		
664	M	6	743	FS	KIDNEY		CYST(S), TUBULAR		
664	M	6	743	FS	KIDNEY		INFLAMMATION		
664	M	6	743	FS	KIDNEY		NEPHROPATHY		
664	M	6	743	FS	PANCREAS		ATROPHY, ACINAR CELL		
664	M	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
664	M	6	743	FS	PROSTATE		INFLAMMATION		
664	M	6	743	FS	SKIN		ULCER, EPIDERMIS		
665	M	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
665	M	6	743	FS	HEART		CARDIOMYOPATHY		
665	M	6	743	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
665	M	6	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
666	M	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
666	M	6	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
667	M	6	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
667	M	6	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
667	M	6	743	FS	HEART		CARDIOMYOPATHY		
667	M	6	743	FS	LIVER		FOCUS, CLEAR CELL		
667	M	6	743	FS	PROSTATE		INFLAMMATION		
667	M	6	743	FS	SKIN	SK	B-GRANULAR CELL TUMOR	19	M



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
667	M	6	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
668	M	6	743	FS	HEART		CARDIOMYOPATHY		
668	M	6	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
668	M	6	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
668	M	6	743	FS	SKIN		ULCER, EPIDERMIS		
668	M	6	743	FS	TESTIS		ATROPHY, BILATERAL		
669	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
669	M	6	745	FS	LIVER		FOCUS, CLEAR CELL		
669	M	6	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
669	M	6	745	FS	NOSE/TURBINATES	NO	B-ADENOMA	1	M
669	M	6	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
670	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
670	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
670	M	6	745	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
670	M	6	745	FS	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	M
670	M	6	745	FS	LIVER		FOCUS, CLEAR CELL		
670	M	6	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
670	M	6	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
670	M	6	745	FS	PROSTATE		INFLAMMATION		
670	M	6	745	FS	SKIN		ULCER, EPIDERMIS		
670	M	6	745	FS	TESTIS		ATROPHY, UNILATERAL		
670	M	6	745	FS	TESTIS		EDEMA, INTERSTITIUM		
671	M	6	745	FS	HEART		CARDIOMYOPATHY		
671	M	6	745	FS	LN-MESENTERIC	LNMES	M-HEMANGIOSARCOMA	62	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
671	M	6	745	FS	LUNG		INFLAMMATION		
671	M	6	745	FS	RECTUM		METAZOAN PARASITE(S)		
672	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
672	M	6	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
672	M	6	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
672	M	6	745	FS	COLON		METAZOAN PARASITE, LUMEN		
672	M	6	745	FS	HEART		CARDIOMYOPATHY		
672	M	6	745	FS	KIDNEY		NEPHROPATHY		
672	M	6	745	FS	LIVER		FOCUS, CLEAR CELL		
672	M	6	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
672	M	6	745	FS	TESTIS		ATROPHY, BILATERAL		
672	M	6	745	FS	TESTIS		EDEMA, INTERSTITIUM		
672	M	6	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
673	M	6	745	FS	HEART	HT	B-SCHWANNOMA, ENDOCARDIAL	33	M
673	M	6	745	FS	SKIN		INFLAMMATION		
674	M	6	745	FS	KIDNEY		NEPHROPATHY		
674	M	6	745	FS	LIVER		FOCUS, CLEAR CELL		
674	M	6	745	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
675	M	6	424	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
675	M	6	424	U2	PROSTATE		INFLAMMATION		
676	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
676	M	6	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
676	M	6	745	FS	HEART		CARDIOMYOPATHY		
676	M	6	745	FS	KIDNEY		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
676	M	6	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
676	M	6	745	FS	PREPUTIAL GLAND		INFLAMMATION		
676	M	6	745	FS	RECTUM		METAZOAN PARASITE(S)		
676	M	6	745	FS	SKIN		ULCER, EPIDERMIS		
676	M	6	745	FS	TESTIS		ATROPHY, UNILATERAL		
677	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
677	M	6	745	FS	HEART		CARDIOMYOPATHY		
677	M	6	745	FS	KIDNEY		NEPHROPATHY		
677	M	6	745	FS	PROSTATE		INFLAMMATION		
677	M	6	745	FS	SKIN		INFLAMMATION		
677	M	6	745	FS	SKIN		ULCER, EPIDERMIS		
678	M	6	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
678	M	6	745	FS	KIDNEY	K	B-ADENOMA, TUBULAR	13	M
678	M	6	745	FS	KIDNEY		INFLAMMATION		
678	M	6	745	FS	KIDNEY		NEPHROPATHY		
678	M	6	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
678	M	6	745	FS	LIVER		FOCUS, CLEAR CELL		
678	M	6	745	FS	NOSE/TURBINATES		INFLAMMATION		
678	M	6	745	FS	NOSE/TURBINATES		SQUAMOUS METAPLASIA (RESPIRATORY EPITHELIUM)		
679	M	6	668	U2	KIDNEY		HYDRONEPHROSIS		
679	M	6	668	U2	KIDNEY		NEPHROPATHY		
679	M	6	668	U2	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	F
679	M	6	668	U2	PREPUTIAL GLAND		INFLAMMATION		
679	M	6	668	U2	SKIN		ULCER, EPIDERMIS		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
679	M	6	668	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
680	M	6	240	U2	BONE MARROW	BM	M-HISTIOCYTIC SARCOMA	63	F
680	M	6	240	U2	EYE		HEMORRHAGE, ANTERIOR CHAMBER		
680	M	6	240	U2	LIVER	LI	M-HISTIOCYTIC SARCOMA	63	I
680	M	6	240	U2	LIVER		DEGENERATION, HEPATOCYTE		
680	M	6	240	U2	LIVER		HYPERPLASIA, BILE DUCT		
680	M	6	240	U2	LIVER		LIPIDOSIS, DIFFUSE		
680	M	6	240	U2	LN-MESENTERIC	LNMES	M-HISTIOCYTIC SARCOMA	63	I
680	M	6	240	U2	LUNG		INFLAMMATION		
721	M	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
721	M	7	729	FS	HEART		CARDIOMYOPATHY		
721	M	7	729	FS	KIDNEY		NEPHROPATHY		
721	M	7	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
721	M	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
721	M	7	729	FS	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	M
721	M	7	729	FS	LUNG	LU	B-ADENOMA, BRONCHIOLAR-ALVEOLAR	4	M
721	M	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
721	M	7	729	FS	SKIN		ULCER, EPIDERMIS		
722	M	7	729	FS	SKIN		HYPERPLASIA, EPIDERMIS		
722	M	7	729	FS	TESTIS		ATROPHY, UNILATERAL		
722	M	7	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
723	M	7	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
723	M	7	729	FS	HARDERIAN GLAND		HYPERPLASIA, GLANDULAR EPITHELIUM		
723	M	7	729	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
723	M	7	729	FS	KIDNEY		NEPHROPATHY		
723	M	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
723	M	7	729	FS	LIVER		LIPIDOSIS, FOCAL		
723	M	7	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
723	M	7	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
723	M	7	729	FS	PREPUTIAL GLAND		INFLAMMATION		
723	M	7	729	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		
724	M	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
724	M	7	729	FS	HEART		CARDIOMYOPATHY		
724	M	7	729	FS	LIVER		FOCUS, CLEAR CELL		
724	M	7	729	FS	LIVER		HEPATODIAPHRAGMATIC NODULE (HDN)		
724	M	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
724	M	7	729	FS	LIVER		HYPERPLASIA, NODULAR, HEPATOCYTE		
724	M	7	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
724	M	7	729	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
725	M	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
725	M	7	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
725	M	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
725	M	7	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
726	M	7	729	FS	HEART		CARDIOMYOPATHY		
726	M	7	729	FS	KIDNEY		NEPHROPATHY		
726	M	7	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
726	M	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
726	M	7	729	FS	LIVER		LIPIDOSIS, MULTIFOCAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
727	M	7	729	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
727	M	7	729	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
727	M	7	729	FS	HEART		CARDIOMYOPATHY		
727	M	7	729	FS	KIDNEY		NEPHROPATHY		
727	M	7	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
727	M	7	729	FS	LIVER		INFLAMMATION		
727	M	7	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
727	M	7	729	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
727	M	7	729	FS	LUNG		INFLAMMATION		
727	M	7	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
727	M	7	729	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
728	M	7	672	U1	ADRENAL GLAND		HYPERPLASIA, CORTEX		
728	M	7	672	U1	HEART		CARDIOMYOPATHY		
728	M	7	672	U1	KIDNEY	K	B-LIPOMA	25	F
728	M	7	672	U1	KIDNEY		NEPHROPATHY		
728	M	7	672	U1	LIVER		FOCUS, CLEAR CELL		
728	M	7	672	U1	LIVER		LIPIDOSIS, MULTIFOCAL		
728	M	7	672	U1	SKIN		INFLAMMATION		
729	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
729	M	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
730	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
730	M	7	731	FS	HEART		CARDIOMYOPATHY		
730	M	7	731	FS	KIDNEY		INFLAMMATION		
730	M	7	731	FS	KIDNEY		NEPHROPATHY		

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
730	M	7	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
730	M	7	731	FS	PANCREAS	PA	B-ISLET CELL TUMOR	22	M
731	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
731	M	7	731	FS	HEART		CARDIOMYOPATHY		
731	M	7	731	FS	KIDNEY		INFLAMMATION		
731	M	7	731	FS	KIDNEY		NEPHROPATHY		
731	M	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
731	M	7	731	FS	STOMACH		INFLAMMATION, GLANDULAR		
732	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
732	M	7	731	FS	HEART		CARDIOMYOPATHY		
732	M	7	731	FS	KIDNEY		INFLAMMATION		
732	M	7	731	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
732	M	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
732	M	7	731	FS	PREPUTIAL GLAND		INFLAMMATION		
732	M	7	731	FS	STOMACH		INFLAMMATION, GLANDULAR		
733	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
733	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
733	M	7	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
733	M	7	731	FS	HEART		CARDIOMYOPATHY		
733	M	7	731	FS	KIDNEY		NEPHROPATHY		
733	M	7	731	FS	LIVER		FOCUS, BASOPHILIC CELL		
733	M	7	731	FS	LIVER		FOCUS, CLEAR CELL		
733	M	7	731	FS	LIVER		FOCUS, EOSINOPHILIC		
733	M	7	731	FS	LIVER		HYPERPLASIA, BILE DUCT		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
733	M	7	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
733	M	7	731	FS	LUNG		INFLAMMATION		
733	M	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
733	M	7	731	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
734	M	7	731	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
734	M	7	731	FS	HEART		CARDIOMYOPATHY		
734	M	7	731	FS	KIDNEY		NEPHROPATHY		
734	M	7	731	FS	LIVER		FOCUS, MIXED CELL		
734	M	7	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
734	M	7	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
734	M	7	731	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
735	M	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
735	M	7	735	FS	HEART		CARDIOMYOPATHY		
735	M	7	735	FS	LIVER		FOCUS, CLEAR CELL		
735	M	7	735	FS	LIVER		HYPERPLASIA, BILE DUCT		
735	M	7	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
735	M	7	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
735	M	7	735	FS	TESTIS		ATROPHY, UNILATERAL		
735	M	7	735	FS	TESTIS		EDEMA, INTERSTITIUM		
735	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
736	M	7	735	FS	HARDERIAN GLAND		INFLAMMATION		
736	M	7	735	FS	HEART		CARDIOMYOPATHY		
736	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
736	M	7	735	FS	LIVER		FOCUS, CLEAR CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
736	M	7	735	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
736	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
736	M	7	735	FS	SKIN	SK	B-TRICHOEPITHELIOMA	37	M
736	M	7	735	FS	TESTIS		EDEMA, INTERSTITIUM		
736	M	7	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
736	M	7	735	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
736	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
737	M	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
737	M	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
737	M	7	735	FS	HEART		CARDIOMYOPATHY		
737	M	7	735	FS	KIDNEY		NEPHROPATHY		
737	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL <sup>c</sup>		
737	M	7	735	FS	LIVER		FOCUS, CLEAR CELL		
737	M	7	735	FS	PREPUTIAL GLAND		INFLAMMATION		
737	M	7	735	FS	TESTIS		EDEMA, INTERSTITIUM		
737	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
738	M	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
738	M	7	735	FS	KIDNEY		NEPHROPATHY		
738	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
738	M	7	735	FS	LUNG		INFLAMMATION		
738	M	7	735	FS	PANCREAS	PA	B-ISLET CELL TUMOR	22	M
738	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
738	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
738	M	7	735	FS	THYROID GLAND	THG	M-CARCINOMA, FOLLICULAR CELL	52	M

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
739	M	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
739	M	7	735	FS	HEART		CARDIOMYOPATHY		
739	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
739	M	7	735	FS	LIVER		FOCUS, CLEAR CELL		
739	M	7	735	FS	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	M
739	M	7	735	FS	PREPUTIAL GLAND		INFLAMMATION		
739	M	7	735	FS	RECTUM		METAZOAN PARASITE(S)		
739	M	7	735	FS	TESTIS		EDEMA, INTERSTITIUM		
739	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
740	M	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
740	M	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
740	M	7	735	FS	HEART		CARDIOMYOPATHY		
740	M	7	735	FS	KIDNEY		NEPHROPATHY		
740	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
740	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
740	M	7	735	FS	SKIN	SK	B-KERATOACANTHOMA	23	M
740	M	7	735	FS	SKIN		HYPERPLASIA, EPIDERMIS		
740	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
741	M	7	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
741	M	7	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
741	M	7	735	FS	HEART		CARDIOMYOPATHY		
741	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
741	M	7	735	FS	PROSTATE		INFLAMMATION		
741	M	7	735	FS	TESTIS		EDEMA, INTERSTITIUM		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
742	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
742	M	7	735	FS	LIVER		FOCUS, CLEAR CELL		
742	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
742	M	7	735	FS	PREPUTIAL GLAND		INFLAMMATION		
742	M	7	735	FS	SALIVARY GLAND		HYPERPLASIA, DUCT EPITHELIUM		
742	M	7	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
743	M	7	735	FS	HEART		CARDIOMYOPATHY		
743	M	7	735	FS	KIDNEY		NEPHROPATHY		
743	M	7	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
743	M	7	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
743	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
743	M	7	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
743	M	7	735	FS	RECTUM		METAZOAN PARASITE(S)		
744	M	7	735	FS	LUNG	LU	M-MESOTHELIOMA	69	M
744	M	7	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
744	M	7	735	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
744	M	7	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
745	M	7	737	FS	HEART		CARDIOMYOPATHY		
745	M	7	737	FS	LIVER		HYPERPLASIA, BILE DUCT		
745	M	7	737	FS	PREPUTIAL GLAND		INFLAMMATION		
746	M	7	737	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
746	M	7	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
746	M	7	737	FS	HEART		CARDIOMYOPATHY		
746	M	7	737	FS	LIVER		FOCUS, BASOPHILIC CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
746	M	7	737	FS	LIVER		FOCUS, CLEAR CELL		
746	M	7	737	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
746	M	7	737	FS	PREPUTIAL GLAND		INFLAMMATION		
747	M	7	737	FS	HEART		CARDIOMYOPATHY		
747	M	7	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
747	M	7	737	FS	RECTUM	R	B-LEIOMYOMA	24	M
747	M	7	737	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
748	M	7	668	U2	EPIDIDYMIS	EP	M-MESOTHELIOMA	69	I
748	M	7	668	U2	LIVER		FOCUS, CLEAR CELL		
748	M	7	668	U2	MESENTERY	ME	M-MESOTHELIOMA	69	I
748	M	7	668	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
748	M	7	668	U2	TESTIS	TE	M-MESOTHELIOMA	69	I
748	M	7	668	U2	TESTIS		EDEMA, INTERSTITIUM		
749	M	7	675	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
749	M	7	675	U1	PROSTATE		INFLAMMATION		
750	M	7	737	FS	HEART		CARDIOMYOPATHY		
750	M	7	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
750	M	7	737	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
750	M	7	737	FS	PREPUTIAL GLAND		INFLAMMATION		
750	M	7	737	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
750	M	7	737	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
751	M	7	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
751	M	7	737	FS	COLON		METAZOAN PARASITE, LUMEN		
751	M	7	737	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
751	M	7	737	FS	JEJUNUM		DIVERTICULUM		
751	M	7	737	FS	LIVER		FOCUS, EOSINOPHILIC		
751	M	7	737	FS	ORAL MUCOSA		CYSTIC SEBACEOUS GLAND, ECTOPIC		
751	M	7	737	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
752	M	7	737	FS	HEART		CARDIOMYOPATHY		
752	M	7	737	FS	KIDNEY		NEPHROPATHY		
752	M	7	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
752	M	7	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
752	M	7	737	FS	SALIVARY GLAND	SA	B-SCHWANNOMA	32	M
752	M	7	737	FS	SKIN		INFLAMMATION		
752	M	7	737	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
753	M	7	739	FS	HEART		CARDIOMYOPATHY		
753	M	7	739	FS	KIDNEY		NEPHROPATHY		
753	M	7	739	FS	LIVER		FOCUS, CLEAR CELL		
753	M	7	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
753	M	7	739	FS	PROSTATE		INFLAMMATION		
753	M	7	739	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
753	M	7	739	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
754	M	7	546	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
754	M	7	546	U2	PREPUTIAL GLAND		INFLAMMATION		
754	M	7	546	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
754	M	7	546	U2	STOMACH		ULCER, NON-GLANDULAR		
754	M	7	546	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
754	M	7	546	U2	THYROID GLAND		HYPERPLASIA, C-CELL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
755	M	7	609	U1	HEART		CARDIOMYOPATHY		
755	M	7	609	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	F
755	M	7	609	U1	PREPUTIAL GLAND		INFLAMMATION		
755	M	7	609	U1	PROSTATE		INFLAMMATION		
755	M	7	609	U1	SALIVARY GLAND		INFLAMMATION		
756	M	7	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
756	M	7	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
756	M	7	739	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
756	M	7	739	FS	HEART		CARDIOMYOPATHY		
756	M	7	739	FS	KIDNEY		NEPHROPATHY		
756	M	7	739	FS	LIVER		FOCUS, BASOPHILIC CELL		
756	M	7	739	FS	LIVER		HYPERPLASIA, BILE DUCT		
756	M	7	739	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
756	M	7	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
756	M	7	739	FS	LUNG		EOSINOPHILIC CRYSTALS		
756	M	7	739	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
756	M	7	739	FS	STOMACH		MUCOSAL CYST, NON-GLANDULAR		
756	M	7	739	FS	TESTIS		ATROPHY, UNILATERAL		
756	M	7	739	FS	TESTIS		EDEMA, INTERSTITIUM		
757	M	7	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
757	M	7	739	FS	HEART		CARDIOMYOPATHY		
757	M	7	739	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	M
757	M	7	739	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
758	M	7	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
758	M	7	739	FS	EPIDIDYMIS		INFLAMMATION		
758	M	7	739	FS	HEART		CARDIOMYOPATHY		
758	M	7	739	FS	KIDNEY		NEPHROPATHY		
758	M	7	739	FS	LIVER		FOCUS, BASOPHILIC CELL		
758	M	7	739	FS	LIVER		INFLAMMATION		
758	M	7	739	FS	LUNG		INFLAMMATION		
758	M	7	739	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
758	M	7	739	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
759	M	7	668	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
759	M	7	668	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
759	M	7	668	U2	HEART		CARDIOMYOPATHY		
759	M	7	668	U2	KIDNEY		NEPHROPATHY		
759	M	7	668	U2	LIVER		FOCUS, CLEAR CELL		
759	M	7	668	U2	ZYMBAL'S GLAND	ZY	M-CARCINOMA, SQUAMOUS CELL	57	F
760	M	7	739	FS	HEART		CARDIOMYOPATHY		
760	M	7	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
760	M	7	739	FS	URINARY BLADDER		HYPERPLASIA, TRANSITIONAL EPITHELIUM		
761	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
761	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, SPINDLE CELL		
761	M	7	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
761	M	7	743	FS	KIDNEY		NEPHROPATHY		
761	M	7	743	FS	SKIN		ULCER, EPIDERMIS		
762	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
762	M	7	743	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
762	M	7	743	FS	HEART		CARDIOMYOPATHY		
762	M	7	743	FS	KIDNEY		NEPHROPATHY		
762	M	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
763	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
763	M	7	743	FS	KIDNEY		NEPHROPATHY		
763	M	7	743	FS	LN-MANDIBULAR		CYSTIC DEGENERATION		
763	M	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
763	M	7	743	FS	PREPUTIAL GLAND		INFLAMMATION		
763	M	7	743	FS	PROSTATE		INFLAMMATION		
763	M	7	743	FS	RECTUM		LYMPHOID HYPERPLASIA, SUBMUCOSA		
764	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
764	M	7	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
764	M	7	743	FS	HEART		CARDIOMYOPATHY		
764	M	7	743	FS	KIDNEY		NEPHROPATHY		
764	M	7	743	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
764	M	7	743	FS	PROSTATE	PRO	B-ADENOMA	1	M
764	M	7	743	FS	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
765	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
765	M	7	743	FS	HEART		CARDIOMYOPATHY		
765	M	7	743	FS	KIDNEY		HYDRONEPHROSIS		
765	M	7	743	FS	LIVER		FOCUS, BASOPHILIC CELL		
765	M	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
765	M	7	743	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
765	M	7	743	FS	PANCREAS		ATROPHY, ACINAR CELL		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
765	M	7	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
766	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
766	M	7	743	FS	HEART		CARDIOMYOPATHY		
766	M	7	743	FS	KIDNEY		NEPHROPATHY		
766	M	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
766	M	7	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
766	M	7	743	FS	SKIN		HYPERPLASIA, EPIDERMIS		
767	M	7	479	U2	KIDNEY		NEPHROPATHY		
767	M	7	479	U2	PREPUTIAL GLAND		INFLAMMATION		
767	M	7	479	U2	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
767	M	7	479	U2	TONGUE	TO	M-CARCINOMA, SQUAMOUS CELL	57	F
768	M	7	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
768	M	7	743	FS	HEART		CARDIOMYOPATHY		
768	M	7	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
768	M	7	743	FS	SKELETAL MUSCLE		ATROPHY		
768	M	7	743	FS	SKIN		ULCER, EPIDERMIS		
769	M	7	641	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
769	M	7	641	U2	KIDNEY		NEPHROPATHY		
769	M	7	641	U2	LN-MESENTERIC	LNMES	B-HEMANGIOMA	21	I
769	M	7	641	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
769	M	7	641	U2	STOMACH		ULCER, NON-GLANDULAR		
769	M	7	641	U2	THYROID GLAND		HYPERPLASIA, C-CELL		
770	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
770	M	7	745	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
770	M	7	745	FS	KIDNEY		NEPHROPATHY		
770	M	7	745	FS	LIVER		FOCUS, BASOPHILIC CELL		
770	M	7	745	FS	SKIN		ULCER, EPIDERMIS		
770	M	7	745	FS	TOOTH		INFLAMMATION		
771	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
771	M	7	745	FS	LIVER		INFLAMMATION		
771	M	7	745	FS	SKIN		INFLAMMATION		
771	M	7	745	FS	SKIN		ULCER, EPIDERMIS		
772	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
772	M	7	745	FS	KIDNEY		NEPHROPATHY		
772	M	7	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
772	M	7	745	FS	LIVER		TELANGIECTASIS		
772	M	7	745	FS	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
772	M	7	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
772	M	7	745	FS	SKIN		INFLAMMATION		
772	M	7	745	FS	THYROID GLAND	THG	B-ADENOMA, FOLLICULAR CELL	7	M
773	M	7	678	U1	HEART		CARDIOMYOPATHY		
773	M	7	678	U1	KIDNEY		HEMORRHAGE		
773	M	7	678	U1	KIDNEY		HYDRONEPHROSIS		
773	M	7	678	U1	KIDNEY		INFLAMMATION		
773	M	7	678	U1	KIDNEY		NEPHROPATHY		
773	M	7	678	U1	KIDNEY		THROMBOSIS		
773	M	7	678	U1	LUNG		HYPERPLASIA, ALVEOLAR EPITHELIUM		
773	M	7	678	U1	PROSTATE	PRO	M-CARCINOMA	44	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
773	M	7	678	U1	URETER		DILATATION		
774	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
774	M	7	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
774	M	7	745	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
774	M	7	745	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
775	M	7	734	U1	LIVER		FOCUS, BASOPHILIC CELL		
775	M	7	734	U1	SEMINAL VESICLE		ATROPHY		
775	M	7	734	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
775	M	7	734	U1	STOMACH		NEUROENDOCRINE TISSUE, ECTOPIC		
775	M	7	734	U1	STOMACH		ULCER, NON-GLANDULAR		
775	M	7	734	U1	TESTIS	TE	M-LEIOMYOSARCOMA	64	F
775	M	7	734	U1	TESTIS		ATROPHY, UNILATERAL		
776	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
776	M	7	745	FS	HEART		CARDIOMYOPATHY		
776	M	7	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
776	M	7	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
776	M	7	745	FS	SKIN		ULCER, EPIDERMIS		
776	M	7	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
777	M	7	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
777	M	7	745	FS	KIDNEY		NEPHROPATHY		
777	M	7	745	FS	LN-MESENTERIC		SINUS HISTIOCYTOSIS		
777	M	7	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
777	M	7	745	FS	TESTIS		ATROPHY, UNILATERAL		
778	M	7	539	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
778	M	7	539	U2	LN-MEDIASTINAL	LNMED	M-LEIOMYOSARCOMA, METASTATIC (TESTIS)	66	I
778	M	7	539	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
778	M	7	539	U2	TESTIS	TE	M-LEIOMYOSARCOMA	64	F
779	M	7	746	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
779	M	7	746	FS	HEART		CARDIOMYOPATHY		
779	M	7	746	FS	LIVER		LIPIDOSIS, MULTIFOCAL		
779	M	7	746	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
779	M	7	746	FS	TESTIS		ATROPHY, UNILATERAL		
779	M	7	746	FS	TESTIS		EDEMA, INTERSTITIUM		
780	M	7	746	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
821	M	8	704	U2	ADRENAL GLAND	AD	F-LYMPHOMA	38	I
821	M	8	704	U2	BONE	BO	F-LYMPHOMA	38	I
821	M	8	704	U2	BONE MARROW	BM	F-LYMPHOMA	38	I
821	M	8	704	U2	BRAIN	BR	F-LYMPHOMA	38	I
821	M	8	704	U2	EYE	EYE	F-LYMPHOMA	38	I
821	M	8	704	U2	HARDERIAN GLAND	HG	F-LYMPHOMA	38	I
821	M	8	704	U2	HEART		CARDIOMYOPATHY		
821	M	8	704	U2	KIDNEY	K	F-LYMPHOMA	38	F
821	M	8	704	U2	LIVER	LI	F-LYMPHOMA	38	I
821	M	8	704	U2	LN-MANDIBULAR	LNMAN	F-LYMPHOMA	38	I
821	M	8	704	U2	LN-MEDIASTINAL	LNMED	F-LYMPHOMA	38	I
821	M	8	704	U2	LN-MESENTERIC	LNMES	F-LYMPHOMA	38	I
821	M	8	704	U2	LN-OTHER	LNO	F-LYMPHOMA	38	I
821	M	8	704	U2	LUNG	LU	F-LYMPHOMA	38	I

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
821	M	8	704	U2	PANCREAS	PA	F-LYMPHOMA	38	I
821	M	8	704	U2	PITUITARY GLAND	PI	F-LYMPHOMA	38	I
821	M	8	704	U2	PREPUTIAL GLAND		INFLAMMATION		
821	M	8	704	U2	PROSTATE	PRO	F-LYMPHOMA	38	I
821	M	8	704	U2	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
821	M	8	704	U2	SALIVARY GLAND	SA	F-LYMPHOMA	38	I
821	M	8	704	U2	SKIN		INFLAMMATION		
821	M	8	704	U2	SPLEEN	SP	F-LYMPHOMA	38	I
821	M	8	704	U2	THYMUS	THY	F-LYMPHOMA	38	I
822	M	8	712	U2	KIDNEY		NEPHROPATHY		
822	M	8	712	U2	LIVER		HYPERPLASIA, BILE DUCT		
822	M	8	712	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
822	M	8	712	U2	STOMACH		INFLAMMATION, NON-GLANDULAR		
823	M	8	729	FS	KIDNEY		NEPHROPATHY		
823	M	8	729	FS	LIVER		FOCUS, BASOPHILIC CELL		
823	M	8	729	FS	LIVER		LIPIDOSIS, FOCAL		
823	M	8	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
823	M	8	729	FS	SKIN		ULCER, EPIDERMIS		
824	M	8	729	FS	KIDNEY		HYDRONEPHROSIS		
824	M	8	729	FS	KIDNEY		NEPHROPATHY		
824	M	8	729	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
824	M	8	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
824	M	8	729	FS	SKIN		ULCER, EPIDERMIS		
824	M	8	729	FS	TESTIS		ATROPHY, UNILATERAL		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
825	M	8	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
825	M	8	729	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
825	M	8	729	FS	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
826	M	8	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
826	M	8	729	FS	HEART		CARDIOMYOPATHY		
827	M	8	641	U2	KIDNEY		NEPHROPATHY		
827	M	8	641	U2	LN-MEDIASTINAL		INFLAMMATION		
827	M	8	641	U2	PANCREAS		CYST(S)		
827	M	8	641	U2	PANCREAS		HEMORRHAGE		
827	M	8	641	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
828	M	8	729	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
828	M	8	729	FS	KIDNEY		NEPHROPATHY		
828	M	8	729	FS	LIVER		HYPERPLASIA, BILE DUCT		
828	M	8	729	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
828	M	8	729	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
828	M	8	729	FS	PROSTATE		INFLAMMATION		
828	M	8	729	FS	RECTUM		METAZOAN PARASITE(S)		
828	M	8	729	FS	TESTIS	TE	B-ADENOMA, INTERSTITIAL CELL	9	M
828	M	8	729	FS	TESTIS		ATROPHY, BILATERAL		
829	M	8	388	U2	HEART		CARDIOMYOPATHY		
829	M	8	388	U2	KIDNEY		INFLAMMATION		
829	M	8	388	U2	PREPUTIAL GLAND		INFLAMMATION		
830	M	8	731	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
830	M	8	731	FS	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
830	M	8	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
830	M	8	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
830	M	8	731	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
830	M	8	731	FS	PROSTATE		INFLAMMATION		
831	M	8	731	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
831	M	8	731	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
831	M	8	731	FS	LIVER		DILATATION, BILE DUCT		
831	M	8	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
831	M	8	731	FS	TESTIS		ATROPHY, BILATERAL		
832	M	8	731	FS	COLON		METAZOAN PARASITE, LUMEN		
832	M	8	731	FS	HEART		CARDIOMYOPATHY		
832	M	8	731	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
832	M	8	731	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
833	M	8	731	FS	HARDERIAN GLAND		INFLAMMATION		
833	M	8	731	FS	HEART		CARDIOMYOPATHY		
833	M	8	731	FS	LIVER		FOCUS, CLEAR CELL		
833	M	8	731	FS	LIVER		FOCUS, EOSINOPHILIC		
833	M	8	731	FS	LIVER		HYPERPLASIA, BILE DUCT		
833	M	8	731	FS	LIVER		INFLAMMATION		
833	M	8	731	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
833	M	8	731	FS	PANCREAS		ATROPHY, ACINAR CELL		
833	M	8	731	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS INTERMEDIA	11	M
833	M	8	731	FS	PREPUTIAL GLAND		INFLAMMATION		
834	M	8	565	U1	BONE MARROW	BM	F-LYMPHOMA	38	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
834	M	8	565	U1	BONE MARROW		INFARCT		
834	M	8	565	U1	HEART		CARDIOMYOPATHY		
834	M	8	565	U1	KIDNEY		NEPHROPATHY		
834	M	8	565	U1	LIVER		HYPERPLASIA, BILE DUCT		
834	M	8	565	U1	NOSE/TURBINATES		INFLAMMATION		
834	M	8	565	U1	PROSTATE		INFLAMMATION		
834	M	8	565	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
834	M	8	565	U1	URINARY BLADDER		INFLAMMATION		
835	M	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
835	M	8	735	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
835	M	8	735	FS	HEART		CARDIOMYOPATHY		
835	M	8	735	FS	KIDNEY		NEPHROPATHY		
835	M	8	735	FS	PITUITARY GLAND	PI	M-CARCINOMA, PARS INTERMEDIA	56	M
835	M	8	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
836	M	8	613	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
836	M	8	613	U2	HEART		CARDIOMYOPATHY		
836	M	8	613	U2	LIVER		INFLAMMATION		
836	M	8	613	U2	LN-MANDIBULAR		CYSTIC DEGENERATION		
836	M	8	613	U2	LN-MEDIASTINAL		INFLAMMATION		
836	M	8	613	U2	LN-MESENTERIC		CYSTIC DEGENERATION		
836	M	8	613	U2	LN-OTHER		CYSTIC DEGENERATION		
836	M	8	613	U2	PANCREAS		ATROPHY, ACINAR CELL		
836	M	8	613	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
836	M	8	613	U2	PREPUTIAL GLAND		INFLAMMATION		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
836	M	8	613	U2	SALIVARY GLAND		INFLAMMATION		
836	M	8	613	U2	STOMACH		INFLAMMATION, GLANDULAR		
836	M	8	613	U2	TESTIS	TE	M-SARCOMA	76	F
837	M	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
837	M	8	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
837	M	8	735	FS	HEART		CARDIOMYOPATHY		
837	M	8	735	FS	KIDNEY		NEPHROPATHY		
837	M	8	735	FS	LIVER		FOCUS, MIXED CELL		
837	M	8	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
837	M	8	735	FS	SKIN		ULCER, EPIDERMIS		
837	M	8	735	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
838	M	8	735	FS	HEART		CARDIOMYOPATHY		
838	M	8	735	FS	KIDNEY		NEPHROPATHY		
838	M	8	735	FS	PANCREAS		LIPOMATOSIS		
838	M	8	735	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
839	M	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
839	M	8	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
839	M	8	735	FS	HEART		CARDIOMYOPATHY		
839	M	8	735	FS	KIDNEY		NEPHROPATHY		
839	M	8	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
839	M	8	735	FS	PANCREAS		ATROPHY, ACINAR CELL		
839	M	8	735	FS	PREPUTIAL GLAND		INFLAMMATION		
840	M	8	735	FS	HEART		CARDIOMYOPATHY		
840	M	8	735	FS	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
840	M	8	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
841	M	8	735	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
841	M	8	735	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
841	M	8	735	FS	HEART		CARDIOMYOPATHY		
841	M	8	735	FS	LIVER	LI	B-ADENOMA, HEPATOCELLULAR	8	M
841	M	8	735	FS	LIVER		FOCUS, BASOPHILIC CELL		
841	M	8	735	FS	PREPUTIAL GLAND	PRE	M-CARCINOMA	43	M
841	M	8	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
841	M	8	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
842	M	8	735	FS	HEART		CARDIOMYOPATHY		
842	M	8	735	FS	KIDNEY		NEPHROPATHY		
842	M	8	735	FS	PREPUTIAL GLAND		INFLAMMATION		
842	M	8	735	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
843	M	8	613	U2	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
843	M	8	613	U2	LIVER		FOCUS, BASOPHILIC CELL		
843	M	8	613	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
843	M	8	613	U2	PANCREAS		ATROPHY, ACINAR CELL		
843	M	8	613	U2	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
843	M	8	613	U2	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
844	M	8	735	FS	KIDNEY	K	B-ADENOMA, TUBULAR	13	M
844	M	8	735	FS	KIDNEY	K	B-LIPOMA	25	M
844	M	8	735	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
844	M	8	735	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
845	M	8	580	U2	HEART		CARDIOMYOPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
845	M	8	580	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
845	M	8	580	U2	PREPUTIAL GLAND		CYST(S)		
845	M	8	580	U2	SPLEEN		ATROPHY, LYMPHOID		
846	M	8	737	FS	HEART		CARDIOMYOPATHY		
846	M	8	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
846	M	8	737	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
847	M	8	737	FS	KIDNEY		NEPHROPATHY		
847	M	8	737	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
848	M	8	618	U1	HEART		CARDIOMYOPATHY		
848	M	8	618	U1	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
848	M	8	618	U1	STOMACH		INFLAMMATION, NON-GLANDULAR		
848	M	8	618	U1	TESTIS		ATROPHY, BILATERAL		
849	M	8	737	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
849	M	8	737	FS	HEART		CARDIOMYOPATHY		
849	M	8	737	FS	KIDNEY		NEPHROPATHY		
849	M	8	737	FS	LIVER		FOCUS, BASOPHILIC CELL		
849	M	8	737	FS	LIVER		FOCUS, CLEAR CELL		
850	M	8	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
850	M	8	737	FS	HEART		CARDIOMYOPATHY		
850	M	8	737	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
850	M	8	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
850	M	8	737	FS	TRACHEA		INFLAMMATION		
851	M	8	737	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
851	M	8	737	FS	HARDERIAN GLAND		HYPERPLASIA, FOLLICULAR LYMPHOID		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
851	M	8	737	FS	HARDERIAN GLAND		INFLAMMATION		
851	M	8	737	FS	HEART		CARDIOMYOPATHY		
851	M	8	737	FS	KIDNEY		CYST(S), TUBULAR		
851	M	8	737	FS	KIDNEY		NEPHROPATHY		
851	M	8	737	FS	PANCREAS		ATROPHY, ACINAR CELL		
851	M	8	737	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
851	M	8	737	FS	PROSTATE		HYPERPLASIA, DUCT EPITHELIUM		
852	M	8	626	U2	HEART		CARDIOMYOPATHY		
852	M	8	626	U2	KIDNEY		HYDRONEPHROSIS		
852	M	8	626	U2	KIDNEY		INFLAMMATION		
852	M	8	626	U2	LUNG	LU	M-CARCINOMA, METASTATIC (SKIN)	53	I
852	M	8	626	U2	PREPUTIAL GLAND		INFLAMMATION		
852	M	8	626	U2	SKIN	SK	M-CARCINOMA, BASAL CELL	48	F
852	M	8	626	U2	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	I
853	M	8	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
853	M	8	739	FS	HEART		CARDIOMYOPATHY		
853	M	8	739	FS	PANCREAS		ATROPHY, ACINAR CELL		
853	M	8	739	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
853	M	8	739	FS	PREPUTIAL GLAND		INFLAMMATION		
854	M	8	692	U2	HEART		CARDIOMYOPATHY		
854	M	8	692	U2	KIDNEY		INFLAMMATION		
854	M	8	692	U2	KIDNEY		NEPHROPATHY		
854	M	8	692	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
854	M	8	692	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
854	M	8	692	U2	PROSTATE		INFLAMMATION		
854	M	8	692	U2	SKIN		INFLAMMATION		
855	M	8	739	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
855	M	8	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
855	M	8	739	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
855	M	8	739	FS	HEART		CARDIOMYOPATHY		
855	M	8	739	FS	KIDNEY		INFLAMMATION		
855	M	8	739	FS	LIVER		FOCUS, MIXED CELL		
855	M	8	739	FS	PREPUTIAL GLAND		INFLAMMATION		
855	M	8	739	FS	SKIN		CYST, EPITHELIAL INCLUSION		
856	M	8	676	U2	EPIDIDYMIS		INFLAMMATION		
856	M	8	676	U2	HEART		CARDIOMYOPATHY		
856	M	8	676	U2	KIDNEY		NEPHROPATHY		
856	M	8	676	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
856	M	8	676	U2	TESTIS		ATROPHY, BILATERAL		
856	M	8	676	U2	THYMUS	THY	F-LYMPHOMA	38	I
856	M	8	676	U2	THYROID GLAND		HYPERPLASIA, FOLLICULAR CELL		
857	M	8	641	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
857	M	8	641	U2	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
857	M	8	641	U2	PANCREAS		ATROPHY, ACINAR CELL		
857	M	8	641	U2	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	F
858	M	8	405	U1	BONE MARROW		INFARCT		
858	M	8	405	U1	KIDNEY		HYDRONEPHROSIS		
858	M	8	405	U1	KIDNEY		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
858	M	8	405	U1	KIDNEY		MINERALIZATION		
858	M	8	405	U1	PROSTATE		INFLAMMATION		
858	M	8	405	U1	SEMINAL VESICLE -		INFLAMMATION		
858	M	8	405	U1	SKELETAL MUSCLE		INFLAMMATION		
858	M	8	405	U1	SKELETAL MUSCLE		MYODEGENERATION		
858	M	8	405	U1	SPLEEN		EXTRAMEDULLARY HEMATOPOIESIS (EMH)		
858	M	8	405	U1	URETER		HEMORRHAGE		
858	M	8	405	U1	URETER		INFLAMMATION		
858	M	8	405	U1	URINARY BLADDER		INFLAMMATION		
859	M	8	739	FS	PREPUTIAL GLAND		INFLAMMATION		
860	M	8	739	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
860	M	8	739	FS	HEART		CARDIOMYOPATHY		
860	M	8	739	FS	LIVER		FOCUS, CLEAR CELL		
860	M	8	739	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
861	M	8	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
861	M	8	743	FS	HEART		CARDIOMYOPATHY		
861	M	8	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
861	M	8	743	FS	SKIN	SK	M-FIBROSARCOMA	61	M
862	M	8	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
862	M	8	743	FS	HEART		CARDIOMYOPATHY		
863	M	8	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
863	M	8	743	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
863	M	8	743	FS	HEART		CARDIOMYOPATHY		
863	M	8	743	FS	KIDNEY		INFLAMMATION		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
863	M	8	743	FS	KIDNEY		NEPHROPATHY		
863	M	8	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
863	M	8	743	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
863	M	8	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
864	M	8	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
864	M	8	743	FS	HARDERIAN GLAND		BASOPHILIC HYPERTROPHIC FOCUS		
864	M	8	743	FS	HEART		CARDIOMYOPATHY		
864	M	8	743	FS	KIDNEY		NEPHROPATHY		
864	M	8	743	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
865	M	8	743	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
865	M	8	743	FS	HEART		CARDIOMYOPATHY		
865	M	8	743	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
866	M	8	743	FS	HEART		CARDIOMYOPATHY		
866	M	8	743	FS	KIDNEY		NEPHROPATHY		
866	M	8	743	FS	TESTIS		ATROPHY, UNILATERAL		
866	M	8	743	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
866	M	8	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
867	M	8	743	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
867	M	8	743	FS	KIDNEY		HYDRONEPHROSIS		
867	M	8	743	FS	KIDNEY		NEPHROPATHY		
867	M	8	743	FS	LIVER		HYPERPLASIA, BILE DUCT		
867	M	8	743	FS	THYROID GLAND		HYPERPLASIA, C-CELL		
868	M	8	564	U2	ADRENAL GLAND		HYPERPLASIA, CORTEX		
868	M	8	564	U2	KIDNEY		NEPHROPATHY		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
868	M	8	564	U2	PITUITARY GLAND	PI	M-CARCINOMA, PARS DISTALIS	55	F
868	M	8	564	U2	TESTIS		ATROPHY, BILATERAL		
869	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
869	M	8	745	FS	HEART		CARDIOMYOPATHY		
869	M	8	745	FS	KIDNEY		NEPHROPATHY		
869	M	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS INTERMEDIA		
869	M	8	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
870	M	8	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
870	M	8	745	FS	HEART		CARDIOMYOPATHY		
871	M	8	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
871	M	8	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
872	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
872	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, MEDULLA		
872	M	8	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
872	M	8	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
872	M	8	745	FS	LUNG		ALVEOLAR MACROPHAGES, INCREASED		
872	M	8	745	FS	TESTIS		HYPERPLASIA, INTERSTITIAL CELL		
873	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
874	M	8	745	FS	HEART		CARDIOMYOPATHY		
874	M	8	745	FS	KIDNEY		NEPHROPATHY		
874	M	8	745	FS	PANCREAS		ATROPHY, ACINAR CELL		
874	M	8	745	FS	SALIVARY GLAND		BASOPHILIC HYPERTROPHIC FOCUS		
875	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
875	M	8	745	FS	KIDNEY		INFLAMMATION		



**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
875	M	8	745	FS	LIVER		FOCUS, CLEAR CELL		
875	M	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
875	M	8	745	FS	SKIN		ULCER, EPIDERMIS		
876	M	8	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
876	M	8	745	FS	HEART		CARDIOMYOPATHY		
876	M	8	745	FS	KIDNEY		NEPHROPATHY		
876	M	8	745	FS	LIVER		HYPERPLASIA, BILE DUCT		
876	M	8	745	FS	PANCREAS		ATROPHY, ACINAR CELL		
876	M	8	745	FS	PITUITARY GLAND	PI	B-ADENOMA, PARS DISTALIS	10	M
876	M	8	745	FS	STOMACH		HYPERPLASIA, MUCOSA, NON-GLANDULAR		
876	M	8	745	FS	THYROID GLAND	THG	B-ADENOMA, C-CELL	5	M
877	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
877	M	8	745	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
877	M	8	745	FS	COLON		HYPERPLASIA, LYMPHOID, SUBMUCOSA		
877	M	8	745	FS	LIVER		DILATATION, BILE DUCT		
877	M	8	745	FS	PANCREAS		ATROPHY, ACINAR CELL		
878	M	8	745	FS	ADRENAL GLAND		HYPERPLASIA, CORTEX		
878	M	8	745	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		
878	M	8	745	FS	HEART		CARDIOMYOPATHY		
878	M	8	745	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
878	M	8	745	FS	THYMUS	THY	F-LYMPHOMA	38	M
879	M	8	746	FS	KIDNEY		NEPHROPATHY		
879	M	8	746	FS	PITUITARY GLAND		HYPERPLASIA, PARS DISTALIS		
880	M	8	746	FS	ADRENAL GLAND		HYPERTROPHY, CORTEX		

**Table C-1. Data Set for Tumor Incidence and Survival Analyses (Continued)**

Animal	Sex	Dose Group	Death Day	Death Status <sup>a</sup>	Tissue	Tissue Code	Diagnosis Text	Diagnosis Code	Rel To Death <sup>b</sup>
880	M	8	746	FS	ADRENAL GLAND		VACUOLIZATION, CYTOPLASM, CORTEX		
880	M	8	746	FS	MAMMARY GLAND	MA	B-ADENOMA	1	M
880	M	8	746	FS	PANCREAS		HYPERPLASIA, ACINAR CELL		

a. U1 = Unscheduled (early) death, found dead; U2 = Unscheduled (early) death, moribund sacrifice; FS = Scheduled death, final sacrifice.

b. I = Incidental; F = Fatal; M = Mortality independent.

**APPENDIX D**  
**SUMMARY TABLES**

**Table D-1. Summary of Statistically Significant Increasing and Decreasing Dose Trends**

Tumor Type	Sex	Tobacco Blend			Tobacco Extract		
		P-Value Trend 1,3,4,5	P-Value Trend 2,3,4,5	P-Value Trend 1&2,3,4,5	P-Value Trend 1,6,7,8	P-Value Trend 2,6,7,8	P-Value Trend 1&2,6,7,8
MAMMARY GLAND - B-ADENOMA	F	0.1537541	0.0042252	0.0164086	0.702029	0.0491488	0.179052
SKIN - M-CARCINOMA, BASAL CELL	F	0.0532471	0.190995	0.4547422	0.0030998	1	0.078115
UTERUS - M-CARCINOMA	F	0.069361	0.0253696	0.0117453	0.3552797	0.1514507	0.153785
EPIDIDYMIS - M-MESOTHELIOMA	M	0.0235588	0.0252965	0.0045476	0.9513822	0.7808396	0.8317044
THYROID GLAND - B-ADENOMA, FOLLICULAR CELL	M	0.1146405	0.0869707	0.076109	0.010398	0.0104615	0.0078204

Decreasing dose trend ( $p \leq 0.0167$ ).

Increasing dose trend ( $p \leq 0.0167$ )

B = Benign.

M = Malignant.

**Table D-2. Summary of Tumor Counts for Statistically Significant Trends – Females**

	Category	CF	CBF	B0.2F	B2F	B5F	E0.2F	E2F	E5F
MAMMARY GLAND - B-ADENOMA	I	3	2	2	2	1	3	2	0
	M	5	9	5	6	1	10	5	7
	F	0	3	2	2	0	1	1	1
	Sum	8	14	9	10	2	14	8	8
SKIN - M-CARCINOMA, BASAL CELL	I	1	0	0	0	0	0	0	0
	M	1	0	0	0	1	0	0	0
	F	2	0	0	0	0	0	0	0
	Sum	4	0	0	0	1	0	0	0
UTERUS - M-CARCINOMA	I	0	0	0	1	0	0	0	0
	M	0	0	2	1	4	2	0	2
	F	1	0	3	1	3	1	0	2
	Sum	1	0	5	3	7	3	0	4

I = Incidental; M = Mortality Independent; F = Fatal.

**Table D-3. Summary of Tumor Counts for Statistically Significant Trends – Males**

	Category	CM	CBM	B0.2M	B2M	B5M	E0.2M	E2M	E5M
EPIDIDYMIS - M-MESOTHELIOMA	I	0	0	0	0	0	0	1	0
	M	0	0	0	0	3	0	0	0
	Sum	0	0	0	0	3	0	1	0
THYROID GLAND - B-ADENOMA, FOLLICULAR CELL	I	0	0	0	0	0	1	0	0
	M	7	7	4	3	3	3	4	0
	Sum	7	7	4	3	3	4	4	0

I = Incidental; M = Mortality Independent; F = Fatal.